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Abstract to Thesis 
 
MITF is the master melanocyte transcription factor and has a complex role in 
melanoma. Both gain- and loss-of function mutations in MITF have been identified 
in melanoma, although its’ role in melanoma development and the effects of 
targeting MITF are unknown. Using a temperature-sensitive mitf zebrafish mutant I 
show that low levels of MITF are oncogenic with BRAFV600E in melanoma 
progression. By pathology and MITF target gene expression, BRAFV600Emitfavc7 
tumours are distinct from BRAFV600Ep53M214K tumours, and represent two melanoma 
subtypes. Melanomagenesis can also be driven independently of BRAFV600E, in a 
transgenic zebrafish with mutations in mitf and p53, representing a new melanoma 
model.  
 
Abrogating MITF activity in BRAFV600Emitfavc7 melanoma leads to regression of the 
tumour, characterised by macrophage infiltration and increased apoptosis. This result 
confirms the dependence on MITF activity in BRAFV600Emitfavc7 melanomas and 
highlights the role of MITF as a therapeutic target for melanoma. Exome and 
transcriptome sequencing has been carried out to gain insight into the expression and 
genomic mutational landscape that is driven by these melanoma transgenic models 
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1.1 Melanoma as a clinical disease 
 
Malignant melanoma is the most deadly form of skin cancer (The Skin Cancer 
Foundation, 2014) and the 5th most common cancer in the UK (Cancer Research 
UK, 2011). The word ‘melanoma’ comes from the Greek word ‘melas,’ meaning 
black and ‘-oma,’ meaning tumour and was first coined in the 1830s to describe a 
pigmented growth (Oxford English Dictionary, 2014). It is cancer of the 
melanocytes, the pigment-producing cells found in our skin, hair and eyes. It 
develops most commonly in the skin, but also less frequently in the eye, on palms of 
the hands and in the nails, as well as in the linings of the nose and mouth.  
 
Skin cancer statistics from Cancer Research UK show the impact of malignant 
melanoma on patients in the UK in 2011. In this year, 13,348 people in the UK were 
diagnosed with malignant melanoma and there were 2,209 deaths from the disease 
(Cancer Research UK, 2011). In contrast, in the same year, around 100,000 people in 
the UK were diagnosed with non-melanoma skin cancer, with only 585 deaths from 
this disease (Cancer Research UK, 2011). This statistic highlights the severity of 
malignant melanoma in particular and its aggressive nature compared to other forms 
of skin cancer. The incidence of malignant melanoma in the UK has increased 
significantly over the last 30 years and interestingly, cases in melanoma have 
increased more rapidly than any of the current ten most common cancers in both 
males and females (Figure 1.1). This increase is thought to be mostly due to changes 
in sun-related behaviour, including an increase in frequency of holidays abroad and 
the use of sunbeds. The impact of these factors is supported by a study published in 
2011, which estimated that 86% of malignant melanomas in the UK in 2010 were 
linked to UV radiation exposure from the sun and sunbeds (Parkin et al., 2011). The 
authors of this study assume that the high percentage of melanomas linked to UV 
radiation is due to altered patterns in human behaviour, through our choice of 
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clothing and recreational sunshine, which causes an increase in incidence that is 
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The critical moment in melanoma development takes place when the clonal evolution 
generates a cell that has the potential to enter the vertical growth phase (VGP) 
(Clark, 1989; Crotty, 2004). There are several key steps, from structurally normal 
melanocytes to metastatic melanoma, which underline the stages of melanoma 
progression. It begins simply with normal melanocytes, the cell type that is essential 
for pigmentation and from which melanomas are derived. Normal melanocytes 
together can form commonly acquired or congenital nevi. The melanocyte structure 
has the capacity to change and form dysplastic nevi. These are atypical or unusual, 
benign moles which could resemble early melanomas. It is at this point at which 
some patients may present to their general practitioners or dermatologists for an 
accurate, early diagnosis. The first growth phase from a dysplastic nevus is called the 
radial growth phase (RGP), in which the nevus transforms but is still non-
tumorigenic without the ability to metastasise. After this stage, vertical growth 
allows the nevus to become tumorigenic with the potential to metastasise. The final 
stage of melanoma progression describes the ability of a melanoma to metastasise 
and invade other tissues. As the stages progress, the patients’ prognosis worsens. 
Models from both Clark (1989), who describes a method to classify the layers of skin 
to which the melanoma has penetrated and Breslow (1970), who stages melanoma by 
thickness are referred to when making decisions on melanoma stage for diagnosis. 
The extent to which the melanoma has progressed through these stages will enable 
choices to be made on treatment, the risk of re-development of the tumour after 
treatment and whether a test is required to check for spreading of the tumour to the 
lymph nodes (Cancer Research UK, 2013). As well as the Clark and Breslow 
methods, the TNM method, which stands for tumour (T), nodes (N) and metastases 
(M), is a staging system that describes melanoma progression (Cancer Research UK, 
2013). In more detail, it can explain the size of a primary tumour (T), whether the 
tumour cells have invaded the lymph nodes (N) and whether the melanoma has 
spread to other areas, known as metastasis (M).  
 
According to Cancer Research UK (2013), most patients diagnosed with melanoma 
in the UK will have only have a ‘T’ value. In other words, in the majority of 
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melanoma patients the tumour will not have begun to spread to either lymph nodes or 
any other area in the body. Treatment by surgery is the most common in the UK, by 
which tumours are simply removed without the need for drug intervention. Surgery is 
usually possible for melanomas that have progressed up to 4mm in thickness, but 
with no sign of lymph node infiltration or metastasis. In the case of lymph node 
spread or metastasis, further treatments are required. Currently, these treatments 
include further surgery to lower the risk of melanoma recurrence, removal of lymph 
nodes by surgery, chemotherapy, radiotherapy or another biological therapies.  
 
The genetic make-up of a melanoma patient can determine the type of biological 
therapies available to them. The discovery of BRAF mutations in melanoma by 
Davies and colleagues in 2002 was a standout example of the potential of cancer 
genome characterisations. Mutations in BRAF are found in approximately 50% of 
melanoma patients, the most common form being V600E, in which valine (V) is 
substituted for a glutamic acid (E) at position 600 (Davies et al., 2002). BRAF 
mutations are also found in melanocytic nevi suggesting that these alterations occur 
early in the cancer’s progression (Pollock et al., 2003; Kumar et al., 2004). 
Vemurafenib, a BRAF inhibitor for example, has been shown to shrink tumours in 
patients with a BRAFV600E mutation and may be a treatment option for those with this 
particular BRAF mutation (Chapman et al., 2011). Combined genetics and 
environmental factors play a role in determining melanoma susceptibility. The 
heritability of melanoma, i.e. the contribution that genetics plays in melanoma 
development is estimated to be between 18-55% (Hemminki et al., 2001; Shekar et 
al., 2009). The advance in genomic technologies has allowed for a better 
understanding of the genetic pathways contributing to the disease and hence a shift in 
the therapeutic options available to patients. Multiple oncogenic pathways that lead 
to melanomagenesis have been identified (Figure 1.2) and this has opened doors for 
the development of new therapeutics to treat this disease.  
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Many of the genetic factors that have been identified through genomic technologies 
and shown to contribute to melanoma have been shown to act in parallel, although 
some are mutually exclusive. NRAS mutations are found in 15-20% of melanomas 
and activate RAF kinases in response to growth factor receptor activation (van 't 
Veer et al., 1989). BRAF mutations confer RAS-independent activation of the 
MAPK pathway and therefore it is not surprising that BRAFV600E and NRAS 
mutations are rarely found together. Mutation, deletion or transcriptional silencing of 
the CDKN2A locus causing loss of p16 expression is also frequent in melanomas and 
is found to overlap with mutations in BRAFV600E (Daniotti et al., 2004). Less 
common mutations in CCND1 and CDK4 are also associated with mutations in 
BRAFV600E and are mutually exclusive with loss of p16 (Curtin et al., 2005). The 
most common, recurrent mutations in melanoma have been found to reside within 
important signaling or developmental pathways that are essential for the survival and 
proliferation of the melanocyte lineage, for example the MAPK pathway (Flaherty et 
al., 2012). As well as these, there are also examples of lineage-restricted oncogenes, 
such as MITF and KIT that are part of pathways that lineage-specific and contribute 
to the metastatic potential of melanoma. Although metastatic melanoma remains a 
destructive disease, the identification of the described oncogenes and others and the 
development of small-molecule inhibitors to target these have provided significant 
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1.2 Therapeutic strategies for melanoma 
 
‘If melanoma is diagnosed early, the survival statistics are very good.’  
(Cancer Research UK, 2013).  
 
The current therapeutic strategies available to melanoma patients are dependent on 
the stage of the disease at the time of presentation. The overall outlook for melanoma 
patients without spread to either lymph nodes or other parts of the body is positive. 
In most of these cases, surgery to remove the melanoma is a cure. As the tumour 
thickness increases and the cancer stages progress over time however, the treatment 
becomes more difficult and the patient prognosis worsens. Metastatic melanoma is 
the leading cause of death from skin disease due to its propensity to metastasise from 
the skin to other areas of the body including the lymph nodes. Most patients 
diagnosed with melanoma that has acquired the ability to metastasise die within two 
years. The following facts summarise the current therapeutic strategies undertaken in 
the UK to treat melanoma patients, as outlined by Cancer Research UK (2013).  
 
Patients with early stage melanoma have tumours less than 2mm thick with no sign 
of metastasis. The usual procedure in these cases is for doctors to remove the 
unusual, suspected mole as well as a small area of surrounding tissue by surgery. 
This is then sent for laboratory analysis for diagnosis. If melanoma is confirmed, the 
patient will undergo a second surgery to remove further tissue from around the 
cancerous site. A lymph gland/node check may also be carried out to check for 
spread of the tumour to these sites, which if positive is a sign that the melanoma has 
metastasised. Lymph gland metastasis can be carried out by ultrasound, fine needle 
aspiration or biopsy. If the lymph gland/node test returns negative and the second 
surgery is successful, the cancer has been cured at the early stage and prognosis is 
good. Follow up appointments with a doctor will usually take place and any other 
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changes in moles or tissue around the primary melanoma will be continually 
monitored. No further treatment is required unless further melanomas develop.  
 
With medium stage melanomas, those which are >2mm thick or >1mm with 
ulcerations, a similar surgical approach to patients with early stage melanomas is 
taken. As well as the primary surgery for disease diagnosis, a second surgery will 
also take place to remove further tissue around the cancer. This is known as wide 
local excision and is carried out to lower the risk of melanoma developing in the 
future. A sentinel lymph node biopsy will usually also be carried out to assess the 
state, if any, of metastasis. This is more likely with tumours that are thicker and have 
therefore penetrated deeper through layers of the skin.  If the nodes are tumour-
negative then no cancer cells have reached this area and no further treatment is 
required. If however, the nodes do contain tumour cells then lymph node dissection, 
surgical removal of the nodes is required. Adjuvant therapy, the treatment after 
surgery to prevent recurrence, may also be required and could include chemotherapy, 
radiotherapy, and/or biological therapy such as interferon therapy. If the melanoma 
recurs, this can be either at a location nearby the primary melanoma that was 
removed (locoregional melanoma) or another site. The prognosis is better for 
locoregional melanoma, but again surgery and further treatment is required to 
remove the melanoma and reduce the risk of recurrence. If the tumour arises at a 
location in an area away from the initial site of trauma this is categorised as stage 
four melanoma. This is the final, most dangerous stage at which a patient can be 
diagnosed.  
 
Advanced melanoma occurs when a tumour recurs at a different area of the body 
after initial surgery and treatment of an initial melanoma. The most common areas 
that melanomas spread to are the lungs, liver, bone, brain, abdomen and lymph 
nodes. The treatment options for this late stage cancer are dependent on the location 
of the melanoma, a patient’s symptoms and the previous treatment that was used to 
treat the primary melanoma. Any treatment choice, from further surgery to intensive 
chemo- or radio- therapy, will not cure the disease but hopes to prolong the patient’s 
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lifetime by causing tumour shrinkage or halting its proliferation. The side effects that 
the therapies cause must be taken into account and be balanced with their ability to 
control the melanoma growth and increase patient survival time. Clinical trials are 
also available as an option for advanced stage melanoma patients. These may 
combine chemotherapy with new biological therapeutics with the aim of identifying 
the best treatments for advanced stage melanomas.  
 
The biological therapies available to medium and advanced stage melanoma patients 
vary greatly. Until recently, interferon therapy was the only therapeutic that showed 
positive results in both relapse-free survival (RFS) and overall survival (OS) of 
melanoma patients (Mitchell et al., 2007). The benefits of interferon treatment, 
although positive, were minor – a 5-10% increase in RFS and 2-5% increase in OS 
(Hauschild, 2009). A breakthrough in therapy for more advanced stage melanoma 
patients came in 2011 with the approval of ipilimumab and vemurafenib. Ipilimumab 
targets immune checkpoints, while vemurafenib inhibits mutated oncoproteins and 
both are proving promising clinical approaches to treatment for advanced stages of 
this disease.  
 
Ipilimumab is a monoclonal antibody that blocks the cytotoxic T-lymphocyte 
antigen-4 (CTLA-4) pathway from inhibiting T cell activation. The US Food and 
Drug Administration (FDA) approved it for the treatment of metastatic melanoma in 
2011 and clinical trials have shown overall survival benefit for patients compared to 
other treatment options (Acharya and Jeter, 2013). Use of ipilimumab simply 
stimulates a patient’s own immune response, which is important to destroy cancerous 
cells. Clinical trial results have shown that around 30% of patients who are 
administered ipilimumab will have a beneficial long-term outcome (Hodi et al., 
2010). Positive results when taking the drug include shrinkage of melanocytic lesions 
and a reduction in the total number of tumours. Side effects when using ipilimumab 
are also observed however, including immune-mediated adverse reactions (Weber, 
2007) and therefore further trials and possible combined therapeutic studies are 
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required for the maintenance of the benefits of this drug for metastatic melanoma 
patients.  
 
Also in 2011, there was further hope for metastatic melanoma patients when 
Plexxikon and Genentech developed the BRAF inhibitor vemurafenib. For patients 
harbouring the V600E activating mutation in BRAF, known to be found in ~60%, 
vemurafenib was shown to yield a positive response in more than 50% of patients 
(Chapman et al., 2011). Vemurafenib is a selective inhibitor of BRAF and its 
development follows the failure of another drug, sorafenib, which was developed as 
a broad-spectrum tyrosine and serine-threonine kinase inhibitor. The inhibitory 
action of sorafenib targeted BRAF, CRAF, PDGFR, VEGFR2, p38 and CKIT and 
was the first RAF-inhibitor to be trialled in melanoma patients (Wilhelm et al., 
2006). It failed to elicit a response in the clinical trials however, as either a single 
agent or combination therapy, due to its inability to adequately inhibit the MAPK 
pathway. Due to the failure of sorafenib, more potent and selective inhibitors of 
BRAF were developed, including the successful vemurafenib. Treatment with 
vemurafenib reduces the levels of pERK by >80% in BRAFV600E mutant tumours and 
correlates with a clinical response (Bollag et al., 2010). Importantly, inhibition of the 
MAPK pathway by vemurafenib is specific only to tumour cells harbouring the 
BRAF mutation, as other cells maintain this signalling pathway through CRAF.  
 
Despite the impressive clinical activity of vemurafenib in BRAFV600E mutant 
melanomas, the drug elicited many common side effects including fatigue and 
nausea. As well as these side effects, more than a quarter of patients treated with 
vemurafenib developed cutaneous squamous cell carcinomas (cSCC) and 60% of 
these tumours harboured HRAS mutations (Su et al., 2012). One mechanism for the 
promotion of tumourigenesis in a different cell type through targeted therapy is 
thought to be that while MAPK signaling is blocked in BRAFV600E-mutant cells, the 
RAF inhibitors increase MAPK signaling in either mutated or activated RAS cells 
(Oberholzer et al., 2012). RAS activation in cutaneous cell populations interacts with 
RAF inhibition therapy to promote cell proliferation and can therefore result in the 
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development of cSCCs, suggesting that formation of these tumours is caused by a 
‘pro-proliferative interaction between RAF inhibitors and latent RAS mutant 
keratinocytes’ (Oberholzer et al., 2012). This finding highlights the need to identify 
strategies to prevent secondary tumour development that occurs as a result of 
inhibitor treatments for melanoma. As well as this, strategies to overcome resistance 
to these inhibitors must also be addressed. Although BRAF inhibitor therapy has 
been shown to produce tumour response in most patients, these are largely partial 
and evidence of clinical tumour resistance usually occurs between 5-7 months.  
 
The clinical benefits of BRAF inhibitors have been limited by both de novo (pre-
existing) and acquired resistance mechanisms. The presence of de novo resistance 
mechanisms has been revealed by the 10% of melanoma patients who do not observe 
a response after drug treatment and in which tumour progression continues 
(Chapman et al., 2011; Hauschild et al., 2012). As well as this 10%, another 30% of 
melanoma patients given BRAF inhibitor treatment will achieve only a minor 
response, characterized by less than 25% reduction in tumour size, and only 5% will 
achieve complete response (Chapman et al., 2011; Hauschild et al., 2012). This 
heterogeneity towards BRAF inhibitors supports the presence of pre-existing 
molecular characteristics that determine patient response. Of the remainder of 
patients that achieve a positive response to BRAF inhibitors, the majority (80-90%) 
will develop acquired resistance within 12 months of treatment, leading to 
progression of melanoma. Many mechanisms of the resistance to BRAF inhibitors 
have been identified and broadly either reactivate the MAPK pathway or activate 
other proliferative or pro-survival pathways (Bucheit and Davies, 2014). To 
reactivate the MAPK pathway, alterations in both BRAF itself and other components 
not involving BRAF have been identified. Both aberrant splicing of BRAF 
(Poulikakos et al., 2011) and a gain in copy number of BRAF (Shi et al., 2012) have 
been observed in melanomas that progressed after an initial response to BRAF 
inhibitors. An increased BRAF inhibitor dosage was able to overcome resistance 
acquired due to the gain in copy number of BRAF but not when due to aberrant 
splicing (Poulikakos et al., 2011; Shi et al., 2012). Alterations of other components 
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of the RAS/RAF/MEK/ERK signaling pathway have also been observed during 
resistance and act to reactivate the MAPK pathway. Activating NRAS mutations are 
found in 20% of tumours after BRAF inhibitor resistance (Nazarian et al., 2010) an 
unexpected result as BRAF and NRAS mutations are usually mutually exclusive in 
untreated melanomas. Secondary mutations in MEK1 have also been shown to 
emerge as a result of BRAF inhibition and result in resistance (Emery et al., 2009; 
Wagle et al., 2011). Overexpression of COT kinase, which directly phosphorylates 
MEK and/or ERK, has also been shown to assist reactivation of the MAPK pathway 
through its regulation of MEK and ERK downstream of BRAF (Johannessen et al., 
2010). Lastly, resistance mechanisms have been shown to utilize BRAF heterodimers 
that use RAF isoforms, ARAF and CRAF, instead of BRAF, hence supporting 
reactivation of the pathway (Villanueva et al., 2010).   
In addition to reactivation of the MAPK pathway, other mechanisms of BRAF 
inhibitor resistance have included activation of the PI3K-AKT pathway. This 
signaling pathway, which is activated genetically by many of the common somatic 
alterations observed in cancer including activating point mutations of PIK3CA, gene 
amplification of HER2 and loss of function mutations of negative regulators of the 
pathway including Pten, plays key roles in proliferation, growth and survival and is 
commonly activated in tumours. Loss of PTEN function has been observed in 
tumours resistant to BRAF inhibitors, suggesting that this mechanism is associated 
with resistance. PTEN negatively regulates the PI3K-AKT pathway and in multiple 
tumour types loss of PTEN correlates with activation of AKT, a critical effector of 
the pathway. Loss of PTEN is found in 10-30% of human melanomas (Wu et al., 
2003) and frequently associated with BRAF activating mutations. BRAF inhibitors 
cause apoptosis in BRAF mutant tumours with normal PTEN function, whereas 
BRAF mutant tumours with PTEN loss are resistant to apoptosis (Paraiso et al., 
2011). As well as PTEN loss, receptor tyrosine kinases (RTKs) that activate the 
PI3K-AKT pathway have also been shown to be involved in BRAF inhibitor 
resistance. The increased expression of two RTKs, PDGFβR and IGF1R, blocked 
apoptosis through increased PI3K-AKT activation (Nazarian et al., 2010; Villanueva 
et al., 2010) and hence acted as a resistance mechanism. Activation of the PI3K-
AKT pathway is also regulated by the tumour microenvironment, specifically by 
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non-malignant cells within the stroma that produce hepatocyte growth factor (HGF). 
Production of HGF induces resistance through activation of the PI3K-AKT pathway 
(Straussman et al., 2012).  
 
The majority of resistance mechanisms stem from reactivation of downstream factors 
of BRAF within the MAPK pathway and therefore to overcome this resistance, a 
combinational treatment targeting BRAF and its targets is required. Combination 
treatments with inhibitors of MEK and ERK have been useful in an attempt to 
overcome most of the acquired resistance mechanisms. Dual BRAF and MEK 
inhibition using dabrafenib and trametinib for example, significantly improved 
progression-free survival in BRAFV600E melanomas compared to monotherapy (76% 
compared to 54%) (Flaherty et al., 2012). As well as improved survival, addition of 
the MEK inhibitor also reduced the development of cSCCs compared to 
monotherapy (7% compared to 19%) (Flaherty et al., 2012) suggesting that the 
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1.3 Zebrafish as a model of melanoma 
 
One of the earliest animal models of melanoma was developed in the freshwater fish, 
Xiphophorus (Anders et al., 1984; Schartl et al., 1985). First recognised in the 1920s, 
the Xiphophorus hybrid melanoma model was utilised by Schartl and colleagues to 
discover that overexpression of the xmrk oncogene in pigment cells is the primary 
change that results in the formation of malignant melanoma (Schartl et al., 1999). 
Xmrk is a duplicate of an orthologue of the mammalian epidermal growth factor 
receptor gene EGFR (Meierjohann et al., 2004). This discovery established the use of 
this model system to identify novel genetic modifiers of nevi and melanoma 
phenotypes.  
 
Despite the opportunities to study melanoma provided by the Xiphophorus model, 
‘for genome-wide genetic screens and dissecting the mechanisms of melanocyte 
development and melanoma progression, the zebrafish and medaka model fish 
systems offer distinct advantages’ (Patton and Nairn, 2010). One main advantage that 
these species offer over the Xiphophorus is their ability to fertilise embryos 
externally. This feature allows visualisation and analysis of embryo development, as 
well as the ability to carry out chemical and genetic screens in vivo. Additionally, 
pairs can be bred and provide hundreds of embryos every week, offering a more high 
throughput approach to experiments.  
 
The zebrafish in particular has become a good disease model for melanoma. In 
addition to the advantages of external embryo fertilisation and high offspring 
numbers, the genomic resources available and the shared tissue, organ and molecular 
pathways with humans allow scientific studies to be carried out in relation to human 
disease. As well as melanoma, other human cancers can be modelled in zebrafish and 
one well established example is liver cancer. The Gong laboratory has been central in 
developing zebrafish liver cancer models and recently showed that these share 
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molecular signatures with human hepatocellular carcinoma (HCC) (Zheng et al., 
2014). Three oncogene transgenic zebrafish lines with inducible expression of xmrk, 
kras or Myc in the liver were generated and each tumour signature showed 
significant correlation with human HCC (Zheng et al., 2014). Together, the three 
models represented almost half (47.2%) of human HCCs, which makes them 
valuable tools for molecular classification of human HCCs and understanding 
molecular drivers of hepatocarcinogenesis of different subtypes (Zheng et al., 2014).  
 
Our understanding of zebrafish genetics has progressed rapidly in the last 10-15 
years. The first vertebrate genome to be sequenced, after the human was a large 
marine fish known as fugu. This was carried out using the whole-genome shotgun 
method and completed in 2002 (Aparicio et al., 2002). In 2001, the Sanger Institute 
began to sequence the zebrafish genome. They initiated the sequencing of the 
Tübingen strain as the reference genome, as this was previously used to identify 
mutations that affected embryogenesis. To carry out the sequencing they used a 
clone-by-clone approach, a similar technique to that used to sequence both the mouse 
and human genomes. The most recent version of the sequenced genome, Zv9, is 
available online. It shows that zebrafish have more than 26,000 protein-coding genes, 
and that interestingly, they have more species-specific genes than any other 
previously sequenced vertebrate (Howe et al., 2013). By comparing zebrafish and 
human protein-coding genes, Howe and colleagues find that more than 70% of 
human genes have at least one zebrafish orthologue and equally, 69% of zebrafish 
genes also have at least one human orthologue (Howe et al., 2013). Access to an 
annotated, fully sequenced zebrafish genome has enabled scientists to make valuable 
discoveries. These include the ‘positional cloning of hundreds of genes from 
mutations affecting embryogenesis, behaviour, physiology, and health and disease’ 
and the ‘generation of accurate whole-exome enrichment reagents, which are 
accelerating both positional cloning projects and new genome-wide mutation 
discovery efforts’ (Howe et al., 2013).  
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The zebrafish genome is now well understood, owing to the high-throughput 
sequencing projects and widely available. Within the zebrafish field there are a range 
of techniques that have been developed to manipulate the genome in an attempt to 
model human disease. Importantly for this project, many techniques have been 
developed to generate zebrafish cancer models, including melanoma. These include 
forward and reverse genetic screens, chemical treatments and transplantation of 
mammalian cells.  
 
Traditionally, forward genetic approaches such as chemical and insertional 
mutagenesis screens have been used to generate zebrafish disease models. This has 
allowed for the identification of a large range of mutants with disruption of 
conserved genes that correlate with human disease loci. Almost two decades ago, the 
Nusslein-Volhard laboratory carried out the first mutagenesis screens in zebrafish 
(Mullins et al., 1994). Since then, screens for almost all phenotypes, including 
cancer, have been carried out. In 2004, Amsterdam and colleagues published a screen 
carried out for embryonic lethality, which by chance identified cancer-related genes. 
They used retroviral insertions to carry out the screen for embryonic lethality but 
noticed that heterozygous founders showed an increased tumour incidence. Eleven of 
the twelve lines with increased tumour incidence carried insertions in ribosomal 
genes, while the other was mutated in one of the two zebrafish homologues of 
neurofibromatosis 2 (nf2), a human tumour suppressor gene (Amsterdam et al., 
2004). This example shows that forward genetic screens are suitable for use in the 
zebrafish and can provide important information that can directly relate to human 
disease and importantly human cancer. Another example is provided by research 
from the Zon laboratory. Here, another zebrafish forward genetic screen was used to 
identify a number of cell proliferation mutants including crb, which represents a loss-
of-function mutation in bmyb, a transcriptional regulator and part of a putative proto-
oncogene family (Shepard et al., 2005). The crb heterozygous mutants have 
increased cancer susceptibility, demonstrating that loss of function of bmyb can be 
associated with cancer and that similar zebrafish screens are useful in uncovering 
cancer pathways (Shepard et al., 2005). 
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Reverse genetic approaches, including morpholino and mRNA injection have also 
resulted in the development of zebrafish disease models. These are both techniques 
used to either transiently knock down or overexpress a disease gene. In order to 
create a stable zebrafish mutant, a technique called target-selected mutagenesis or 
TILLING can be used. This technique, first described in 2000 for mutation detection 
in Arabidopsis (McCallum et al., 2000) combines standard ENU mutagenesis with 
gene targeting. The TILLING method involves the formation of DNA 
heteroduplexes during PCR amplification and the subsequent separation of these 
DNA strands by size using techniques such as high-performance liquid 
chromatography (HPLC). Targeted-selected mutagenesis was first used in the 
zebrafish system in 2004 (Wienholds and Plasterk, 2004) and since then several 
zebrafish mutants, including those for known human tumour suppressors have been 
generated. An example of the use of reverse genetics in the zebrafish to create a 
tumour model is that of tp53, one of the most frequently mutated genes in human 
cancer. The tp53M214K zebrafish mutant contains a missense mutation in the DNA-
binding domain of the gene and 28% of mutants develop tumours by 14 months of 
age (Berghmans et al., 2005). All but one of these tumours were shown to be 
malignant peripheral nerve sheath tumours (MPNSTs), the other was found to be a 
melanoma.  The tp53M214K zebrafish mutant is a good example of how reverse genetic 
techniques can be used to study human disease in this model organism.  
 
The forward and reverse genetic techniques described showcase the ability to 
manipulate the zebrafish genome and model human disease. As well as this, the now 
fully sequenced zebrafish genome also allows high-throughput sequencing projects 
of zebrafish tissues, including cancers and those from phenotypic mutants to be 
carried out (Howe et al., 2013). The mapping of sequencing reads, from 
transcriptome, exome or whole genome to an annotated reference genome allows the 
detection of mutations and other variants. As the human and zebrafish genomes show 
a high degree of conservation, relationships between genes and pathways identified 
in the zebrafish can be translated to a human context. During this project, the latest 
version of the zebrafish genome, Zv9 (Howe et al., 2013) has enabled high 
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confidence mapping of RNA-seq reads and the sequential analysis of the 
transcriptome data by bioinformatics. For this reason, the comprehensive genetics 
that are known today and our ability to utilise these makes the zebrafish an ideal 
animal model to work with as an aid to understand human disease.  
 
Similar to the high conservation between the human and zebrafish genomes 
identified through sequencing projects, the tissues, organs and molecular pathways of 
these two organisms are found to share many characteristics (Zon, 1999). This, in 
addition to the genetics is another advantage of the zebrafish as a model organism for 
which to study human disease. 
  
Importantly for this project, melanocytes are found in both humans and zebrafish and 
perform similar functions. In humans, melanocytes are the pigment-producing cells 
that colour the hair, skin and eyes and play an important role in protecting the skin 
from the harmful effects of UV radiation. When they are stimulated by UV radiation, 
human melanocytes produce melanin that is then distributed to surrounding 
epidermal cells as a form of protection. In zebrafish, melanocytes are one of three 
pigment cell types that pigment the body and make up their characteristic stripe 
pattern. Zebrafish melanocyte development is highly conserved with other 
vertebrates, including humans and therefore our understanding of human 
melanocytes can be improved by studying this cell type in the zebrafish. The main 
difference between human and zebrafish melanocytes is that unlike humans, 
zebrafish do not distribute melanin from their cells, but rather move it around within 
melanocytes during background adaptation. Distinguishing melanocytes that cluster 
to form nevi and those that have progressed to melanoma can be carried out by 
observation (Figure 1.3). Nevi are simple clusters of melanocytes that lie within the 
epidermal layer but do not have the capacity to protrude either through this or the 
underlying dermal layer and tissues (Figure 1.3A,B). Tumours are made up of 
densely packed melanoma cells (black) that can be seen forming nodules and 
invading underlying tissues (Figure 1.3C).  
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1.4 Melanoma cancer gene discovery 
 
Our understanding of zebrafish genetics has improved greatly due to high-throughput 
sequencing projects such as those carried out at the Sanger Institute, Hinxton by 
Howe and colleagues (2013). These and other projects have been key to further 
identification of important genes and biological pathways involved in melanoma and 
this in turn has led to the development of better therapeutic strategies for melanoma 
patients.  
 
Melanoma is a complex disease influenced by many genetic and environmental 
factors and it has therefore been a challenge to understand its development and 
improve therapeutics. The classical melanoma genes known are BRAF, NRAS and 
those coded by the CDKNA2 locus, p14 and p16. The mutational burden of 
commonly altered genes BRAF and RAS is responsible for approximately 70% of 
melanoma progression. Over the last 10 years, our understanding of the roles of these 
classical genes, as well as the discovery of novel genes that contribute to melanoma 
development has been greatly improved using new techniques in DNA sequencing.  
 
In 2007, Greenman and colleagues described one of the first projects using deep-
sequencing methods on a large scale covering the whole genome. In this study 210 
human cancers, including melanomas were sequenced and the results found over 
1000 somatic mutations in 274Mb of DNA corresponding to the coding exons of 
over 500 protein kinase genes (Greenman et al., 2007). An average of 18.54 
mutations/Mb were found in melanoma cell lines and of these more than 90% (of a 
total of 144) were shown to be C to T transitions, which is a typical UV signature 
(Greenman et al., 2007). 
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In parallel to the Greenman study, Pleasance and colleagues (2010) provided the first 
comprehensive catalogue of somatic mutations from an individual cancer, using the 
whole genome of a melanoma cell line and lymphoblastoid cell line from the same 
patient. They identified over 33,000 somatic mutations including 292 somatic base 
substitutions in protein-coding sequences, of which 187 were non-synonymous 
mutations leading to amino acid changes (Pleasance et al., 2010). Similar to the 
Greenman study (2007), about 75% of the total number of mutations were found to 
be C to T mutations, again indicating their association with UV exposure. The group 
also noticed that there was an ‘uneven distribution of mutations across the genome, 
with a lower prevalence in gene footprints’ (Pleasance et al., 2010), suggesting that 
the DNA repair mechanisms were used preferentially in transcribed regions. In 
conjunction with the results from Greenman and colleagues (2007), this study 
highlights the power of the cancer genome sequence in our understanding of the 
processes of cancer development.  
 
More recently, Berger and colleagues (2012) advanced the use of sequencing 
technologies to understand cancer genome signatures by using metastatic melanoma 
samples and tumours from different areas of body mass.  In agreement with both 
Greenman (2007) and Pleasance (2010), this study found an elevated mutational rate 
and a UV-associated signature in melanomas. Analysis of melanomas from different 
areas of the body, including acral and trunk, also provided information on differences 
in mutational rate and C to T substitution number between melanoma subtypes. One 
of the most interesting findings from the whole-genome sequence data was the 
identification of PREX2 as a new, recurrently mutated gene in melanoma (Berger et 
al., 2012). PREX2 mutations were found at a frequency of 14% (15/107) in non-
synonymous mutations and functional analysis of these mutations showed that 
overexpression of PREX2 accelerates tumourigenicity (Berger et al., 2012). This 
suggests that some melanoma cells could gain oncogenic activity through PREX2 
mutations and that it could be a novel therapeutic target.  
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As well as whole genome sequencing described by the Greenman, Pleasance and 
Berger studies, exome sequencing has also been beneficial in identifying novel genes 
involved in melanoma development. One study by Nikolauv and colleagues in 2011 
carried out exome sequencing of seven melanoma cell lines with donor-matched 
germline cells and, like the whole genome sequencing studies described previously, 
showed that all samples had a high number of somatic mutations and showed a 
hallmark of UV-induced DNA repair (Nikolauv et al., 2011). The study also 
identified recurrent somatic MAP2K1 and MAP2K2 (MEK1 and MEK2 respectively) 
mutations in the melanoma samples and new potentially candidate genes FAT1, 
LRP1B and DSC1 (Nikolauv et al., 2011). A separate exome-sequencing project in 
2011 by Stark and colleagues used eight metastatic melanoma samples and found 
new somatic mutations in MAP3K5 and MAP3K9, both members of the MAPK 
pathway. Both mutations resulted in a decrease in the kinase activity of the proteins 
as well as a reduction in the level of phosphorylated MEK-ERK and JNK, which are 
both pathways involved in apoptosis, differentiation, survival and senescence (Stark 
et al., 2011). A third exome-sequencing project carried out by Krauthammer and 
colleagues (2012) used a much higher sample size, a total of 147 melanomas, and 
were able to identify new cancer genes including PPP6C and a recurrent UV-
signature in the RAC1 gene. An activating mutation in RAC1 was identified in 9.2% 
of sun-exposed melanomas and through functional studies they were able to show 
that this alteration promoted melanocyte proliferation and migration (Krauthammer 
et al., 2012). RAC1 had previously been shown to play an important role in 
melanoblast migration, cytokinesis and cell cycle progression during normal 
development (Li et al., 2011), which are suggestive of its role within melanoma.  
 
Although both whole genome and exome sequencing efforts have identified many 
mutations in melanoma, most of these can be categorised as ‘passenger’ mutations, 
those that do not contribute to cancer development but have occurred during its 
growth phase. The challenge proposed therefore was to be able to distinguish this 
type of mutations from ‘driver’ mutations, those that push cells towards cancer and 
are critical for its development. In 2012, Hodis and colleagues presented data that 
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could overcome this problem by sequencing both the exons and introns of melanoma 
samples and comparing their frequency to identify positively selected genes. They 
were able to identify six novel melanoma genes, PPP6C, RAC1, SNX31, TACC1, 
STK19 and ARID2, as well as provide an insight into BRAF and NRAS-driven 



























The motivation for this body of work lies in the statistics of increasing melanoma 
incidence, particularly in young females in the UK, and the deficit of successful drug 
treatments currently available for these patients. With most of the basic scientific 
research and therapeutic developments presently focused on BRAF and other MAPK 
pathway inhibition strategies, I felt it was essential to broaden our understanding of 
other important genes and pathways that play key roles in melanomagenesis. 
Through research and improved understanding of genes such as MITF, it is hoped 
that novel or combination therapeutics will be developed and lead to more successful 
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Chapter 2: MITF is a cancer gene 
 
In this first results chapter, I describe the genetics that I have used to identify MITF 
as a cooperating mutation with BRAFV600E in zebrafish to drive melanomagenesis. I 
will introduce the role of MITF in development, human disease and cancer and then 
outline the importance of the BRAFV600E mitfavc7 zebrafish as an in vivo cancer model. 
 
With the BRAFV600Ep53M214K mutant already established as a melanoma model 
(Patton et al., 2005), I (in collaboration with J.A. Lister) describe how BRAFV600E 
cooperates with a mutation in mitf (Johnson et al., 2011) to promote melanoma. I 
also describe a new model of melanoma that is independent of a BRAF mutation, in 



















2.1.1 The role of MITF in development 
 
Named the ‘master’ melanocyte regulator, MITF is one of the key transcription 
factors in regulating melanocyte development and is essential for melanocyte cell 
survival (McGill et al., 2002; Levy et al., 2006; Arnheiter, H., 2010). The gene is 
encoded by the microphthalmia locus and expressed in developing neural crest-
derived melanocyte precursors and the neuroepithelium-derived retinal pigmented 
epithelium (RPE). With multiple target genes and an essential role in melanocyte 
development and cell survival, MITF is also important in cellular processes including 
proliferation, differentiation and cell cycle progression.  
 
In a comprehensive review by Steingrímsson and colleagues (2004), the authors 
describe four key experiments that highlight the importance of MITF as a 
determinant of melanocyte development. In the first experiment, Tachibana and 
colleagues showed that by ectopically expressing MITF they were able to transform 
fibroblasts into cells with characteristics of melanocytes (Tachibana et al., 1996). 
The transformed cells were dendritic and expressed melanocyte-specific marker 
genes including tyrosinase and tyrosinase-related protein 1, which indicated that 
MITF is involved in melanocyte differentiation (Tachibana et al., 1996). In the 
second experiment, Planque and colleagues investigated the role of Mitf in cell 
proliferation and pigmentation by transfecting mouse Mitf cDNA into chicken 
neuroretinal cells (Planque et al., 1999). They showed that the transfected cells 
quickly became pigmented and expressed QNR-71 mRNA, which encodes a 
melanosomal protein, both of which indicated that Mitf could transdifferentiate 
neural cells into pigment cells (Planque et al., 1999). In the third experiment, Lister 
and colleagues identified a new mutation in the zebrafish neural crest that affected 
pigment cell fate (Lister et al., 1999). Nacre zebrafish mutants carry a mutation in 
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the zebrafish mitf gene and are unable to develop melanophores, however this 
pigmentation phenotype can be rescued by injecting wild-type mitf into early-stage 
embryos (Lister et al., 1999). In the last set of experiments, Béjar and colleagues 
showed that mitf expression is sufficient for the ‘differentiation of medaka 
pluripotent stem cells into melanocytes’ (Béjar et al., 2003). By expressing mitf in 
medaka ES-like cells, they induced fully differentiated pigment cells (Béjar et al., 
2003). Together, these four experiments using four different species – human, 
chicken, zebrafish and medaka – suggest that Mitf functions as the master regulator 
of melanocyte development in vertebrates and is a determinant of melanocyte 
differentiation (Steingrímsson et al., 2004).  
 
In addition to these four species, the mouse model has also played an important part 
in understanding the role of Mitf in melanocyte development. Melanocyte precursors 
arise from neural crest progenitor cells (NCPCs) and are dependent on Mitf for their 
survival and migration from the neural tube (Hornyak et al., 2001). The maintenance 
of melanocyte stem cells (MSC), a self-renewing population of melanocytes found in 
the bulge region of hair follicles in the mouse (Nishimura et al., 2002), is also 
dependent on MITF activity. In an Mitf mouse mutant, loss of MITF causes a 
premature loss of MSCs and results in premature hair greying (Nishimura et al., 
2005). The maintenance of these MSCs by MITF prevents physiological hair 
greying, which is part of the aging process developed through loss of the 
differentiated progeny (Nishimura et al., 2005). 
 
During development and throughout adulthood, the expression of Mitf is highly 
regulated. Its expression is first observed in 22-somite-stage embryos within the 
optic vesicle of the developing eye (Nguyen and Arnheiter, 2000). Later, its 
expression is limited to the RPE, before being expressed in cells with neural crest 
characteristics, firstly in the head and later towards the tail region (Nakayama et al., 
1998). These mitf-positive cells were presumed to be neural crest-derived 
melanoblasts as their location, expression markers and number all fit with this 
description (Steingrímsson et al., 2004). As well as embryos, Mitf expression has 
been explored in adult tissues from both mouse and human. In adults, as well as in 
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melanocytes and melanoma cells, MITF protein is expressed in osteoclasts 
(Weilbaecher et al., 1998) and mast cells (King et al., 2002). Although mutations in 
Mitf have been identified in all four of these mitf-positive cell types, none have been 
found in mouse heart or skeletal muscle, although Mitf expression has also been 
shown to be present in these tissues (Hodgkinson et al., 1993).  
 
Mitf mouse mutants display a range of distinctive defects including loss of 
pigmentation leading to a white phenotype, reduced eye size compared to wild-type, 
early onset deafness, failure of secondary bone resorption and a reduced number of 
mast cells (Hodgkinson et al., 1993). MITF (and its human counterpart) is a structure 
containing a basic helix-loop-helix-leucine zipper (bHLH-LZ) that is essential for 
DNA binding and dimerization. It consists of 419 amino acids and shares more than 
90% identity with human MITF (Tachibana et al., 1994). MITF consists of at least 
nine isoforms that differ in their amino termini including MITF-A, MITF-B, MITF-
C, MITF-H and MITF-M (Amae et al., 1998). The Mitf gene itself consists of at least 
four promoters, their consecutive first exons (1A, 1H, 1B and 1M) and eight 
downstream exons that are common to all isoforms (Udono et al., 2000). The 
different promoters generate transcriptional diversity while the different isoforms 
themselves provide functional diversity (Shibahara et al., 2001).  
 
The zebrafish has two mitf genes, namely mitfa and mitfb, which occur as a result of 
a gene duplication event. mitfa is essential for the development and specification of 
all neural-crest derived melanocytes, while mitfb is responsible for development of 
melanocytes in the retinal pigment epithelium (RPE) (Lister et al., 2001). mitfa was 
the first mitf gene to be identified in zebrafish and shares the most similarity with the 
mouse neural crest-specific Mitf-M isoform. mitfb shares greater similarity to Mitf 
isoforms present in the mouse RPE, especially in the amino terminal region (Lister et 
al., 2001). Conservation between both Mitf gene structure and function in humans, 
mice and zebrafish has been shown ((Steingrímsson et al., 2004) with mutations 
affecting the development of neural crest-derived pigment cells and those in the RPE 
of the eye.  
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2.1.2 MITF mutations in human disease 
 
In humans, there is a single MITF gene located at chromosome 3p14.1, 
encompassing 229kb and 9 exons. There are 9 isoforms (A, B, C, D, E, H, J, M and 
MC) each of which has its’ own 5’ specificity and have exons 2-9 in common. Exon 
1, in which the transactivation domain (TAD) and basic helix-loop-helix-leucine 
zipper (bHLH-LZ) are found, varies between isoforms. Some isoforms are cell type-
specific, such as MITF-M and –MC, which are only found in melanocytes and mast 
cells respectively (Steingrímsson et al., 2004). 
 
In 1994, Tassabeliji and colleagues identified mutations in MITF that caused 
Waardenburg Syndrome type 2 (WS2), an autosomal dominant inherited condition 
that causes hearing loss and abnormal pigmentation of the eyes, hair and skin. Prior 
to this identification, the mouse microphthalmia mutant was suggested as a possible 
candidate homologue of some forms of WS, as all mi mutant mice have no or 
reduced pigmentation in their eyes and coat, as well as a no or small eye phenotype 
(Asher and Friedman, 1990). By screening WS2 patients for mutations in MITF, 
Tassabeliji and colleagues identified mutations in two WS2 families that affected the 
splice sites of MITF (Tassabeliji et al., 1994).   
 
Tietz syndrome patients, similar to those with WS2, suffer from profound deafness 
and generalised hypopigmentation (Tietz, 1963). In 2000, Smith and colleagues re-
ascertained the original family reported with these features described by Tietz 
(1963). From these family members with Tietz syndrome, Smith identified a 
missense mutation in the basic region of the MITF gene (Smith et al., 2000). Amiel 
and colleagues also found this mutation in another family of Tietz syndrome (Amiel 
et al., 1998).  
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Interestingly, in vitro studies show that the mutant mitf protein predicted by the Tietz 
syndrome mutation has a dominant-negative effect, whereas the proteins predicted 
for the mutations in WS2 do not (Nobukuni et al., 1996; Tachibana, 1997) As both 
conditions are autosomal dominant, the symptoms of each occur in patients that are 
heterozygous, with one copy of the wild-type gene and one copy carrying the 
mutation. In Tietz syndrome, the mutant mitf protein is thought to interfere with the 
normal mitf protein causing a depletion of mitf function and a failure in the 
development of melanocytes (Tachibana, 2000). In contrast, the mutant mitf protein 
in WS2 patients does not have a dominant-negative effect and so although the mitf 
protein is present, its level is not sufficient to allow the full development of 
melanocytes (Nobukuni et al., 1996; Tachibana, 1997). The variation in levels of 
functioning mitf protein in WS2 patients explains the variation in the severity of 
symptoms observed in the patients (Tachibana, 2000). 
 
As MITF has been shown to play a multifaceted role in supporting differentiation, 
proliferation and cell death of normal melanocytes (White and Zon, 2008) this 
suggests that changes in MITF signalling could support melanoma formation. In 
addition to the amplification of MITF in 10-20% of melanoma cases (Garraway et 
al., 2005) in 2009, Cronin and colleagues identified somatic MITF mutations in 
metastatic melanoma cell lines. By sequencing 13 MITF exons that encompass the 
full coding sequences of all MITF isoforms and comparing tumour to patient-
matched normal DNA, they found six changes including four non-synonymous point 
mutations and one splice-site alteration (Cronin et al., 2009). These mutations, 
shown in Figure 2.1, were located in the regions encoding the transactivation, DNA 
binding or basic-helix-loop helix domains, and interestingly, were found to occur in a 
mutually exclusive pattern to MITF amplifications. More recently, a SUMOylation 
MITF mutation (MITFE318K) that associated with melanomagenesis was identified by 
two separate studies (Yokoyama et al., 2011; Bertolotto et al., 2011) and shown to 
affect the activation domain of MITF (Figure 2.1). In total, seven MITF mutations 
have been identified in melanoma cell lines or patient samples and it is estimated that 
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20% of metastatic melanoma cases have alterations in the MITF pathway, through 
MITF itself or its downstream targets (Cronin et al., 2009).  
 
Recently, a study of 24 human MITF mutations in WS2, TS and melanoma patients 
has revealed how mutations in a single gene, MITF, can lead to such great variation 
in disease phenotype (Grill et al., 2013). In a graphical representation of the human 
MITF protein, Figure 2.1 shows the locations of these mutations causing both 
melanoma (red) and WS2 or TS (blue) in patients. The research in this paper 
characterised the DNA-binding and transcription activation properties of different 
MITF mutations found in these two pigment deficiency syndromes and melanoma. 
Eleven of 18 WS2 and TS mutations were found within the bHLH-LZ domains of 
MITF where they fail to bind DNA and are unable to activate melanocyte-specific 
promoters (Grill et al., 2013). The remaining seven mutations had normal or reduced 
DNA-binding and transcription activity. In contrast, MITF mutations in melanoma 
were found in the amino- and carboxyl domains of MITF where they were able to 
bind DNA at a level similar to wild-type MITF. These mutations affect the 
transactivation potential of MITF however and hence it was concluded that the 
structural location of these MITF mutations identified in melanoma plays an 
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2.1.3 The role of MITF in cancer 
 
Since 1999, anti-MITF antibodies have been used as sensitive and specific markers 
for malignant melanoma histologic specimens (King et al., 1999) suggesting that 
MITF could play an oncogenic role in melanoma. In the first study by King and 
colleagues, 100% (76/76) of human melanomas stained positively for MITF in the 
nucleus, in some cases where the most commonly used markers of melanoma, HMB-
45 and S-100, had failed (King et al., 1999). Human melanoma black (HMB)-45 is a 
monoclonal antibody that recognises melanosomal glycoprotein gp100 (Pmel17) 
(Gown et al., 1986), whereas S-100 is an acidic protein. Although both have 
previously been shown to be markers of melanoma, other more specific markers have 
been superior in diagnosis of melanoma micrometastases (Shidham et al., 2001). In 
the study by King and colleagues using non-melanoma samples, no nuclear staining 
of MITF was observed (0/60) although 2 (2/60) samples showed cytoplasmic 
staining (King et al., 1999). The two samples with positive MITF cytoplasmic 
staining were derived from breast cancer specimens. As MITF is normally expressed 
in both osteoclasts and mast cells and many breast cancers are known to express 
genes involved in bone resorption, it was suggested that the expression of MITF may 
play a role in bone metastasis of breast cancer and be a predictor of osteotrophic 
tumours (King et al., 1999). In a second study by Dorvault and colleagues (2001), 81 
cell blocks from patients with both melanoma and non-melanoma tumours were 
immunostained with a monoclonal antibody against mitf (D5). They found that 100% 
of melanomas (44/44) stained positively for MITF and only one (1/37) non-
melanoma malignancy showed mitf staining, which was rare (<10%) and weak 
(Dorvault et al., 2001). In contrast to the 100% sensitivity staining of malignant 
melanomas with MITF, staining with two current standard melanoma markers, 
HMB-45 antigen and S-100 protein was not as specific (Dorvault et al., 2001).  In a 
third study, Sheffield and colleagues used the same anti-MITF antibody to stain 72 
melanoma and non-melanoma malignant neoplasms, alongside antibodies S-100, 
HMB-45, Melan-A and tyrosinase (Sheffield et al., 2002). Similar to Dorvault and 
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colleagues (2001), they found that MITF stained 100% (40/40) of melanomas and 
only one non-melanocytic tumour. In addition, they used a combination of anti-MITF 
and anti-Melan-A staining to show that this was the most sensitive and specific tool, 
with 100% of melanomas and no non-melanocytic tumours stained using this method 
(Sheffield et al., 2002). Taken together, the results from King, Dorvault and 
Sheffield confirm that MITF is a sensitive and specific marker for malignant 
melanoma in histologic sections and superior to the current markers used for 
diagnosis (King et al., 1999; Dorvault et al., 2001; Sheffield et al., 2002). 
 
In 2005, Garraway and colleagues used high-density SNP arrays to investigate 
chromosomal alterations in human cancer cell lines and their results reinforced an 
oncogenic role for MITF in human melanoma. They combined SNP array-based 
genetic maps and gene expression signatures to identify MITF as the target of a novel 
melanoma amplification. They identified six out of eight melanoma cell lines from 
the NCI60 tumour cell lines containing a region of amplification on chromosome 3p 
and MITF was the only highly expressed gene to be found within this amplified 
region (Garraway et al., 2005). They also examined human tumours and found that 
while no benign moles harboured this amplification, 10% of primary melanomas and 
21% of metastatic melanomas did, indicating an association between MITF 
amplification and the ability to metastasise. In metastatic melanomas, the 
amplification was associated with a decreased 5-year survival, implicating an 
association between the amplification and lethality. The identification of the genomic 
amplification of MITF also suggested that the melanocyte lineage dependency on 
MITF might be maintained in melanoma cells. Garraway and colleagues tested this 
theory by introducing an adenovirus that expressed a dominant-negative MITF 
mutant (Ad-dnMITF) into NCI60 melanoma cell lines with varying levels of MITF 
amplification. They found that the Ad-dnMITF, as well as a knockdown of MITF 
using short hairpin (sh) RNAs resulted in growth inhibition of the melanoma cells. 
This suggests that deregulation of MITF through amplification or other mechanisms 
may preserve a critical lineage survival function in melanoma (Garraway et al., 
2005). 
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As Garraway and colleagues discovered the MITF oncogenic amplification in human 
melanomas, also in 2005 Wellbrock and Marais confirmed interplay between MITF 
and BRAF (Wellbrock and Marais, 2005). They showed that in melanocytes, MITF 
expression is suppressed by oncogenic BRAF and if re-expressed in BRAF-
transformed melanocytes, proliferation is inhibited. In melanoma cells, they showed 
that low levels of MITF were present with oncogenic BRAF, but that if MITF 
expression is increased by differentiation-inducing factors, proliferation is inhibited. 
Together, the data suggested that the down-regulation of MITF by BRAF signalling 
is crucial for progression of oncogenic BRAF melanomas and that MITF may play 
an anti-proliferative role in melanoma (Wellbrock and Marais, 2005).  
 
The study by Garraway and colleagues that identified a novel amplification of MITF 
in between 10-20% of human melanomas, suggesting that MITF could act as a 
dominant oncogene, is in contrast to data from both Carreira (2005) and Loercher 
(2005). Their data shows that MITF regulation of p21, a cell cycle gene, and 
mutations of melanoma-associated genes that would lower the transcriptional activity 
of MITF could remove its control of the cell cycle (Carreira et al., 2005; Loercher et 
al., 2005). An explanation for these contrasting results came from Hoek and 
colleagues (2006), whose data provided a model for the metastatic potential of 
melanomas that is defined by a specific gene expression profile (Hoek et al., 2006).  
This study carried out three separate microarray analyses on 86 cultures of 
melanoma. In contrast to previous studies, which identified correlations between 
gene expression and activating mutations in BRAF or NRAS, Hoek and colleagues 
showed through multiple testing correction that there was no relationship between 
gene expression pattern and a mutation in these two MAPK pathway genes. Instead, 
they were able to identify three distinct sample groups that represented differing 
degrees of melanoma metastatic potential and were regulated by changes in Wnt and 
TGF-β signalling (Hoek et al., 2006). Their gene regulation model for melanoma 
metastatic potential describes two different phenotypes driven by different signalling 
pathways and defined by individual patterns of gene regulation. The first are highly 
proliferative cells with weak metastatic potential, which maintain a neural crest-like 
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signature through Wnt signalling. The second are weakly proliferative cells with high 
metastatic potential that are driven by TGF-β signalling, which activates a positive 
feedback loop, changes the extracellular environment and inhibits Wnt signalling. 
With respect to MITF, this model describes how low levels of MITF drive an 
invasive and more metastatic phenotype, while high levels of MITF drive a more 
proliferative but less metastatic phenotype (Hoek et al., 2006). As melanoma cells 
are known to be a heterogeneous population (Fidler, 1978) driven by environmental 
factors (Postovit et al., 2006), the rheostat model also predicts that levels of MITF 
could drive phenotypic switching between the different states, as described by Hoek 
and Goding (2010).  
 
As the evidence presented so far implicated a central role for MITF in melanoma 
progression and somatic mutations are relevant to the progression of cancer, in 2009 
Cronin and colleagues sequenced melanoma tumour DNA to assess whether MITF 
was somatically mutated in melanoma (Cronin et al., 2009). They compared 
sequences of MITF from primary and metastatic melanomas to patient-matched 
normal DNA. Out of 50 metastatic melanoma tumour lines, they identified 4 with 
genomic amplifications of MITF and 4 with MITF mutations in regions encoding 
transactivation, DNA binding and basic, helix-loop-helix domains (8/50, 16%) 
(Cronin et al., 2009). As they had found MITF mutations in the 50 samples analysed, 
they hypothesised that other MITF pathway genes may also be altered in the 
melanoma samples. One of these genes, SOX10, is a transcription factor found 
upstream of MITF and is known to synergise with MITF in transactivation of DCT 
and TYR. Cronin and colleagues found three mutations in SOX10 in the same 50 
metastatic samples, but showed that MITF and SOX10 were mutated in a mutually 
exclusive fashion, confirming disruption of a common genetic pathway (Cronin et 
al., 2009). As well as metastatic tumours, they also evaluated whether somatic 
mutations in MITF and SOX10 were present in primary melanoma samples. They 
identified 2 MITF mutations in 26 primary samples (7.7%) and 6 SOX10 mutations 
in 5 of 55 primary samples (9%), none of which were observed in a control panel of 
lymphocyte DNA, suggesting that these mutations arose somatically. None of the 
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primary lesions contained amplifications, hinting that MITF amplification may only 
occur in the later stages of melanoma development. Overall, the study successfully 
identified both non-synonymous mutations and amplifications with frequencies of 
13.2% in MITF and 8.6% in SOX10 in primary and metastatic melanomas, 
emphasising the involvement of the MITF signalling pathway in melanomagenesis 
(Cronin et al., 2009).  
 
As described, MITF is amplified in some melanomas and its ectopic expression has 
been shown to cooperate with BRAFV600E to transform both human melanocytes and 
neural crest cells (Garraway et al., 2005, Kumar et al., 2013). Recently, Kumar and 
colleagues showed that MITF cooperates with BRAFV600E to increase the proliferative 
capacity of human neural crest progenitor cells (hNCPCs) and that overexpression of 
MITF in these cells increases tumorigenicity, resulting in fully transformed tumour 
cells (Kumar et al., 2013). 
 
Although the identification of amplifications and somatic mutations of MITF in 
human melanoma samples provided good evidence that the MITF signalling pathway 
played an important role in melanomagenesis, as yet very few mutations have been 
linked to familial melanoma. The two most established, but rare, high-penetrance 
genes for melanoma are CDKN2A and CDK4 (Hussussian et al., 1994; Liu et al., 
1995; Zuo et al., 1996). Since the discovery of these two high-risk alleles, only other 
more common, moderate- or low-penetrant genes have been associated with 
melanoma. At the end of 2011 however, two papers were published simultaneously 
that showed the discovery of an MITF mutation in melanoma patients (Bertolotto et 
al., 2011, Yokoyama et al., 2011). The identified germline SUMOylation E318K 
mutation is a melanoma risk factor and confers differential gene expression of MITF 
target genes. Patients carrying the mutation have a five-fold increased risk of 
developing melanoma, as well as an increased risk of developing renal cell 
carcinoma (RCC) (Bertolotto et al., 2011). The mutation identified occurs in a small-
ubiquitin-like modifier (SUMO) consensus site and impairs the ability of MITF to be 
SUMOylated (Bertolotto et al., 2011). SUMOylation is a post-translational 
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modification that determines transcriptional activity and stability. The E318K 
mutation of MITF enhances its protein binding ability to the HIF1A promoter and in 
turn increases its transcriptional activity compared to wild type controls. The mutant 
MITF protein enhances melanocyte and renal cell clonagenicity, migration and 
invasion, which is consistent with a gain-of-function role for MITF in both 
melanoma and RCC. Two studies using different populations, from Italy and 
Queensland, Australia, also identified carriers of the E318K mutation of MITF 
(Ghiorzo et al., 2013; Sturm et al., 2014) and support the finding that MITF is a 
medium-penetrance melanoma gene.  
 
Despite our improved understanding of melanoma genetics in recent years, one 
outstanding problem in the field is the identification of novel driver mutations, owing 
to the high number of passenger mutations, which are caused by UV exposure. To 
address this problem, Hodis and colleagues analysed whole exome sequencing data 
from over 120 melanoma tumour and normal pairs and used an approach that ‘infers 
positive selection at each gene locus based on exon/intron mutational distributions, 
as well as the predicted functional impact of each mutation’ (Hodis et al., 2012). This 
allowed them to ‘control for passenger mutational load on a per gene basis’ and in 
doing so they were able to identify six new melanoma genes, three of which 
harboured functional, potentially targetable mutations, as well as driver mutations 
that were directly attributable to UV exposure (Hodis et al., 2012). The study also 
included an analysis of somatic copy number aberration profiles, allowing them to 
confirm expected melanoma alteration including gains of MITF.  
 
The importance of MITF and its role in the melanocyte lineage during melanoma 
MAPK pathway inhibitor resistance was recently highlighted. Although RAF and 
MEK inhibitors have shown clinical efficacy in BRAFV600E mutant melanomas 
(Flaherty et al., 2012), resistance to these agents still poses a challenge. Johannessen 
and colleagues discovered that a cyclic-AMP-dependent melanocytic signalling 
network was associated with this drug resistance and was also conferred through 
expression of downstream transcription factors of both the MAPK and cAMP 
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pathways, including MITF (Johannessen et al., 2013). Using a combination of 
MAPK and histone-deacetylase (HDAC) inhibitors (the latter of which impairs MITF 
expression) they could suppress both MITF expression and cAMP-mediated 
resistance. Their results ‘support a model in which aberrant signalling from 
melanocyte lineage pathways may converge on MITF or other transcription factors to 
drive resistance to MAPK pathway inhibitors’ (Johannessen et al., 2013). This 
suggests that the addition of HDAC inhibitors in combination with RAF-MEK 
inhibition may be a novel therapeutic strategy to successfully control the growth of 
some BRAFV600E melanomas and overcome resistance.  
 
In relation to my research, an important study was carried out in 2011 showing that 
MITF is required to coordinate differentiation with cell cycle arrest (Taylor et al., 
2011). Using a transgenic zebrafish mitf model, they identified a subpopulation of 
differentiated melanocytes that arose through cell division. These were separate from 
those that are derived from undifferentiated precursor cells, the primary mechanism 
that results in the adult melanocyte population of developing adults (Parichy, 2003; 
Yang and Johnson, 2006). Although MITF is known to control both differentiation 
and cell cycle progression in melanocytes (Levy and Fisher, 2011), the effect of 
MITF levels in differentiated cells had not been studied in an animal model as MITF 
first affects specification and survival. Taylor and colleagues found, using the 
temperature-sensitive mitfavc7 model, that mitfa hypomorphic melanocytes underwent 
serial differentiated cell divisions (Taylor et al., 2011). In other experiments using 
the mitfavc7 model, they were able to show that the human melanoma MITF4TΔ2B 
mutation (Cronin et al., 2009) could stimulate cell division and differentiation in 
melanocytes. This result ‘underscores the importance of MITF anti-proliferative 
activity in vivo’ (Taylor et al., 2011). 
 
The temperature-sensitive mitfavc7 zebrafish model utilised by Taylor and colleagues 
(2011) and described above was successfully used throughout my research as a tool 
to manipulate mitf activity and further our understanding of the role of mitf in 
melanomagenesis. The mitfavc7 allele is a ‘mutation in a splice donor site that reduces 
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the level of correctly-spliced transcripts’ and was first identified through an ENU-
mutagenesis screen (Johnson et al., 2011). The vc7 mutation is found in the intron 6 
splice donor site and results in various alternative transcripts, all with a preserved 
reading frame (Figure 2.2). The predominant transcript is a product that extends 
through intron 6 to exon 7, introducing 39 amino acids within the basic region 
(Figure 2.2B). Two minor transcripts are also produced as a result of the vc7 
mutation – one correctly spliced and of the correct size, suggesting that the mutation 
does not completely abrogate splicing, and one that skips exon 6 and leaves a 
truncated basic region (Figure 2.2B) (Johnson et al., 2011). These alternative spliced 
transcripts are not functionally active and therefore allow regulation of MITF activity 
to study its role in vivo.  
 
 



























2.2.1 BRAFV600E cooperating mutations drive melanomagenesis 
 
BRAFV600E cooperates with p53 to induce melanoma in zebrafish 
 
In 2005, Patton and colleagues described the role of BRAF in nevi and melanoma in 
the zebrafish. They generated a transgenic zebrafish that expressed the most common 
BRAF mutation, V600E, under the control of the melanocyte mitfa promoter (Patton 
et al., 2005).  Expression of this mutant, in contrast to wild-type (Figure 2.3A), led to 
a cloak-like clustering of melanocytes on the surface of the skin, which obscures the 
stripe patterning (Figure 2.3B). When mitfa-BRAFV600E was injected into zebrafish 
embryos harbouring a homozygous missense mutation in exon 7 of the zp53 gene 
(zp53M214K) the activated BRAF induced melanocytic lesions that progressed to 
invasive tumours and closely resembled human melanomas (Patton et al., 2005). The 
key result from this significant paper was that BRAF activation is sufficient for nevi 
formation, but that a cooperating mutation, for example in p53, is required to induce 
melanoma (Patton et al., 2005). I replicated this experiment by crossing BRAFV600E 
homozygote mutants to p53M214K homozygote mutants to give BRAFV600E/+p53M214K/+ 
transgenic zebrafish. This generation of heterozygous zebrafish mutants were then 
incrossed to create double homozygote BRAFV600E/V600E p53M214K/M214K transgenic 
zebrafish (Figure 2.3C). These fish are grown at a stable temperature of 28°C in the 
aquatic system and develop nevi and melanoma.  
 
Although mutations and deletions of TP53 are found in approximately 50% of 
human cancers, they are less common in melanomas (0-10%) (Box and Terzian, 
2008). Mouse models expressing a melanocyte-specific activated HRAS allele on a 
p53-null background provided initial evidence for p53 inactivation during 
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melanomagenesis (Bardeesy et al., 2001) and more recently, an epithelial-like 
subtype of melanoma was identified in which p53 inactivation was significantly 
more frequent than first described (Shields et al., 2007). In 2009, Yu and colleagues 
identified a subpopulation of BRAFV600E mutant melanocytes in which oncogene-
induced senescence had been bypassed. The additional disruption of p53 
immortalizes these cells and leads to a transformed cell phenotype both in vitro and 
in vivo (Yu et al., 2009). This data supports a tumour suppressor role for p53 in 
melanoma and, similar to the BRAFV600E/V600E p53M214K/M214K transgenic zebrafish, 
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BRAFV600E cooperates with mitfa to induce melanoma in zebrafish 
 
I used the hypomorphic temperature-sensitive mitfa mutant, mitfavc7, to study the role 
of mitf in melanoma and test its function as a cancer gene in the zebrafish. The main 
advantage of the temperature-sensitive mitfavc7 mutant is that we can alter the mitf 
activity by simply changing the temperature of the water. At high, restrictive 
temperatures of 32°C mitf activity is too low to allow normal development of 
melanocytes and both the embryos and adult appear non-pigmented or white in 
colour. At lower temperatures of 28°C, levels of mitf activity is still insufficient to 
promote the development of melanocytes and both embryos and adults appear white. 
At even lower temperatures <26°C, mitf activity is sufficient for some body 
melanocytes to develop, which are observable in embryos and adults grown at this 
temperature. To illustrate the temperature-sensitive activity of the mitfavc7 allele, 
wild- type and mutant mitfavc7 embryos were grown at different temperatures to 
48hpf (or until stage-matched) and the melanocyte development was observed 
(Figure 2.4). The number of melanocytes able to develop at each temperature varied 
as the mitf activity was altered by temperature. At 24°C, mitfavc7 mutant embryos 
develop similar numbers of melanocytes to wild-type embryos. Increasing 
temperature to 26°C reduces mitf activity and the number of melanocytes able to 
develop in embryos is reduced. At both 28°C and 32°C, mitf levels are insufficient to 
allow development of any melanocytes and so the embryo appears white.  
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In collaboration with J.A. Lister, I crossed the mitfavc7 mutants with the BRAFV600E 
mutants. I hypothesised that at temperatures at which mitf was sufficient to allow 
melanocyte development, but not cell cycle arrest (Taylor et al., 2011) it would 
cooperate with BRAFV600E to promote melanomagenesis. I found that BRAFV600E/V600E 
mitfavc7/vc7 zebrafish grown at the permissive temperatures below 26°C, at which 
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2.2.2 The mitfa allele in tumour samples 
 
To confirm that the mitfavc7 allele was present in the BRAFV600E mitfavc7 melanomas, I 
carried out an RT-PCR using RNA prepared from four BRAFV600E mitfavc7 tumour 
samples. To act as controls, I repeated the RT-PCR experiment using RNA prepared 
from a wild-type adult, an mitfavc7 mutant embryo grown at 28°C and four 
BRAFV600E/V600E p53M214K/M214K tumour samples. From this experiment I could 
confirm that the mitfavc7 mutant allele was present in all four of the BRAFV600E 
mitfavc7 melanomas tested as it produced the same molecular weight band on an 
agarose gel as the RT-PCR product from the mitfavc7 mutant embryo grown at 28°C 
(Figure 2.6). In contrast, a wild-type mitf band was found in the four BRAFV600E/V600E 
p53M214K/M214K tumour samples and corresponded to the same molecular weight band 
as the wild-type sample. These results confirm that the mitfavc7 allele is present in the 
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2.2.3 Incidence of zebrafish melanoma 
 
By counting the number of fish that developed tumours from a single genetic 
background, I could quantitate the incidence of melanoma. Collecting tumour 
numbers from other genotypes, as well as recording the age of tumour occurrence 
allows for a comparison of tumour incidence between different genetic backgrounds.  
 
After collating tumour incidence data for both BRAFV600Emitfavc7 and 
BRAFV600Ep53M214K zebrafish, I compared both the age of onset and frequency of 
tumours in these genetic backgrounds. Eighteen tumours were observed and 
collected from a total of 67 BRAFV600E mitfavc7 zebrafish (18/67), while 48 tumours 
were observed from a total of 177 BRAFV600Ep53M214K zebrafish (48/177). Converting 
these numbers into percentage gives an overall tumour incidence of 26.9% for 
BRAFV600Emitfavc7 zebrafish and 27.1% for BRAFV600Ep53M214K zebrafish (Table 1). 
The similar percentages calculated indicate that the tumour incidence in 
BRAFV600Emitf and BRAFV600Ep53M214K zebrafish is similar. Both genetic 
backgrounds were also similar in the age of tumour onset. In both BRAFV600Emitfavc7 
and BRAFV600Ep53M214K zebrafish, tumours first occurred between 4-5 months of age 
and continued to present up to one year old. Median tumour onset was calculated for 
each melanoma subtype, with BRAFV600Ep53M214K zebrafish showing an earlier 
median age of onset at 10 months than BRAFV600Emitfavc7 zebrafish, which showed a 
median tumour onset of 12 months (Table 1). To compare the tumour incidence 
between BRAFV600E mitfavc7 and BRAFV600Ep53M214K zebrafish a log-rank test was 
used. This analysis tests the null hypothesis that there is no difference between these 
two genotypes in the probability of developing a tumour at any age and is based on 
the age in months at which the tumour develops. For each month, I calculated the 
observed number of tumours in each genotype and the number expected if there were 
no difference between genotypes. For example, the first melanomas to develop were 
observed at 5 months of age, at which point one tumour was observed in the 
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BRAFV600Ep53M214K population and four tumours were observed in the 
BRAFV600Emitfavc7 population. In total, there were 66 tumours that developed 
between the two populations, so the risk of developing a tumour at 5 months was 
5/66 (0.0758). There were a total of 18 tumours that developed in the 
BRAFV600Emitfavc7 background so if the null hypothesis were true the expected 
number of tumours developing at this stage is 1.364 (18*0.0758). Similarly, there 
were a total of 48 tumours that developed in the BRAFV600Ep53M214K background, so 
if the null hypothesis were true, the expected number of tumours developing at this 
stage is 3.636 (48*0.0758). The same calculations were carried out for 5-18 months 
until the experiment was ended. From these, the total numbers of expected 
melanomas were 22.16 in the BRAFV600Emitfavc7 background and 44.84 in the 
BRAFV600Ep53M214K background. To then test the null hypothesis, Χ2 = Σ (O-E)2/E, 
where O and E are the total numbers of observed and expected tumours respectively, 
is calculated. In this case, ((18-22.16)2/22.16 + (48-44.84)2/44.84) = 1.167. The 
degrees of freedom (DF) are the number of groups (genetic backgrounds) compared 
minus one, i.e. 2-1=1 (DF=1). The p-value is found by referring the outcome of the 
log rank test (1.167) to a Χ2 distribution with 1 degree of freedom. By calculating 
this, the p-value given is 0.280019 (>0.05) and therefore the difference in tumour 
incidence between BRAFV600E mitfavc7 and BRAFV600Ep53M214K genetic backgrounds is 
not statistically significant.  
 
Tumour incidence and age of onset for both BRAFV600Emitfavc7 and 
BRAFV600Ep53M214K zebrafish are displayed graphically in Figure 2.7. As opposed to 
the incidence of tumours within a population, the percentage of tumour-free 
individuals is presented as a variable on the y-axis. This allows the data to be clearly 
interpreted as tumour incidence can be correlated with age and the percentage of 
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BRAFV600E/V600Emitfavc7/vc7 12 18 22.16 26.87 
BRAFV600E/V600Ep53M214K/M214K 10 48 44.84 27.12 
BRAFV600E/V600Emitfavc7/vc7p53
M214K/M214K 
7 31 23.96 100 
BRAFV600E/V600Emitfavc7/vc7p53
M214K/wt 
6 49 49.04 100 
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2.2.4 Zebrafish mutants of BRAF, mitfa and p53 
 
One question I asked after we confirmed that both mitfavc7 and p53 could cooperate 
with BRAFV600E to promote melanoma was if a triple zebrafish mutant, with 
mutations in BRAF, MITF and p53, would cooperate to induce melanoma with 
increased incidence. To create a zebrafish transgenic containing mutations in all 
three genes I crossed BRAFV600E mitfavc7 mutants with the p53M214K mutant fish. This 
genetic cross resulted in mutant fish with heterozygous mutations in BRAF, MITF 
and p53, so these were then incrossed to achieve homozygous mutants.  
 
A BRAFV600Emitfavc7p53M214K zebrafish mutant (Figure 2.8) developed both nevi and 
melanoma when grown at temperatures between 24-28°C, which are hypomorphic 
for levels of mitf activity. Melanomas from this transgenic line could be observed 
from 3 months and occurred more frequently than both BRAFV600Emitfavc7 and 
BRAFV600Ep53M214K double mutants (Figure 2.7). I observed tumour incidence in both 
BRAFV600Emitfavc7p53M214K/M214K and BRAFV600Emitfavc7p53M214K/wt mutants, in which 
the only difference is the homozygous vs. heterozygous p53 mutation. To assess 
whether the difference in p53 mutation affected tumour incidence I carried out the 
log-rank test, with the null hypothesis that there is no difference in incidences 
between these two genetic backgrounds. I found no significant difference between 
tumour incidence in zebrafish with p53 homozygous and heterozygous mutations 
(p=0.150).  
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2.2.5 A BRAF – independent melanoma model 
 
 mitfavc7 cooperates with p53M214K to induce melanoma in zebrafish 
 
One experiment that evolved from a genetic cross in the fish facility has proved to be 
fruitful in our understanding of the importance of MITF in BRAF-independent 
melanoma progression. Zebrafish with homozygous mutations in both mitfavc7 and 
p53M214K, but lacking a BRAFV600E mutation, develop melanomas at 28°C (Figure 
2.9). As controls, neither mitfavc7 or p53M214K mutants develop melanomas, although 
two mitfavc7/vc7 mutants develop nevi and seven p53M214K/M214K mutants develop 
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 mitfavc7 p53M214K melanomas occur with higher frequency but at later age than 
BRAFV600E p53 M214K and BRAFV600E mitfavc7 melanoma models 
 
In a similar manner to the BRAFV600E p53M214K and BRAFV600E mitfavc7 melanoma 
models, I collected tumour incidence data for the mitfavc7 p53 zebrafish to compare 
both the age of onset and frequency of tumours. As well as this, I counted both 
mitfavc7/vc7 and p53M214K/M214K mutant zebrafish populations, none of which developed 
melanomas. All mitfavc7/vc7, p53M214K/M214K and mitfavc7 p53 zebrafish included in the 
population counts were raised at 28°C.  
 
Of 142 mitfavc7/vc7 zebrafish, 2 developed nevi (2/142, 1.4%), and of 22 
p53M214K/M214K zebrafish, 7 developed malignant peripheral nerve sheath tumours 
(MPNSTs) (7/22, 31.8%). Zebrafish MPNSTs are identifiable upon external 
visualisation because of ocular or abdominal cavity localisation and by 
histopathological staining in which the tumours are composed of mainly spindle-
shaped cells (Berghmans et al., 2005). In comparison, 94/129 mitfavc7p53 M214K 
zebrafish developed melanomas (72.9%). This tumour incidence is extremely high 
compared to both BRAFV600Ep53M214K (27.1%) and BRAFV600Emitfavc7 (26.9%) 
zebrafish melanoma models. It is comparable to the incidence of 
BRAFV600Emitfavc7p53M214K zebrafish mutants, in which 51/60 (85%) develop 
tumours.  
 
The age of tumour onset also differed between mitfavc7p53M214K zebrafish and the 
previously described models. In BRAFV600Emitfavc7 and BRAFV600Ep53M214K zebrafish, 
tumours were observed between 4-5 months of age and continued to present up to 
one year old. In mitfavc7 p53 M214K zebrafish, tumours were first observed after 8 
months and by 10 months of age, 46.5% (60/129) had developed tumours. From 
observation, tumours from mitfavc7p53M214K zebrafish, once initiated, were quick to 
progress. Although the age of tumour onset is greater than both BRAFV600Emitfavc7 
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and BRAFV600Ep53M214K mutants, the impact of tumour initiation in mitfavc7p53M214K 
zebrafish is more severe. Once melanomas develop in mitfavc7p53M214K zebrafish, 
their health deteriorates rapidly and this requires them to be sacrificed. Similar to the 
median tumour onset calculated for BRAFV600Ep53M214K mutants (Table 1), 
mitfavc7p53M214K zebrafish showed a median tumour onset of 10 months.  
 
To compare tumour incidence between these three genetic backgrounds, mitfavc7/vc7, 
p53M214K/M214K and mitfavc7/vc7p53M214K/M214K and the effect of combining the mitfavc7 
and p53M214K mutations, I carried out a three-way log-rank test. The null hypothesis 
for this statistical analysis is that there is no difference between these three genotypes 
in the probability of developing a tumour at any age. The p-value, found by referring 
the outcome of the log rank test (215.19) to a Χ2 distribution with 2 degrees of 
freedom, is <0.00001. The difference in tumour incidence between mitfavc7/vc7, 
p53M214K/M214K and mitfavc7/vc7p53M214K/M214K zebrafish is therefore statistically 
significant.  
 
Both tumour incidence and age of onset for mitfavc7/vc7, p53M214K/M214K and 
mitfavc7p53M214K zebrafish are displayed graphically in Figure 2.10. As Figure 2.7, 
the percentage of tumour-free individuals is presented as a variable on the y-axis.  
































In this first results chapter I focused on the role of MITF in melanoma and asked if, 
like a mutation in p53, the temperature-sensitive mitfavc7 allele could cooperate with 
BRAFV600E to drive melanoma progression. Identifying new mutations that cooperate 
with BRAFV600E to induce melanoma in this model is an essential step in the 
development of new therapeutics and understanding the resistance that occurs with 
current drugs. As reviewed by Tsao and colleagues (2012), the activity of MITF is an 
important contributing factor in melanoma. Here, I show for the first time in an 
animal model that a low level of wild-type mitf activity is oncogenic with BRAFV600E. 
  
Initially, I aimed to replicate the work of Patton and colleagues (2005) to create 
BRAFV600Ep53M214K transgenic zebrafish and confirm that these animals develop 
melanoma (Patton et al., 2005). I then took advantage of the temperature-sensitive 
nature of the mitfavc7 allele (Johnson et al., 2011) to create a BRAFV600Emitfavc7 
model. Over 26% of BRAFV600Emitfavc7 zebrafish developed melanomas from 3-4 
months of age when grown at temperatures <26°C, a similar incidence rate to 
BRAFV600Ep53M214K zebrafish.  
 
Our model of melanoma in the BRAFV600Emitfavc7 zebrafish is relevant to human 
melanoma as it was found that a low level of MITF is oncogenic with BRAFV600E, a 
trend that is also observed in human melanoma patients in which low MITF 
expression levels are associated with disease progression and poor prognosis (Levy 
et al., 2006). As described by Salti and colleagues, patients with < 50% MITF 
expression have significantly more nodal metastases after nodal dissection than those 
with > 50% MITF expression (Salti et al., 2000) suggesting that MITF or its target 
genes are commonly downregulated in cases of advanced melanoma, with the 
exception of those with MITF amplifications. In these cases with low MITF 
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expression, exogenous expression of MITF leads to inhibition of proliferation (Selzer 
et al., 2002; Wellbrock and Marais, 2005).  
 
In contrast to low levels of MITF in association with melanoma progression, MITF 
amplification has also been shown to be an indicator of poor prognosis of the disease, 
as it cooperates with BRAFV600E to transform melanocytes (Garraway et al., 2005). 
One argument for the differences in the relationship between MITF activity and 
disease prognosis is that they may reflect different melanoma subtypes. A second 
possibility is that in the context of high BRAFV600E signalling, MITF activity must be 
maintained at a sufficient level to guarantee melanoma cell survival, and MITF 
amplification reflects this requirement (Garraway et al., 2005; Wellbrock et al., 
2008). One of the essential features of melanoma therefore would be ‘fine-tuning’ 
MITF activity. There must be a sufficient level of MITF activity for survival and 
proliferation, but higher levels of activity that would promote cell cycle arrest and 
differentiation, or lower levels that would lead to cell cycle arrest and apoptosis must 
be limited (Gray-Schopfer et al., 2007; Hoek and Goding, 2010).  
 
In this project, the temperature-sensitive nature of the zebrafish mitfavc7 mutant allele 
has enabled MITF activity to be varied within an individual animal by altering the 
water temperature. Taking advantage of this allele has revealed the role of MITF 
activity levels in melanomagenesis and survival in vivo, although it is possible that it 
also has additional functions that contribute to melanoma. 
 
The potential of MITF as a drug target for melanoma is highlighted by the novel 
finding that the mitfavc7 mutation cooperates with a mutation in p53 to drive 
melanoma in zebrafish. It is important to note that this new melanoma model 
presented is independent of a BRAFV600E mutation. Much of the recent therapeutic 
developments have focused on the use of inhibitors that target BRAF, as this is found 
mutated in about 40% of melanomas (Bamford et al., 2004). The degree of this focus 
seems unjustified however, owing to the development of resistance mechanisms and 
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side effects that arise as a consequence of BRAF inhibitor treatments such as 
vemurafenib. It is necessary to broaden the therapeutic development scope to include 
BRAF-independent melanomas as these represent more than half of melanoma cases 
and would therefore greatly benefit from novel therapeutics. As the research and 
literature is dominated by BRAF mutant melanomas and lacks that of BRAF-
independent melanomas, our finding of a BRAF-independent zebrafish model is 
important.  
 
In the context of MITF and the identification of the first animal model presented here 
in which low levels of wild-type MITF activity is oncogenic with BRAFV600E, it is 
important to relate this to the recent development of MITF as a resistance mechanism 
for current BRAF inhibitors or BRAF/MEK combination therapies. MITF was 
recently found to be a novel regulator of ERK-independent de novo and acquired 
resistance to BRAF and MEK inhibitors (Smith et al., 2013). In this study, an 
increase in MITF levels was observed in patients treated with BRAF inhibitors, 
which then decreased at time of progression. In resistance to either MEK inhibition 
or a combination of BRAF/MEK inhibition however, these high levels of MITF 
continued to be elevated. The authors found that SMAD-specific E3 ubiquitin protein 
ligase 2 (SMURF2) depletion reduced MITF levels as well as lowering the threshold 
of MEK inhibitor-induced apoptosis (Smith et al., 2013). This suggested that 
targeting SMURF2 could be a novel therapeutic strategy to increase the efficacy of 
MEK inhibitors that are currently used in combination with BRAF inhibitors. The 
study both highlights the discovery of MITF as a resistance mechanism and 
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Chapter 3: MITF mutations direct pathological and molecular 
features of melanoma 
 
In the first results chapter, I described the genetics of the BRAFV600Emitfavc7 
melanoma model. I showed that, like p53, a mutation in mitf could cooperate with 
BRAFV600E to drive melanomagenesis in the zebrafish.  
 
The aim of this second data chapter was to use pathology to determine whether 
melanomas driven by BRAFV600E and a cooperating mutation in either p53 or mitfa 
could be characterised as distinct subtypes. I will first introduce features of human 
melanoma pathology and describe how these can relate to characteristics of 
melanomas induced in zebrafish.  I will then outline the target genes of MITF that 
have been discovered and are detailed in the literature.  
 
I will show how I have used the BRAFV600E mutant line to identify two melanoma 
subtypes that can be distinguished by their pathology. I will also describe how these 
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3.1 Introduction  
 
3.1.1 Human melanoma pathology 
 
In humans, there are four types of cutaneous melanoma – superficial spreading, 
nodular, lentigo maligna and acrallentigineous (McGovern et al., 1973). These 
subtypes can be histopathologically distinguished by examining serial sections cut 
through the tumour mass, using haematoxylin and eosin (H&E) stain and identifying 
characteristic cellular features. As well as histologic subtype, other prognostic factors 
in melanoma include time of diagnosis, tumour thickness, Clark level of invasion, 
anatomic site, mitotic rate and growth phase. A combination of these prognostic 
factors and a histological analysis is useful in providing answers relating to patient 
prognosis and the most suitable therapeutic regimens for successful treatment to 
achieve the best overall outcome.  
 
An accurate diagnosis of a human melanoma relies on the ability to determine what 
stage of tumour progression the melanoma has reached upon presentation (reviewed 
by Balch et al., 2001). The progression of melanoma from small patches of 
pigmented skin through radial and vertical growth phases to allow tumour cells to 
enter and spread within the lymphatic and vascular networks was described in 
Chapter 1. With each growth stage progression comes increased survival risk. 
Important factors when deciding stage progression are the ‘Clark level’ (Clark et al., 
1969) and ‘Breslow’s depth’ (Breslow, 1970), which both refer to the degree of 
tumour invasion at a microscopic level.   
 
As well as tumour thickness and invasion, the cellular proliferation within a primary 
tumour, reflected by the mitotic rate, is now used to stage melanoma patients and 
predict survival. In 2003, Azzola and colleagues showed that tumour mitotic rate 
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(TMR) was ‘an important, independent predictor of survival for melanoma patients.’ 
They showed that patients with 0 mitoses/mm2 had a significantly better survival rate 
than those with 1 mitoses/mm2  (Azzola et al., 2003). More recently, Thompson and 
colleagues (2011) concluded from a study that, of the independent predictors of 
melanoma-specific survival, mitotic rate is the strongest predictor after tumour 
thickness.  
 
Like a pathologist’s investigation into a human melanoma, zebrafish melanomas can 
be dissected and studied using similar methods. Zebrafish and other teleost cancers 
share many histopathological features with human cancers (Amatruda et al., 2002; 
Stern and Zon, 2003). In 1985, Hawkins and colleagues induced tumours using 
carcinogens in seven small fish species, including medaka and guppies (Hawkins et 
al., 1985). This work highlighted the importance of these fish and others as models 
of cancer from which to study the human disease. In 2000, Spitsbergen and 
colleagues emphasised that zebrafish were an invaluable tool ‘in which to study the 
mechanistic aspects of the carcinogenesis process,’ using the carcinogen DMBA to 
induce a range of tumours in different tissues characterising individual histologic 
types (Spitsbergen et al., 2000). Likewise, in 2000, Beckwith and colleagues used 
ethylnitrosourea (ENU) to induce epidermal lesions or papillomas, which established 
the feasibility of the zebrafish as an experimental model for the study of skin 
tumours (Beckwith et al., 2000).  
 
Drawing parallels between features of melanoma in the zebrafish and that of the 
human patient demonstrates that the zebrafish is a good model to study this disease. 
In this chapter, I will examine the histological sections of melanoma and stain with 
antibodies to identify specific parts of tumour tissue architecture and molecular 
characteristics. We can then compare features observed in the zebrafish melanoma 
with tumour characteristics already known to be present in the human melanoma and 
use this to establish how MITF for example contributes to melanoma pathology.  
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3.1.2 MITF target genes 
 
The so-called ‘master melanocyte regulator’ MITF is essential for melanocyte 
development (Steingrímsson et al., 2004). As well as its role in melanocytes, it plays 
an important function in the development and homeostasis of other cell types 
including the retinal pigment epithelia (RPE) (Planque et al., 2004). It has also been 
shown to be a critical factor in regulating proliferation in melanoma (Carreira et al., 
2006; Hoek et al., 2008).  
 
Due to its complex and important role in both development and melanoma, this 
transcription factor is thought to function in multiple pathways and affect many other 
target genes. It was initially shown to control the transcription of just three genes 
involved in pigmentation – tyrosinase (TYR) (Hou et al., 2000), tyrosinase-related 
protein 1 (TYRP1) (Fang et al., 2002) and dopachrome tautomerase (DCT) 
(Yasumoto et al., 2002). MITF is now known to regulate the transcription of a wide 
range of genes. The transcription of other genes involved in growth and/or survival 
were shown to be under the control of MITF, as suggested by the lack of 
melanocytes in Mitf-deficient mice (reviewed by Cheli et al., 2010). Now, many 
target genes of MITF have been confirmed, including those involved in growth and 
survival – BCL2 and CDK2.  
 
In a study by Hoek and colleagues in 2008, a list of around 40 genes were given as 
already confirmed MITF target genes. Their research aimed to continue the search 
for novel genes whose expression was regulated by MITF, in order to ‘further 
characterise the role of MITF in melanocyte and melanoma development’ (Hoek et 
al., 2008). Using an approach combining two DNA microarray studies and a cross-
validation protocol to help eliminate false-positives in the data, they confirmed 13 
previously identified targets and discovered 71 novel targets of MITF (Hoek et al., 
2008).  
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One observed relationship between MITF and melanoma development is its role as a 
transcriptional activator of senescence- and proliferation-associated genes. By 
driving changes to overcome cellular senescence and promote proliferation, MITF 
can initiate events leading to tumorigenesis. Senescence mediator proteins p14, p16 
and p21, encoded by MITF target gene CDKN2A, may be transcribed to assist a 
transformation between a melanocyte and a melanoma cell for example. Similarly, 
MITF target gene TBX2 (Carreira et al., 2000) is highly expressed in melanomas and 
has been shown to repress p19 and p21, which are effectors of senescence, promote 
proliferation and suppress senescence in melanoma (Vance et al., 2005). Both of 
these examples demonstrate the ability of MITF to transcriptionally activate genes 
involved in senescence and proliferation, which are properties essential in 
melanomagenesis and therefore provide an additional link between MITF and 
melanoma.  
 
As well as anti-senescence and proliferation, anti-apoptosis is another key process in 
melanoma development. One known anti-apoptotic gene, BCL-2 is widely expressed 
in melanomas (Cerroni et al., 1995; Ramsay et al., 1995) and has been confirmed as 
an MITF target gene (McGill et al., 2002). Similarly, hypoxia-inducible factor 1 α 
(HIF-1α) has been shown to be an anti-apoptotic factor in melanoma cells (Buscà et 
al., 2005) and MITF has been shown to bind directly to the HIF-1α promoter site to 
activate its transcription. The MITFE318K mutation identified in melanoma and renal 
cell carcinoma (Bertolotto et al., 2011) was shown to enhance MITF protein binding 
to the HIF-1α promoter and increase its transcriptional activity compared to wild-
type MITF.  
 
The MITF target gene HIF-1α targets vascular endothelial growth factor (VEGF), a 
gene that contributes largely to angiogenesis (Buscà et al., 2005), another critical 
step in the process of tumorigenesis. As well as angiogenesis, the ability of cells to 
invade structures is also important for tumour development. Another MITF target, 
the C-MET proto-oncogene, which encodes hepatocyte growth factor receptor 
(HGFR), is highly expressed in melanomas and has been linked with its ability to 
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metastasize (Halaban et al., 1992; Natali et al., 1993; Hendrix et al., 1998; McGill et 
al., 2006). In 2006, McGill and colleagues investigated whether the HGF/c-Met 
signaling pathway elicited some of its downstream signaling through Mitf. They 
found that stimulating both melanocytes and melanoma cells with HGF leads to 
phosphorylation of Mitf via the MAPK pathway (McGill et al., 2006). In addition, 
they identified ‘conserved Mitf binding sequences in the human and mouse c-Met 
promoters that are bound by Mitf’ and regulate the expression of c-Met in 
melanocytes (McGill et al., 2006). Importantly, they also found that while HGF 
could stimulate invasive growth in melanocytes and melanoma cells, suppressing 
endogenous Mitf could abrogate this invasiveness. This suggests that there is 
potential to inhibit the invasive capacity of melanomas by targeting Mitf.  
 
In summary, MITF has many known target genes and with this the ability to 
upregulate both melanoma-inducing (BLC-2, C-MET) and -repressing genes (p16, 
p21). It is likely that the level or activity of MITF changes to drive either a 
melanoma-promoting or -inhibiting role and so this must be carefully regulated to 
transform melanocytes to melanoma cells. Low levels of MITF expression promote 
proliferation in melanoma, whereas high levels promote differentiation driven by 
senescence and melanin production (Goding and Meyskens, 2006; Hoek and Goding, 
2010). Due to these opposing roles that are dependent on MITF expression, it seems 
that it is a balancing act to regulate MITF and in doing so either promote or inhibit 
the change from melanocyte to melanoma cell.  
 
In this chapter, I will examine the expression of these known, described MITF target 










3.2.1 Pathology of BRAFV600E melanomas 
 
After fixation and embedding, transverse sections were cut through the body of the 
tumours and stained with H&E (Figures 3.1 and 3.2). From the BRAFV600E mitfavc7 
genetic cross, 26 tumour sections were examined and in the same process, 21 
BRAFV600E p53M214K tumours were also examined by pathology. This body of work 
was carried out under the supervision of NHS pathologist Marie Mathers, a clinical 
pathologist specializing in skin cancer. For each tumour from either genetic 
background, several characteristics were examined including tumour growth pattern, 
degree of pigmentation, cell type within the tumour mass and the presence or 
absence of mitoses. The similarities and differences between subtypes of each of 





















The first trait observed was the growth pattern of the melanoma. Although the 
tumour initiation site is difficult to distinguish, by looking at the area and location of 
tumour progression and its invasive potential, I can describe an individual tumour’s 
growth pattern in detail. A clear difference in the pattern of tumour growth was 
visible between the genetic backgrounds from which the tumour had arisen.  
 
In the BRAFV600E mitfavc7 tumours (Figure 3.1), 22/26 showed a superficial spreading 
pattern of growth, with some invasion into the underlying muscle. Exclusive to this 
type of growth, the tumour cells spread along the surface dermal layer of the skin 
with minimal, if any, invasion into other muscle or organs. In contrast, 19/21 
BRAFV600E p53M214K tumours (Figure 3.2) displayed a growth pattern described as 
nodular and highly invasive, with tumour cells found in multiple organs. In this 
subtype of melanoma, the tumour growth was more aggressive than that seen in 
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BRAFV600Emitfavc7 tumours. In most of these tumours, although the melanoma seems 
to have initialised within the skin, tumour cells have been able to penetrate through 
dense muscular regions and organs such as the kidney. In Table 2, levels of invasion 
are determined by observation of H&E stained tumour sections (Figure 3.1; Figure 
3.2). Low levels of invasion were observed in tumours in which a superficial 
spreading growth pattern was dominant and there was minimal invasion into 
underlying musculature. Tumours with high levels of invasion, as shown in Figure 
3.2, showed highly aggressive invasive behaviour in which melanoma cells 
progressed through musculature and to nearby organs including the kidney.   
 
The distinction between a superficial spreading type of tumour growth and one that is 
highly invasive is a simple way to distinguish between melanomas from these two 
genetic backgrounds. With each melanoma harbouring a homozygous BRAFV600E 
transgene and a different cooperating mutation, it is clear that mutations in mitfa and 
p53 drive unique patterns of melanoma growth that are individual to that genotype.  
 
Pigmentation 
As well as distinct growth patterns, the two melanoma subtypes also displayed a 
different degree of pigmentation. In the BRAFV600Emitfavc7 mutant melanomas, 
macro-melanophages are recognisable as dark brown stained cells, the colour coming 
from the melanin contained within the cell. These cells also appear larger than other 
surrounding cells in the tumour tissue and have poorly defined cytoplasmic borders, 
characteristics typical of melanophages (Busam et al., 2001).  
 
In BRAFV600Emitfavc7 stained melanoma sections, a high degree of pigmentation was 
observed in the tumour cell population, with many macro-melanophages present 
(white arrows, Figure 3.1B, C). In contrast, although pigmented cells were also 
present in the tumour tissue of BRAFV600Ep53M214K melanomas (white arrow, Figure 
3.2B), no macro-melanophages were present. This difference allows classification of 
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melanoma subtype by the presence or absence of macro-melanophages within the 
tumour tissue.  
 
Cell type 
Tumour tissue can be composed of different cell shapes, namely spindle-like (long, 
narrow, stretched-like cells) and epithelioid (rounded, condensed, sphere-like cells). 
Differences in cell shape can be observed in different tumours or in areas of the same 
tumour that may have developed at different time points. In BRAFV600Emitfavc7 
tumours, both spindle and epithelioid shaped cells were present (yellow arrows, 
Figure 3.1B, C). In contrast, only epithelioid shaped cells were present in the tumour 
tissue of BRAFV600Ep53M214K melanomas, allowing these melanoma subtypes to be 
distinguished by the dominant cell shape within the tumour cell population. Whether 
the dominant cell type is spindle or epithelioid shaped may affect prognosis. Spatz 
and colleagues for example, found that tumours with mostly spindle cell populations 
were more frequently observed in long-term survivors of the disease (Spatz et al., 




The last distinguishable feature between BRAFV600Emitfavc7 and BRAFV600Ep53M214K 
tumours was identified by looking for the presence of mitoses in each tumour cell 
population. Mitotic events were observable by identifying single cells in the tumour 
population that were undergoing mitosis. Very few mitotic events were observed in 
the BRAFV600Emitfavc7 tumour sections we looked at, compared to a high number in 
the tumour sections from BRAFV600Ep53M214K melanomas. The comparison of mitotic 
events here are descriptive observations only and need to be followed up by 
quantification to ascertain true differences between melanoma subtypes. Notably, a 
high degree of nuclear pleomorphism was observed in BRAFV600Ep53M214K tumour 
tissue, recognisable by either an increase or variability in the size or number of nuclei 
present within some cells (yellow arrow, Figure 3.2C). In human melanoma, marked 
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nuclear pleomorphism is typical of aggressive tumour behaviour (Broekart et al., 
2010; Patton et al., 2011). Similar to the observation of mitotic events, presence of 
nuclear pleomorphism identified here is descriptive and should be quantified to 
strengthen this difference between melanoma subtypes.  
 
In summary, I saw clear differences in tumour growth pattern, pigmentation, cell 
shape and mitoses between tumours from BRAFV600Emitfavc7 and BRAFV600Ep53M214K 
genetic backgrounds (summarised in Table 2). From these observations, I can 
conclude that BRAFV600E - cooperating mutations, mitfa and p53, direct specific 
characteristic features of melanoma pathology.  
 
 
Table 2. Characteristic features of the BRAFV600Emitfavc7 and BRAFV600Ep53M214K 
melanoma subtypes defined by pathology. 
Pathology feature BRAFV600Emitfavc7 BRAFV600Ep53M214K 
Growth pattern Superficial spreading Nodular 





Pigmentation in melanoma 
cells 
Tumour cell shape Spindle and epithelioid Primarily epithelioid 
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3.2.2 Macrophages in BRAFV600Emitfavc7 tumours 
 
One of the characteristics that distinguished BRAFV600Emitfavc7 tumours from 
BRAFV600Ep53M214K tumours was the degree of pigmentation. Although there were 
pigmented tumour cells present in the BRAFV600Ep53M214K melanomas, there were 
higher numbers of pigmented cells observed in the tumour tissues of 
BRAFV600Emitfavc7 melanomas. Also noticeable was the presence of ‘macro-
melanophages’ in the BRAFV600Emitfavc7 tumours – large, heavily pigmented cells 
that were densely packed with melanin so they appeared solid and almost black in 
colour (white arrows, Figure 3.1B, C). These cells were absent in the 
BRAFV600Ep53M214K melanomas.  
 
To confirm the presence of macrophages in the BRAFV600Emitfavc7 tumour tissue 
population, a macrophage-specific antibody marker (anti-CD68) was used to stain 
the tissue of six fixed tumours from this genotype. Positively stained cells, depicting 
macrophages, were observed in all BRAFV600Emitfavc7 tumours and were distributed 
randomly (Figure 3.3). This staining confirmed our observation of macrophages 
present in the BRAFV600Emitfavc7 tumours and these became another distinguishing 
feature when describing the two melanoma subtypes from BRAFV600Emitfavc7 and 
BRAFV600Emitfavc7 genetic backgrounds.  
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3.2.3 Pathology of BRAFV600E-independent mitfavc7p53M214K 
melanomas 
 
In collaboration with NHS pathologist Marie Mathers, the histopathology of 
melanomas from the mitfavc7p53M214K genetic background was also examined (Figure 
3.4). In 7/8 melanomas, the tumour growth pattern was similar to that of the 
BRAFV600Ep53M214K melanomas, with a highly aggressive behaviour and invasion into 
musculature and internal organs. In 3/8 mitfavc7p53M214K melanomas examined, the 
tumour growth was also reminiscent of the BRAFV600Emitfavc7 subtype, with 
superficial spreading along the dermis in addition to invasion. All mitfavc7p53M214K 
melanoma tissues (8/8) were highly pigmented, with melanin observable in most 
tumour cells, but no macro-melanophages were present. A mixture of both spindle 
and epitheliod cell types were present within the tumour cell populations and all 
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3.2.4 Immunohistochemistry of BRAFV600E and BRAFV600E-
independent melanomas 
 
Immunohistochemical staining, using a variety of antibodies was carried out to 
determine further differences between melanoma subtypes identified by pathology.  
 
Positive melan-A staining in both tumour subtypes confirms melanoma status 
 
Melan-A, isolated as a melanoma-specific antigen, is expressed in the skin, retina, 
melanocytes and melanomas (Busam and Jungbluth, 1999; Shidham et al., 2001). 
The melan-A stain used in IHC is useful to confirm that our zebrafish tumours are 
melanoma. All BRAFV600Emitfavc7 and BRAFV600Ep53M214K stained positively with this 
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Activation of the MAPK cascade in both melanoma subtypes 
Members of the MAPK/ERK pathway (mitogen-activated protein kinases, once 
called extracellular signal-regulated kinases) include ERK and MEK. Antibody 
staining using anti phospho-ERK and anti phospho-MEK was carried out on 
BRAFV600Emitfavc7 and BRAFV600Ep53M214K tumour sections to look at the activity of 
these signalling molecules in these important pathways.  
Positively stained cells were observed in the tumour populations of both melanoma 
subtypes using these two antibodies (Figure 3.6). This result confirmed that the 
MAPK pathway was highly active both BRAFV600Emitfavc7 and BRAFV600Ep53M214K 
tumours.  
 
Activation of the MAPK cascade in mitfavc7p53M214K melanomas 
The same antibody staining using anti phospho-ERK and anti phospho-MEK was 
carried out on mitfavc7p53M214K tumour sections. This assessed whether, like 
BRAFV600E melanomas, this BRAFV600E-independent melanoma subtype had MAPK 
cascade activity. Few positively stained cells were observed in mitfavc7p53M214K 
tumour tissue these antibodies (Figure 3.7), however sections focused on 
musculature to which these tumours had invaded.  To ascertain whether either ERK 
or MEK are active in these melanomas it would be useful to repeat this antibody 
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Increased levels of p53 mutant protein in BRAFV600Ep53M214K tumours 
Using an antibody to detect mutant p53 protein allowed the comparison of levels of 
mutant p53 between BRAFV600Emitfavc7 and BRAFV600Ep53M214K tumours (Figure 3.7). 
The anti-p53 monoclonal antibody (gifted by David Lane) was validated using IHC 
to show that exposure of zebrafish embryos to p53-activating agents resulted in p53 
protein accumulation in the gut, liver and pancreas (Lee et al., 2008). 
 
By IHC it was clear that no staining was present in tumour sections from the 
BRAFV600Emitfavc7 genotype, indicating that this melanoma subtype did not have 
mutant p53 (Figure 3.7). In contrast, all BRAFV600Ep53M214K tumours stained 
positively for mutant p53 (Figure 3.7). 
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Similar levels of phospho-H2AX activity in both melanoma subtypes 
To assess levels of DNA damage in tumour populations, an antibody against p-
H2AX was used in IHC. The polyclonal anti-p-H2AX antibody (gifted by James 
Amatruda) recognises the zebrafish p-H2AX histone variant. Phosphorylation of the 
H2AX histone variant occurs along tracks of chromatin at double strand breaks, 
which enables detection of DNA damage sites using the antibody (Sharma et al., 
2012).  
 
Phospho-H2AX-positively stained cells were found in both BRAFV600Emitfavc7 and 
BRAFV600Ep53M214K tumours (Figure 3.8). This result indicates that both melanoma 
subtypes show a similar degree of DNA damage, of which H2AX is marker. 
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Increased mitotic activity in BRAFV600Ep53M214K tumours 
Levels of mitotic activity were assessed using an anti-phospho-Histone H3 antibody. 
Tumours were stained with the antibody and in both subtypes positively stained cells 
were observed (Figure 3.9A). 
 
By simple visualisation of the staining, I hypothesised that there was a difference in 
the degree of positively stained cells between tumour tissues from each melanoma 
subtype. To test this hypothesis, I quantified the number of positively stained cells in 
a population from each tumour. Dark brown (positive) cells were counted within a 
cell population for each tumour and each subtype to quantify the degree of anti-
phospho-Histone H3 staining. The results were represented as a boxplot (Figure 
3.9B). 
 
Higher numbers of phospho-Histone H3 stained cells were found in 
BRAFV600Ep53M214K tumours compared to BRAFV600Emitfavc7 tumours. Using a T-test, 
I could show that the difference in phospho-Histone H3 staining was significant 
between melanoma subtypes (p=0.0078). This result confirms that there is a 
statistically significant difference in mitotic activity levels between melanoma 
subtypes BRAFV600Emitfavc7 and BRAFV600Ep53M214K. In humans a high mitotic rate, 
measured by number of mitoses/mm2, is associated with a lower survival probability 
(Thompson et al., 2011) suggesting that BRAFV600Ep53M214K melanomas, with a 
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3.2.5 Using quantitative real-time PCR to quantify the expression 
levels of MITF target genes in melanoma subtypes 
 
As an important transcription factor involved in processes including differentiation 
and the cell cycle, many target genes of MITF have been identified (Figure 3.10). 
Genes involved in proliferation, cell survival and oxygen stress including CDK2, 
TBX2, BCL-2, MET, HIF-1α and APE-1 are all MITF target genes. MITF also 
controls transcription of genes involved in cell cycle arrest including p16 and p21. 
Genes involved in pigmentation, including DCT and TYR are also under the 
transcriptional control of MITF. Important for their role in melanoma, genes 
involved in metastasis and invasiveness such as SLUG, MET and DIA have also been 
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The aim of the following experiments was to ascertain the expression levels of some 
of these known MITF target genes in our melanoma subtypes. I hypothesised that 
these target genes may be differentially expressed between the melanoma subtypes 
BRAFV600Emitfavc7 and BRAFV600Ep53M214K. To address the aim, I carried out 
quantitative real-time PCR using cDNA prepared from BRAFV600Emitfavc7 and 
BRAFV600Ep53M214K tumours and a range of primer sequences specific to the MITF 
target gene in question. The results of this set of experiments are described in the 
following sections and as boxplots.  
 
Target genes expressed at similar levels of melanoma subtypes 
I found that certain MITF target genes were expressed at a similar level in both 
melanoma subtypes. These included genes CDK2, p16 and p21 (Figure 3.11A-C 
respectively), which are involved in proliferation and cell cycle arrest. Using an anti-
phospho-Histone H3 antibody in IHC, BRAFV600Ep53M214K tumours showed a higher 
level of staining, indicating a higher degree of proliferation in this melanoma subtype 
compared to BRAFV600Emitfavc7 tumours. 
As well as MITF target genes involved in proliferation showing no change in 
expression, genes BCL-2, HIF-1α or p53 were also expressed at similar levels 
between melanoma subtypes (Figure 3.12A-C). 
These results show that the tumour genotype and the BRAFV600E – cooperating 
mutation have no affect on the levels of expression of MITF target genes CDK2, p16, 
p21, BCL-2, HIF-1α and p53. Together they indicate that despite the reduced levels 
of MITF in BRAFV600Emitfavc7 melanomas, there is sufficient MITF activity to control 
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Differentiation genes TYR and DCT are expressed at lower levels in 
BRAFV600Emitfavc7 tumours  
Differences in cycle threshold (Ct) values, which indicate levels of expressed RNA, 
were observed in other MITF target genes when comparing melanoma subtypes 
BRAFV600Emitfavc7 and BRAFV600Ep53M214K by qRT-PCR. Pigmentation genes DCT 
and TYR were expressed at lower levels in BRAFV600Emitfavc7 tumours, indicated by 
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Differential expression of C-MET between melanoma subtypes 
Another difference observed between melanoma subtypes was in the MITF target 
gene, C-MET (Figure 3.14). A statistically significant difference in RNA expression 
was observed between BRAFV600Emitfavc7 and BRAFV600Ep53M214K tumours 
(p=0.00024). BRAFV600Emitfavc7 tumours expressed significantly higher levels of c-
















‘Zebrafish cancer models for a variety of human cancers demonstrate similar features 
both histopathologically and genetically, underscoring the tight conservation of 
cancer-related pathways between fish and human’ (Liu and Leach, 2011).  
 
In this chapter, I investigated whether previously identified BRAFV600E-cooperating 
mutations p53 and mitf contributed to melanoma pathology. The histopathological 
characteristics of human melanoma are determined by many factors including 
genetic background (Whiteman et al., 2011). As an example of this, BRAFV600E 
melanomas are clinically classified as a subtype of melanoma owing to their 
histomorpological features (Viros et al., 2008). Melanomas with BRAF mutations 
have distinct morphological features including upward migration of intraepidermal 
melanocytes, thickening of the epidermis and heavy pigmentation (Viros et al., 
2008). As a consequence, melanoma BRAF mutational status can be predicted with 
~90% accuracy by simply observing histological features. Using histologically 
stained sections of zebrafish melanomas, I show for the first time that BRAFV600E-
cooperating mutations play an important role in determining pathological features of 
melanoma.   
 
The growth pattern of melanomas can be a distinguishing subtype-distinct feature. In 
humans, three different subtypes of melanoma can be differentiated, based on their 
intraepidermal growth pattern or radial growth phase (Whiteman et al., 2011). 
Superficial spreading melanoma (SSM), lentigo maligna melanoma (LMM) and acral 
lentiginous melanoma (ALM) all differ within their early growth phase in which the 
tumour spreads on the surface of the skin. With SSM in particular, as opposed to 
LMM and ALM, the growth pattern is described as ‘pagetoid,’ referring to the 
resemblance to the intraepidermal spread of breast cancer in the nipple epidermis 
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(Paget’s disease) (Whiteman et al., 2011). SSM also presents with enlarged 
melanocytes that often aggregate into clusters. 
  
Similar to human melanoma, the BRAFV600Emitfavc7 zebrafish melanomas contain 
large, heavily pigmented cells that are not present in the BRAFV600Ep53M214K subtype. 
They also display a superficial spreading growth pattern with evidence of invasion 
into the underlying muscle. Characteristic BRAFV600Emitfavc7 melanoma histological 
features include the presence of large, heavily pigmented cells throughout the tumour 
mass, few mitoses and a low degree of nuclear pleomorphism. With these features, 
an NHS skin pathologist could reliably identify tumours from BRAFV600Emitfavc7 
zebrafish on blind assessment.  
 
As well as their differences in pathology, BRAFV600E melanomas with cooperating 
mutations in either p53 or mitf also differ in their mitotic activity. BRAFV600Ep53M214K 
melanomas have increased mitotic activity compared to BRAFV600Emitfavc7 tumours, a 
result confirmed by immunostaining for phospho-Histone H3, a marker of late G2/M 
phase. As expected, BRAFV600Ep53M214K melanomas also have increased levels of p53 
mutant protein, providing another method of distinction between these two 
melanoma subtypes. These results, taken together with those from histopathology, 
show that there is a strong genotype-phenotype correlation for cooperating mutations 
that can directly affect growth features and cellular histology.  
 
Although they share some similar features, the histopathology of the mitfavc7p53M214K 
melanomas, which are BRAFV600E – independent, represents a novel phenotype 
compared to the BRAFV600E melanomas described. The most distinguishing feature 
of these tumours is their invasiveness nature. Although invasion was observed in the 
BRAFV600Ep53M214K subtype, it is much more pronounced in this genetic background 
with tumour masses forcing themselves into areas of musculature and organs. Due to 
the observation of this aggressive and invasive behaviour it would be useful to 
determine the mitotic activity within these tumours using immunohistochemical 
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staining such as phospho-Histone H3. Comparing the number of positively stained 
cells using the phospho-Histone H3 antibody between mitfavc7p53M214K and the other 
melanoma subtypes, particularly BRAFV600Ep53M214K, would give further insight into 
the relative degree of aggressiveness of the tumours and how it could relate to a 
human melanoma subtype. 
 
To further understand how hypomorphic MITF activity contributed to melanoma I 
assessed the levels of MITF target gene expression in the melanoma subtypes. I used 
real-time PCR to calculate expression levels of known MITF target genes involved in 
important cellular processes including proliferation (CDK2), differentiation (TYR, 
DCT), cell cycle arrest (p16, p21) and survival (BCL-2, HIF-1α and C-MET). Despite 
the observed difference in phospho-Histone H3 staining between BRAFV600Emitfavc7 
and BRAFV600Ep53M214K melanomas, expression of CDK2, p16 and p21 were not 
significantly different between the melanoma genotypes. There was also no 
difference between melanoma subtypes in expression, as indicated by cycle threshold 
values of p53, BCL-2 or HIF-1α. Together, these results indicate that despite the 
lower levels of MITF in BRAFV600Emitfavc7 melanomas, there is a sufficient level of 
MITF activity to control those target genes involved in proliferation and cell 
survival. One striking difference observed from the real-time PCR was the 
expression of differentiation genes, DCT and TYR. BRAFV600Emitfavc7 melanomas 
expressed both of these genes at a much lower level than BRAFV600Ep53M214K 
melanomas. In contrast, and unexpectedly, BRAFV600Emitfavc7 melanomas expressed 
significantly higher levels of C-MET than BRAFV600Ep53M214K melanomas. Although 
the tumours are known to be heterogeneous, both the low expression of 
differentiation genes, DCT and TYR, and the high expression of C-MET suggest that 
hypomorphic MITF activity may maintain melanocytes in a less differentiated state 
that is more susceptible to BRAFV600E transformation.  
 
It is important to note that the low levels of oncogenic MITF shown here to 
cooperate with BRAFV600E to promote melanoma are distinct from data from both 
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mouse models and human. As described by Nobukuni and colleagues in 1996, loss-
of-function mutations of the MITF gene results in haploinsufficiency of the MITF 
protein, which is necessary for normal melanocyte development. These mutations are 
found in individuals with Waardenburg syndrome type 2 (WS2) causing defects in 
pigmentation and hearing due to the lack of normal melanocytes (Nobukuni et al., 
1996). To date however, no patient with either WS2 or Tietz syndrome, a similar 
disease also characterised by pigmentation and hearing defects caused by alterations 
in MITF, has developed melanoma. This distinction between the low levels of MITF 
promoting melanoma in the zebrafish and loss-of-function/hypomorph mitf mutants 
modelled in mice and observed in patients, in which there is no increased incidence 
in melanoma compared to wild-type, must be recognised. Our temperature-sensitive 
BRAFV600Emitfavc7 zebrafish, which has shown that low levels of MITF are 
oncogenic, has provided the scientific field with a model to assess varying MITF 
conditions and how these are linked to melanomagenesis.  
 
The differential expression of C-MET between BRAFV600E melanoma subtypes was 
an interesting finding as there is an abundance of genetic and biochemical research 
demonstrating that the growth and motility hepatocyte factor/scatter factor (HGF/SF) 
and its receptor MET have a causal role in uncontrolled cell survival, growth, 
angiogenesis and metastasis, many of the essential hallmarks of cancer (To and Tsao, 
1998). In many human cancers overexpression of MET contributes to invasive 
growth and MET activation confers selective advantage to cancer cells in tumour 
progression and during drug resistance (Stella et al., 2010). The overexpression of 
MET accompanies ras-mediated cellular transformation (Webb et al., 1998) and 
directly contributes to this ras-mediated tumorigenesis and metastasis (Furge et al., 
2001). As some of the research leading to these findings used melanoma cell lines 
and MET overexpression is found consistently in melanoma it is justified that 
inhibitors of c-MET are currently in preclinical development (Flaherty, 2006). 
Inhibitors of MET are also being thought of as part of combination treatment with 
BRAF inhibition, after it was shown that the tumour microenvironment confers 
innate resistance to therapy via MET activation (Straussman et al., 2012). After RAF 
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inhibitor treatment of BRAF mutant melanomas, Straussman and colleagues found 
that stromal cell secretion of HGF resulted in activation of MET, reactivation of 
MAPK and PI(3)K-AKT pathways and immediate resistance to RAF inhibition. 
They identified a similar resistance mechanism in both BRAF mutant colorectal and 
glioblastoma cells lines, suggesting that RAF inhibition in combination with either 
HGF or MEK inhibition could act as a potential therapy for BRAF mutant cancers 
(Straussman et al., 2012). As I found C-MET to be expressed at a higher level in 
BRAFV600Emitfavc7 melanomas compared to BRAFV600Ep53M214K, it may be interesting 
to compare these levels with that found in human melanoma both before and after 
BRAF inhibitor treatment. High C-MET levels identified in this tumour subtype also 
provide an animal model in which to test novel MET inhibitors and combination 
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Chapter 4: MITF is essential for melanoma survival 
 
In the first two results chapters I showed how BRAFV600E could cooperate with a 
mutation in MITF to drive an individual melanoma subtype. I also showed that 
BRAFV600Emitfavc7 melanomas were distinct from those of BRAFV600Ep53M214K 
background by histopathology and MITF target gene expression.  
 
The aims of this third data chapter are to test if MITF activity is required for 
melanoma survival in our BRAFV600Emitfavc7 model and identify the cellular process 
by which MITF-dependent melanomas regress.  
 
I will first describe how animal models, including zebrafish, have been vital in 
identifying and confirming the status of MITF and other cancer genes. I will then 
outline examples of tumour regression in relation to melanoma and explain the 
evidence that MITF could act as a future therapeutic target for melanoma.  
 
In the results section of this chapter, I will demonstrate how the temperature-
sensitive nature of the mitfavc7 allele in cooperation with the BRAFV600E mutation has 
allowed me to show that loss of MITF causes melanoma regression in zebrafish. 
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4.1 Introduction  
 
4.1.1 Importance of animal models in establishing a role for cancer 
genes in vivo 
 
The emergence of animal models has been vital in the establishment of the roles for 
cancer genes such as BRAF and MITF. Using BRAF as an example, its identification 
and mechanistic action as an oncogene was established through studies using human 
tumour samples and cell lines. In the past, one of the limitations of this method was 
the accessibility of human cancer material, in particular from early stage tumours that 
could potentially be used to identify genes and pathways involved in tumour 
progression.  To overcome this restriction and aid further understanding of cancer 
genes, genetically engineered animal models, such as mice and zebrafish, have now 
been generated. More recently, the availability of primary human melanoma samples 
for research has greatly improved, although again, samples from early stage tumours 
are rare. The generation of disease models is therefore vital to improve understanding 
of disease progression and to test new therapeutics.   
 
As the most commonly found mutation in human melanoma, BRAFV600E has been 
shown to stimulate constitutive cell signalling and growth factor independent 
proliferation (Davies et al., 2002; Goodall et al., 2004; Wellbrock et al., 2004; 
Hoeflich et al., 2006; Wellbrock et al., 2008). In vitro studies have shown that 
BRAFV600E inhibitors block proliferation and induce apoptosis in melanoma, while in 
vivo studies have shown that they slow the growth of melanoma xenografts. Despite 
this data confirming that BRAFV600E is necessary for human melanoma survival and 
progression, an animal model of BRAFV600E in the zebrafish showed that 
overexpression of BRAFV600E only induces nevi, which do not progress to melanoma 
unless p53 is also deleted (Patton et al., 2005). In addition to this finding, BRAFV600E 
Chapter 4 – MITF is essential for melanoma survival 
 95 
was shown to induce classical oncogene-induced senescence (Michaloglou et al., 
2005). Together, this data implied that in addition to BRAFV600E, other genetic or 
epigenetic alterations are required to drive melanomagenesis. To determine these 
additional changes, Dhomen and colleagues engineered a BrafV600E mouse model of 
melanoma that emulated the human disease (Dhomen et al., 2009). This was an 
important model as the close similarities between tumours that developed in the 
mouse model and those observed in human advanced the ability to study melanoma 
genetics and pathology.   
 
As previously described, despite the success of BRAF inhibitors, many BRAFV600E-
treated melanomas develop resistance. This highlights the requirement for additional 
melanoma pathways to be targeted, and as suggested by Johannessen and colleagues, 
one of these may involve MITF (2013). Prior to the development of novel 
therapeutics against targetable pathways however, our understanding of these must 
be improved through study, for example, of animal models. Das Thakur and 
colleagues provide one standout example of the use of an animal model in 
melanomagenesis (2013). They developed two primary human melanoma xenograft 
mice models to study the cause and consequences of vemurafenib resistance in 
BRAFV600E mutant melanomas. Drug resistance was selected for by continuous 
vemurafenib administration and it was found that resistant tumours showed 
‘continued dependency on BRAFV600E → MEK → ERK signaling owing to elevated 
BRAFV600E expression’ (Das Thakur et al., 2013). They also found that vemurafenib 
resistant tumours became drug dependent for their continued proliferation, as when 
drug treatment was stopped the established drug-resistant tumours regressed. Das 
Thakur and colleagues went on to show that a discontinuous dosing strategy using 
vemurafenib would delay the onset of lethal drug-resistant disease and suggest that 
this alternative therapeutic approach may improve the durability of the vemurafenib 
response. The xenograft mice used in this study demonstrate the importance of using 
animal models to study human disease.  
 
Chapter 4 – MITF is essential for melanoma survival 
 96 
In the subsequent results section of this chapter, I will present evidence that MITF 
may be a potential target for melanomagenesis. Zebrafish models of melanoma have 
been engineered and, for the first time, provide in vivo data to show that MITF is 
essential for BRAFV600E – driven melanoma survival.  
 
 
4.1.2 Melanoma regression and MITF as a potential therapeutic target 
 
In 2010, the first trial of PLX4032 (Plexxikon and Roche), an orally available 
inhibitor of mutated BRAF, was conducted in humans (Flaherty et al., 2010). Using a 
dose-escalation method of administration, treatment of the drug in 16 patients with 
BRAFV600E mutant melanoma resulted in 10/16 having a partial response and one 
having a complete response, while in patients with metastatic disease, 24/32 showed 
a partial response while two had a complete response (Flaherty et al., 2010). For all 
patients receiving BRAF inhibitor treatment, PLX4032 induced either partial or 
complete regression in 81% of patients and produced a median progression-free 
survival estimate of more than 7 months (Flaherty et al., 2010). The ‘response’ 
referred to here indicates regression, both partial and complete as stated. In pre-
clinical trials using human melanoma tumours transplanted onto immune-
compromised mice, the drug first simply inhibited the growth and then at higher 
concentrations induced regression (Tsai et al., 2008). The promising results from 
both the mouse and human trials with PLX4032 meant that the drug was accelerated 
through clinical trial phases quickly, a trend that has been observed for other target 
cancer drugs such as crizotinib, an ALK inhibitor used to treat non-small cell lung 
carcinoma (Chabner, 2011). Targeting c-KIT mutant melanomas using tyrosine 
kinase inhibitors such as imatinib have also been shown to lead to tumour regression. 
Imatinib mesylate is the most well established tyrosine kinase inhibitor for 
melanomas harboring c-KIT mutations with response rates of more than 20% in two 
separate clinical human trials (Guo et al., 2011; Carvajal et al., 2011). As well as 
molecular targeted therapy, targeted immunotherapy has also proved to be an 
important direction for research and therapeutic development in the treatment of 
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melanoma. This concept relies on the idea that tumours are immunogenic and can 
independently stimulate an immune-mediated anti-tumour response (Liu and 
Colegio, 2013). In early studies, melanoma patients were treated with a human 
antibody to cytotoxic T-lymphocyte antigen-4 (anti-CTLA-4) and results showed 
both complete (2/56) and partial (5/56) tumour regression (Attia et al., 2005). More 
recently, a monoclonal antibody known as ipilimumab, which acts by promoting T-
cell activation, has been shown to elicit anti-tumour effects on melanoma (Hodi et 
al., 2010). Results of initial trials using this treatment regime were promising but 
improved significantly in combination with dacarbazine, a common 
chemotherapeutic agent (Robert et al., 2011). Future treatment regimes for 
melanoma patients are leading in the direction of combination therapies including 
BRAF inhibitors with MEK inhibitors (discussed in Chapter 2) and immunotherapy. 
An interesting finding that connects these two methods of treatment is that BRAF 
inhibitors increase the expression of melanocyte differentiation antigens, which is 
associated with improved recognition by antigen-specific T lymphocytes (Boni et al., 
2010). This result suggests that combining BRAF inhibition with an immunotherapy 
such as ipilimumab could improve tumour response rates compared to individual 
treatment regimes.  
 
As described in Chapter 2, MITF is a potential therapeutic target in melanomas 
treated with BRAF inhibitors that have developed resistance. BRAF inhibition with 
vemurafenib has been shown to cause an increase in MITF levels (Smith et al., 
2013), a result that suggests a potential to include MITF inhibitors in combination 
therapy to overcome resistance mechanisms. As a transcription factor without a 
ligand dependency, aiming to target MITF incurs difficulties, however HDAC 
inhibitors have been shown to repress MITF expression in both clear cell carcinoma 
and melanoma cells (Yokoyama et al., 2008). It is well established that inhibiting 
oncokinases, such as BRAF in melanoma, is the foundation of current, successful 
cancer treatments but also that this therapeutic strategy is hindered by innate drug 
resistance mediated by upregulation of the HGF receptor, MET (Webster et al., 
2014). In a recent study, lineage-specific MET enhancers were identified, including a 
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melanoma-specific enhancer downstream of the MET TSS that displayed inducible 
chromatin looping with the MET promoter to upregulate MET upon BRAF inhibition 
(Webster et al., 2014). Interestingly, the study also found that MITF mediates this 
enhancer function and that deleting the MITF motif in the MET enhancer suppresses 
inducible chromatin looping and drug resistance, while maintaining MITF-
dependent, inhibitor-induced melanoma cell differentiation (Webster et al., 2014). 
This result demonstrates how MITF can be targeted in a novel way to block 






















4.2.1 Regression of tumour growth in BRAFV600Emitfavc7 mutants at 32°C 
 
Melanoma developed in BRAFV600Emitfavc7 fish after 3 months at <26°C (Figure 2.3). 
To test the role of MITF in these tumours, I utilised the temperature-sensitive nature 
of this genetic cross to control the levels of MITF. By upshifting the fish to static 
tanks at 32°C after the tumours have developed at <26°C, I could observe changes 
that occurred when the level of MITF activity is insufficient to promote melanocyte 
development. Photographs were taken before and after the upshift to track any 
changes in tumour growth.  
 
It is noteworthy that at the restrictive temperature of 32°C, Johnson and colleagues 
(2011) confirmed that none of the aberrant mitfavc7 splice products are sufficient for 
melanocyte development and MITF activity is not required to maintain the activity of 
the mitfa promoter fragment driving the BRAFV600E transgene (Dooley et al., 2013).  
 
Twelve BRAFV600Emitfavc7 fish with tumours grown at <26°C were upshifted to 32°C 
for 2 weeks. Before and after photographs were taken of each fish to identify changes 
that had taken place during the upshift period at 32°C. After 2 weeks, 8/12 
melanomas had dramatically regressed (Figure 4.1). This was clear simply by 
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The upshift experiment was also continued for a total of 2 months with 15 
BRAFV600Emitfavc7 fish. After 2 months at the upshift temperature of 32°C, 12/15 very 
large tumours had regressed and 6/15 showed complete regression, as well as healing 
at the tumour site (Figure 4.2).  
 
In an additional experiment, BRAFV600Emitfavc7 zebrafish that showed melanoma 
regression at the restrictive temperature (32°C) were transferred back to the semi-
permissive temperature (<26°C). Despite the striking loss of tumour mass that 
occurred after 2 weeks at 32°C, after one month at <26°C melanomas recurred (6/6). 
I hypothesise that there is a small subpopulation of melanoma cells with very low or 
no MITF levels that are able to survive. It is also possible that during upshift at 32°C, 
the tumour microenvironment is maintained and acts as a niche for the recurring 
tumours. After the tumour regression and subsequent temperature downshift to 
<26°C for one month, this population of melanoma cells is able to repopulate the 
original tumour site. This is shown by the observation that tumours recur in the same 
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4.2.2 BRAFV600Ep53M214K/M214K mutants at the restrictive temperature do 
not regress 
 
To confirm that the melanoma regression was due to the change in levels of MITF 
and not the temperature of the water, the upshift experiment was carried out with 
BRAFV600Ep53M214K fish, which do not have a mutation in mitf. Six 
BRAFV600Ep53M214K zebrafish with melanomas were upshifted to 32°C for 2 weeks as 
a control. In 6/6 fish, no melanoma regression was observed and the tumours 
continued growing (Figure 4.3). Additional nodules also formed within the tumours 
of the controls during the temperature upshift period. This result confirms that 
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4.2.3 Mechanism of regression in BRAFV600E melanomas involves 
macrophage infiltration and apoptosis 
 
To understand the mechanism of BRAFV600Emitfavc7 tumour regression, I aimed to 
capture a time point at which the tumour had began to regress but some tumour tissue 
still remained. To do this, I upshifted 7 BRAFV600Emitfavc7 fish with tumours to the 
restrictive temperature (32°C) for 7 days. After this time, melanoma regression was 
obvious by eye, however tumour tissue was still present indicating only partial 
regression. I analysed the melanoma regression in progress by sacrificing the fish at 
this stage.  
 
Histological analysis of these partially regressing tumours allowed us to understand 
the mechanism of regression. By haematoxylin and eosin (H&E) staining, I could 
observe the extent to which the tumour had regressed and showed that the regression 
was characterised by marked loss of tumour density and an accumulation of heavily 
pigmented macrophages (Figure 4.4A). In 7/7 of partially regressing 
BRAFV600Emitfavc7 melanomas, these characteristics were present.  
 
Our initial hypothesis as to the mechanism of regression, after observation of the 
characteristics shown by H&E staining, was apoptosis. This was largely due to the 
presence of large melanophages within the regressing melanoma, which may have 
played a role in clearance of the dying or dead tumour cells, brought about by 
apoptosis. To address whether apoptosis contributed to the regression mechanism I 
stained sections of the partially regressing BRAFV600Emitfavc7 melanomas with an 
antibody to detect active (cleaved) caspase-3 (Adams et al., 2007) (Figure 4.4B). I 
found that high levels of active (cleaved) caspase-3 were present in these regressing 
tumours (5/5). In contrast, as a control, I also stained non-regressing 
BRAFV600Emitfavc7 melanomas with the same antibody and no activity was observed 
(5/5).  
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4.2.4 Regression of tumour growth in mitfavc7 p53M214K (BRAFV600E-
independent) mutants at 32°C 
 
To take further advantage of the temperature-sensitive nature of the mitfavc7 allele 
and test the dependence of mitfavc7p53M214K melanomas on MITF, I upshifted 
mitfavc7p53M214K zebrafish with pre-established tumours grown at 28°C, to 32°C for 
14 days. Before, during and after the upshift period, I took photographs of the 
zebrafish to record external, visible changes in the tumours. I observed melanoma 
regression in 11/11 mitfavc7p53M214K zebrafish upshifted to 32°C for 14 days, visible 
by reduced tumour size and pigmentation (Figure 4.5). The experiment was 





















Aside from the identification of the somatic mutation, MITFE318K (Bertolotto et al., 
2011, Yokoyama et al., 2011), MITF mutations in human melanoma are rare 
compared to MITF amplifications, which are found in 10-20% of melanomas. 
Garraway and colleagues first identified MITF as an amplified oncogene in 
melanoma using integrated SNP array and expression profile analyses. They also 
found that these amplifications were more prevalent in metastatic disease and 
correlated with a reduced patient survival rate and that MITF cooperates with 
oncogenic BRAF to transform melanocytes (Garraway et al., 2005). MITF is 
expressed in most human melanomas and its continued expression is essential for the 
survival of melanoma cells as well as for their proliferation (Levy et al., 2006). Its 
expression however, is much lower in melanoma cells than normal melanocytes and 
if increased, melanoma cell proliferation is reduced, even in the presence of 
oncogenic BRAF (Wellbrock and Marais, 2005). High expression of MITF has also 
been shown to reduce melanoma cell tumorigenicity (Levy et al., 2006). In 2007, 
Gray-Schopfer and colleagues proposed that ‘MITF regulates distinct functions in 
melanocytic cells at different levels of expression,’ suggesting that levels of MITF 
protein must be carefully controlled in a melanoma environment to maintain 
tumorigenicity (Gray-Schopfer et al., 2007). MITF expression levels vary 
considerably between melanoma specimens; in some they are high (in cases of 
amplifications) and in others expression is low or decreased (Steingrímsson et al., 
2004).  
 
How can MITF be simultaneously lost and amplified during melanoma progression?  
 
The discovery of MITF amplifications highlights the need for melanoma cells to be 
able to maintain a sufficient level of MITF activity for survival, in the presence of 
oncogenic BRAF. A common feature of melanomas therefore, may involve the 
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maintenance of sufficient levels of MITF activity for survival and proliferation, or in 
other words, carefully regulating the MITF rheostat described by Carreira and 
colleagues (2006). The rheostat model provides a framework to further our 
understanding of the role of MITF in both melanocyte development and its opposing 
pro- and anti-proliferative roles in melanoma progression (Carreira et al., 2006). In 
melanoma, the balance of MITF activity must be finely regulated. Both high levels of 
MITF that promote cell cycle arrest and differentiation, as well as lower levels, 
which lead to cell cycle arrest and apoptosis must be restricted (Carreira et al., 2006). 
The rheostat accounts for MITF function in melanoma and provides a model in 
which low MITF is a hallmark of stem cell-like cells and higher MITF levels 
promote proliferation or differentiation (Carreira et al., 2006). Although we now 
understand that different levels of MITF promote different cellular phenotypes, what 
controls this MITF rheostat is still unclear. One possibility is simply that MITF 
levels control it, but other factors including post-transcriptional modifications and the 
transcriptional regulation of downstream target genes may also be important.  
 
Our BRAFV600Emitfavc7 melanoma model shows that low levels of MITF are 
oncogenic with BRAFV600E and, for the first time, MITF is required for the survival 
of melanoma in vivo. By taking advantage of the temperature-sensitive nature of the 
mitfavc7 allele, I have shown that upshifting established BRAFV600Emitfavc7 tumours 
grown at <26°C to 32°C causes regression due to insufficient MITF levels. From this 
result, we can confirm that BRAFV600Emitfavc7 melanomas are dependent on MITF for 
their maintenance.   
 
As I have shown that depleting endogenous MITF activity in vivo causes dramatic 
tumour regression, we can speculate that MITF may be a good therapeutic target. 
The current status of melanoma treatment remains challenging due to the recurrence 
of tumours after BRAFV600E inhibition (Das Thakur et al., 2013). The ability to use 
combination therapies that target alternative melanoma pathways is therefore 
essential to improve patient survival. Our work suggests that MITF may be a 
potential target and an effective approach to melanoma therapy, which correlates 
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with research from the literature attempting to target MITF using different 
approaches.  
 
CDK2 has been shown to be a target gene of MITF (Du et al., 2004) and therefore 
one approach to target melanomas with amplification of MITF, as well as a BRAF 
mutation was to use a combination of CDK2 and BRAF inhibitors. Du and 
colleagues found that depletion of CDK2 suppressed growth and cell cycle 
progression in melanoma and, as CDK2 activity is tightly regulated at the 
transcriptional level by MITF, it also represents an additional drug target in 
melanoma.  
 
A second pharmacological approach by Yokoyama and colleagues (2008) utilised 
histone deacetlyase (HDAC) inhibitors to suppress MITF and promote anti-
melanoma efficacy in vitro and in mouse xenografts. One of the problems of 
targeting MITF is that it is a transcription factor that is not dependent on ligand 
binding. This means that drugs cannot simply be designed that will block its 
transcriptional activation. Despite this disadvantage, Yokoyama and colleagues 
showed that HDAC inhibitors could antagonize MITF specifically in melanocytes 
through transcriptional downregulation of the MITF promoter. This suggests that 
HDAC inhibitor drugs are potential candidates as therapeutics to target conditions 
affecting the melanocyte lineage, including melanoma (Yokoyama et al., 2008).  
 
There is potential for MITF inhibitors to be part of future melanoma therapeutics as 
MITF is a lineage survival factor in melanocytes and many melanomas retain and 
depend on MITF as a survival factor. It is possible therefore to suspect that even for 
melanomas without an MITF amplification, targeting against MITF may be 
therapeutically beneficial. McGill and colleagues for example showed that 
suppression of MITF expression was lethal to most melanoma cell lines, causing 
apoptosis that could be rescued by overexpression of BCL2, an MITF target gene 
(McGill et al., 2002).  
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In contrast to the potential use of MITF inhibitors described, it is expected that a 
subset of melanomas with downregulated or loss of MITF will not respond to MITF-
targeted therapeutics. From our data, it is also important to note that while targeting 
MITF may be effective in a melanoma therapeutic setting, we must address this 
strategy with careful attention as we have also shown that low levels of MITF are 
oncogenic. 
 
Our results also highlight the variation of MITF expression observed in human 
melanoma samples and this would have a direct effect on the therapeutic range for 
which MITF inhibitors may be beneficial. I found that 4/12 BRAFV600E mitfavc7 
tumours did not regress when temperature was increased to 32°C, at which levels of 
MITF were reduced. Explanations for this could include differences in initial levels 
of MITF expression or the degree of melanoma progression prior to the temperature 
upshift. These tumours may also possess additional mechanisms to overcome MITF 
shutdown, similar to those identified for BRAF inhibition resistance. Whatever the 
reason for this divergence, it is important for the way in which MITF inhibitor 
treatment is managed. MITF inhibitors may prove beneficial to some patients not 
others and, like trials with the BRAF inhibitor vemurafenib, prolonged use of the 
drug may lead to tumours developing resistance. As suggested by Das Thakur and 
colleagues (2013), it may be important to take drug ‘holidays’ during treatment 
regimes to prolong their use and prevent resistance developing.  
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Chapter 5: Exploring the melanoma genomic mutation and 
expression landscape 
 
In Chapter 4, I showed how BRAFV600E-cooperating mutations mitf and p53 play an 
important role in determining pathological features of melanoma and are responsible 
for drive two distinct melanoma subtypes. 
 
In this final data chapter, my aims are to explore the gene expression landscape of 
BRAFV600Emitfavc7, BRAFV600Ep53M214K, and BRAFV600Emitfavc7p53M214K melanomas 
using RNA-seq and identify novel mutations in these tumour samples through exome 
sequencing. This was an important part of my research, as it would not only identify 
differences in gene expression that characterise the individual melanoma subtypes, 
but also has the potential to discover new genes and pathways involved in 
melanomagenesis.  
 
I will first introduce the current melanoma target genes that have been identified 
through multiple sequencing projects and briefly describe the protocol taken to 
acquire data from RNA-seq (in collaboration with Genepool, Dr James Prendergast, 
Graeme Grimes and Dr Ian Overton) of my zebrafish melanomas. I will then 
describe the results from the exome sequencing (in collaboration with Jennifer Yen, 
Sanger Institute, Hinxton) and RNA-seq of the zebrafish melanomas collected from 










5.1 Introduction  
 
5.1.1 Current melanoma target genes identified by sequencing methods 
 
The advances in genomic technologies have allowed us to gain better understanding 
of melanoma genetics. Techniques have progressed from single candidate gene- and 
family- sequencing to whole exome- and genome-sequencing. This has greatly 
improved our ability to identify new drug targets and develop personalised 
therapeutics for melanoma patients.  
 
The mutational burden of melanoma is greater than that of other cancer types, as it 
harbours a larger number of genomic changes. The reason for this is the major 
environmental factor that influences melanoma development, UV light, which 
induces point mutations that cause cytosine to thymidine (C>T) nucleotide 
substitutions (Pleasance et al., 2010). Mutated genes are classified as either 
oncogenes or tumour suppressors and the mutations themselves are either drivers or 
passengers. To distinguish between driver and passenger mutations, four 
characteristics are taken into account: recurrence; non-synonymous to synonymous 
(N:S) ratio; bioinformatic analysis; and biochemical or biological analysis (Walia et 
al., 2012).  
 
Primary studies using candidate gene sequencing, a technique that focused on genes 
that had a previous association with cancer, identified mutations in genes including 
p14 and p16 in melanomagenesis. These mutations were accountable for only a small 
proportion of sporadic and familial melanomas (Chin, 2003). Additional genes with 
identified mutations using this early, basic type of sequencing include BRAF, NRAS, 
CKIT, MITF, GNAQ and others.  
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After completion of the human genome project, single candidate gene identification 
progressed to candidate gene family sequencing. Using this technique, hundreds of 
genes could be studied at once instead of singly, allowing a faster and more high-
throughput approach. The protein tyrosine kinase (PTK) family of genes was the first 
family to be fully sequenced using this method. It was chosen because many 
members of this family had already been associated with tumorigenesis and, as part 
of the kinase superfamily they were known to be susceptible to pharmalogical 
inhibition and so were potential new drug targets. Prickett and colleagues (2009) 
carried out the mutational analysis of this gene family in cutaneous metastatic 
melanoma and identified 30 somatic mutations affecting the kinase domains of 19 
PTKs in 79 melanoma samples. The study found ERBB4 to be the most commonly 
mutated PLK gene, with mutations resulting in increased kinase activity and 
transformation ability (Prickett et al. 2009). This result showed that candidate gene 
family sequencing could identify mutations in genes within families and these could 
be used as potential new therapeutic targets.  
 
Although sequencing gene families proved to be a powerful tool to identify 
melanoma candidate genes, new high-throughput technologies became available that 
allowed whole exomes and genomes to be sequenced. Wei and colleagues carried out 
the first exome-wide study of melanoma in 2011. They performed exome-sequencing 
of 14 matched normal and metastatic tumour samples from untreated melanoma 
patients (Wei et al., 2011). The study identified 68 genes that were ‘somatically 
mutated at an elevated frequency’ and most importantly found a previously 
unidentified gene, GRIN2A, mutated in 33% of the melanoma samples (Wei et al., 
2011). GRIN2A is part of a family of genes that encode glutamate receptors that bind 
NMDA. Together the data from Prickett and colleagues (2011) showing that 16% of 
melanomas have mutations in GRM3, and Shin and colleagues (2008) showing that 
the expression of GRM1 results in melanocyte transformation, implicates the 
importance of glutamate receptor signalling in melanoma.    
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In contrast to whole-exome sequencing, which was fruitful in its ability to identify 
new cancer genes as described above, whole-genome sequencing provided a more in-
depth investigation into mutational changes, including those within regulatory gene 
regions. In 2010, Pleasance and colleagues described the first whole-genome study of 
melanoma, comparing somatic mutations found in malignant melanoma and 
lymphoblastoid cell lines derived from the same patient. Missense mutations were 
identified in two novel cancer genes, SPDEF and UVRAG and overall the study 
showed that DNA repair mechanisms were initiated preferentially at transcribed 
DNA regions rather than those untranscribed (Pleasance et al., 2010).  
 
As sequencing technologies have progressed from single-gene to whole-genome so 
has our ability to learn more about the human genome and the way it is altered in, for 
example, cancer. Our approach to carry out RNA-seq/whole transcriptome shotgun 
sequencing (WTSS) of zebrafish melanomas from different genetic backgrounds was 
chosen with the aim to explore their expression landscape and identify to changes in 
















5.1.2 Whole transcriptome shotgun sequencing (WTSS) (RNA-seq) of 
tumour tissue from zebrafish melanomas 
 
The approach I took to explore the expression landscape of melanoma involved the 
preparation of RNA from zebrafish melanomas, paired-end transcriptome sequencing 
(carried out by an University of Edinburgh-based company, Genepool) and 
bioinformatical analysis of the output reads. Details of RNA preparation and quality 
control testing are detailed in Chapter 7: Material and Methods. 
 
Prepared RNA from 34 zebrafish melanomas was sent to Genepool, a next-
generation genomics and bioinformatics facility based within the School of 
Biological Sciences at The University of Edinburgh (http://genepool.bio.ed.ac.uk). 
Here, an Illumina platform was used to carry out paired-end sequencing of the 
tumour samples from different genetic backgrounds.  
 
The more recent development of next generation sequencing (NGS) has allowed for 
the sequencing of RNA transcripts and, as a consequence, the ability to investigate 
alternative splicing, gene fusion, post-translational modification and changes in gene 
expression. Prior to NGS, these types of transcriptome and gene expression level 
change studies were carried out using expression microarrays. An expression (or 
DNA) microarray is a collection of DNA sequences that are spotted onto a solid 
surface, which is then used to measure expression levels of many genes at the same 
time. One advantage that RNA-seq has over expression microarrays is the depth of 
coverage obtained. The arrays used were only ever as good as the database they were 
designed from, so for this reason they had a limited application. Importantly for my 
project, many types of cancer are caused by very rare mutations and would be 
undetectable using microarrays. NGS technologies such as RNA-seq are therefore 
essential tools to identify small, but important, changes in gene expression, which 
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could lead identification of novel therapeutic targets. For this reason, RNA-seq 
technology was chosen as the technique to use for this project with an aim to 
understand the genetic expression landscape of zebrafish melanomas. Combining 
RNA-seq and exome sequencing in this project is also advantageous as it allows 
detection of both gene mutation and expression.  
 
To summarise the RNA-seq workflow in brief, the RNA prepared from the sample 
tissue is converted to cDNA through a process of fragmentation. From the cDNA, 
short reads are obtained and then aligned to the reference genome, which can then be 
classified as exonic, junction or poly (A) reads to form a comprehensive, base-
resolution expression profile (Wang et al., 2009).  An Illumina platform is then used 
to carry out paired-end transcriptome sequencing and produces millions of reads, 




















5.2 Results of exome sequencing 
 
In collaboration with Dr Jennifer Yen, Dr Derek Stemple and Professor Andy Futreal 
(Wellcome Trust Sanger Institute, Hinxton, UK), we carried out exome sequencing 
of zebrafish melanomas to explore their genetic heterogeneity and mutational burden 
(Yen et al., 2013).  
 
My role in this study was to provide melanoma and non-tumour samples from 
BRAFV600E – driven transgenic zebrafish. The protein coding exons of these samples, 
in combination with melanomas from NRASQ61K mutant zebrafish, were sequenced. 
The main finding from the exome sequencing was that, surprisingly, the engineered 
zebrafish melanomas harboured a low mutational burden with a strong, inverse 
association with the number of initiating germline driver mutations (Figure 5.1; Yen 
et al., 2013). The number of coding mutations identified in the zebrafish samples was 
significantly lower that that previously reported in human melanoma (4 as opposed 
to 171, Krauthammer et al., 2012). As well as a low number of substitutions, the 
study identified very few recurrent mutations, providing evidence that very few 
additional mutations are required to drive melanomagenesis in BRAFV600E and 
NRASQ61K – driven transgenic zebrafish. This result also suggests that these models 
could be used to estimate the number of events in human cancer. A reassuring 
finding was that 60% of the genes mutated in the zebrafish melanomas were also 
found with at least one mutation in human melanoma.  
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One aspect of the study involved the comparison of UV- and non-UV- mutational 
spectra. Recent studies have shown that more than half of the driver mutations 
identified in human melanoma are not associated with the UV radiation signature. As 
the zebrafish melanoma samples were collected from an environment without UV 
light exposure, they could be used as an example of a UV-independent dataset. 
Consistent with other human cancers, including melanoma, the most common 
mutational change identified in the zebrafish melanomas was the C > T substitution. 
This type of change accounted for 24.4% of the total number of mutations identified 
across all samples in the experiment. As reported by Krauthammer and colleagues 
(2012), like melanomas from non sun-exposed areas, zebrafish melanomas showed 
no significant bias in mutations from any class on any strand. This is in contrast to 
human melanoma from sun-exposed areas, which have a characteristic UV mutation 
signature and a mutation strand-bias due to transcription-coupled repair.  The loss of 
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this signature in the zebrafish melanomas suggests that these repair pathways are not 
activated unless they are triggered by a stress or DNA damage factor such as UV.  
 
The presence of indels in the melanoma samples from zebrafish was much lower 
than the average identified in human melanoma (Figure 5.1; Krauthammer et al., 
2012). One interesting result however, was the identification of a single nucleotide 
deletion that resulted in a frameshift mutation in pik3ip1. This gene is a negative 
regulator of PI3K and has a known role in cancer as a suppressor of hepatocellular 
carcinoma development (He et al., 2008).  The mutation was identified in one of the 
BRAFV600E melanoma samples that I provided for the study. The identification of this 
mutation in this particular sample is consistent with a role for PI3K cooperation with 
MAPK deregulation in human melanoma, as first described by Davies in 2012.  
 
One of the key findings of this sequencing project was the identification of a 
recurrently amplified region in a subset of melanoma samples. The most frequently 
amplified genes in this region were prkacaa, samd1, as1ba, wu:fj41e11 and tecra. 
No evidence of amplification of these genes has been found in human cancer datasets 
or other melanoma studies. In addition to these genes, another gene called tert was 
found to amplified in fewer zebrafish melanoma samples but with statistical 
significance. The tert gene is of interest in particular as it is the only known cancer 
gene that is recurrently mutated in this dataset. TERT is amplified in human 
melanoma (Garraway et al., 2005 and Hodis et al., 2012) and has promoter mutations 
in 90% of melanoma patients (Huang et al., 2013 and Horn et al., 2013).  
 
Among the homozygous deletions identified in this zebrafish melanoma sample set 
were four nitr genes from the novel immune type receptor family found in teleosts. 
Unlike immune receptors, these genes do not rearrange, but show structural 
similarities to the T-cell and Ig-like receptors found in mammals. The loss of these 
genes could be relevant in cancer progression in terms of their ability to avoid 
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immune surveillance, consistent with a critical role for immune regulation in human 
melanoma (Miller and Mihm, 2006).   
 
The final analysis of the exome sequencing looked at the functional characterization 
of the most frequently mutated genes in the zebrafish melanomas. Like human 
cancers, the zebrafish melanomas were highly heterogeneous and the majority (68%) 
of genes were mutated in only one tumour sample. Using KEGG pathway analysis, it 
was shown that although most genes are not frequently mutated and significant 
alone, the biological pathways to which they belong are significantly mutated. 
Importantly, the most enriched pathways identified in this study are directly linked to 
the hallmarks of cancer – apoptosis and VEGF signalling. The MAPK signalling and 
cell cycle pathways were also found to have significant enrichment in this study, 
supporting functions important in human melanoma development.   
 
In summary, this study was the first to describe the spectrum of sporadic coding 
mutations in an engineered model of melanoma. The analysis of the exome 
sequencing described provides an understanding of the genetic paths that lead to 
melanomagenesis in BRAF- and NRAS- driven melanoma models. It also provides 
the field with a standard for further studies using engineered animal models of 
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5.3 Results of transcriptome sequencing 
 
5.3.1 Alignment of raw reads to the zebrafish transcriptome 
 
The raw reads produced from the RNA-seq were first aligned to the reference 
genome, in this case the latest assembly of the zebrafish genome, Zv9 (Howe et al., 
2013) using TopHat (Trapnell et al., 2009). The reads were mapped using a tool 
called Bowtie (Langmead et al., 2009), one of the applications available on an in-
house Galaxy server – a general-purpose platform for computational biology that 
supports RNA-seq analysis. Read counts were then estimated using Cufflinks 
(Trapnell et al., 2010), another application available on the Galaxy server.  
 
 
5.3.2 Differential gene expression between melanoma subtypes 
 
The approach I took to explore the differences in gene expression between our 
melanoma subtypes was using a method called DESeq. This is based on the ‘negative 
binomial distribution, with variance and mean linked by local regression’ (Anders 
and Huber, 2010). It is often used to analyse data produced from high-throughput 
sequencing assays, including RNA-seq and test for differential expression (Anders 
and Huber, 2010).  
 
With help from Dr James Prendergast, a heatmap to visualise the differential gene 
expression patterns between melanoma subtypes was developed (Figure 5.2). This 
shows variation in expression of over 50 genes between three melanoma subtypes. 
The zebrafish genotypes from which the melanomas were collected are shown on the 
x-axis: six BRAFV600Emitfavc7, thirteen BRAFV600Ep53M214K and thirteen 
BRAFV600Emitfavc7p53M214K melanomas. On the right are Ensembl gene identities of 
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the genes differentially expressed. The colours represent variation in gene 
expression: down-regulated genes compared to other subtypes are blue, up-regulated 
genes compared to other subtypes are yellow. Black dotted lines surround clusters of 
up- or down-regulated genes that group within genetic subtypes. The dendrograms 
(or tree diagrams) show how closely related both the melanoma subtypes and genes 
are.  
 
A total of 53 genes were differentially expressed between melanoma subtypes and 
are represented in the heatmap (Figure 5.2). Of particular interest were the genes that 
clustered as up- or down-regulated in only one subtype, for example those shown in 
yellow in the lower right corner of the heatmap (Figure 5.2). In this cluster, 28 genes 
are up-regulated in the majority of BRAFV600Ep53M214K melanomas (yellow/green) 
compared to BRAFV600Emitfavc7 and BRAFV600Emitfavc7p53M214K melanomas in which 
they are down-regulated (blue/green). Of these 28 genes, many were unique to 
zebrafish while others included URAH, PGBD4, NTRK3A, HOXD9A and HOXD10A. 
Using DAVID, no functional association between the set of 28 genes was found, 
which could be true or as a result of the high number of un-annotated zebrafish genes 
for which function is unknown. Another interesting cluster included those genes 
found to be mostly up-regulated in both BRAFV600Emitfavc7 and 
BRAFV600Emitfavc7p53M214K melanoma subtypes (yellow/green) compared to 
BRAFV600Ep53M214K melanomas (blue) shown in the top half of the heatmap (Figure 
5.2). Included within this set of 25 genes were NPH2, ENTPD3, HOMER1B, CPA2, 
CPA4, CALCR, FGFR1B and HYAL2. Similar to the first cluster, no functional 
association between these genes was identified.    
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5.3.3 Validation of differential gene expression 
 
I attempted to validate the differential gene expression shown to cluster by 
melanoma subtype in the heatmap (Figure 5.2). In an approach similar to that 
described in section 3.2.5 to identify differentially expressed MITF target genes, I 
carried out qRT-PCR to quantify the expression level of two genes that were 
differentially expressed by RNA-seq. The genes were homeo box D9a 
(ENSDARG00000059274) and homeo box D10a (ENSDARG00000057859). Both 
of these genes were shown to be up-regulated in all BRAFV600Ep53M214K melanomas 
(Figure 5.2, yellow) and down-regulated in most tumours from both 
BRAFV600Emitfavc7 and BRAFV600Emitfavc7p53M214K genetic backgrounds. I 
hypothesised that this same trend would be observed using qRT-PCR, and expression 
of both hoxd genes would be greater in BRAFV600Ep53M214K tumours than the two 
other melanoma genotypes. Using six tumour samples from each genotype, I carried 
out qRT-PCR for both hoxd genes and found that neither matched the expression 
patterns shown by the RNA-seq data (not shown). As well as being unable to observe 
the same trend in gene expression by qRT-PCR, the number of differentially 
expressed genes that clustered in the heatmap was low (51), causing a bottleneck in 
further analysis. To overcome this, the next step utilised network analysis to identify 
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5.4 Network analysis of RNA-seq data 
 
For this analysis, I focused on the comparison of BRAFV600Emitfavc7 versus 
BRAFV600Ep53M214K melanomas. This simplified the data analysis so I could 
concentrate on the cleanest genetic subtypes, as all tumours in this comparison were 
from double homozygote backgrounds.  
 
5.4.1 STRING network 
 
Two types of network were used to carry out analysis of differentially expressed 
genes identified by RNA-seq. The first was a STRING network, which represents 
pathway co-membership based on KEGG. STRING is a database of known and 
predicted protein interactions constructed for the analysis of associations between 
proteins and the genes that encode them (von Mering et al., 2003). These interactions 
can be either direct (physical) or indirect (functional) and are derived from sources 
including genomic context, high-throughput experiments, co-expression and previous 
knowledge (Franceschini et al., 2013). The database currently describes over 5.2 
million proteins from over 1100 different species. The Kyto Encyclopedia of Genes 
and Genomes (KEGG) is a collection of databases, including the KEGG Pathway 
database, which collects and stores information on networks of molecular 
interactions in cells and their variants. Using the STRING network, which integrates 
data from the KEGG Pathway, I inputted the DESeq data from RNA-seq using an R 
package. Of the differentially expressed genes identified by DESeq, I took the top 
and bottom 1500 genes to take forward for the network. I then visualized the 
STRING network results using Cytoscape, a software platform that allows 
visualization of molecular interaction networks and biological pathways (Figure 5.3). 
The groups of genes (listed in Appendix I, Table A-1) shown by Cytoscape represent 
clustered genes, as defined by the network. Each node (circle within a cluster) 
represents an individual gene and the different coloured nodes represent different 
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tumour genotype comparisons (Yellow: BRAFV600Emitfavc7 vs. BRAFV600Ep53M214K; 
blue: BRAFV600Emitfavc7 vs. BRAFV600Emitfavc7p53M214K; orange: BRAFV600Emitfavc7 
vs. BRAFV600Ep53M214K and BRAFV600Ep53M214K vs. BRAFV600Emitfavc7p53M214K; 
purple: BRAFV600Ep53M214K vs. BRAFV600Emitfavc7p53M214K and BRAFV600Emitfavc7 vs. 
BRAFV600Emitfavc7p53M214K). The node edges differentiate between up-regulated (red) 
and down-regulated (green) gene expression, when comparing BRAFV600Emitfavc7 and 
BRAFV600Ep53M214K melanomas. Cytoscape allows simple modification of colour, 
shape and background and images can be exported as picture files for presentation.  
 
As a result of the STRING network analysis, twenty clusters of differentially 
expressed genes that shared pathway membership were identified (annotated in 
Figure 5.3). A few of these pathways overlapped, including those involved in ion 
binding, membrane-association and proteolysis. One of the clusters identified, which 
through DAVID annotation was associated with voltage-gated potassium channels, 
contained thirteen genes, seven of which were members of the voltage-gated 
potassium channel family – KCNC1A, KCNC4, KCNH5B, KCNF1B, KCNAB1, 
KCNH3 and CKMB. These genes were all up-regulated in BRAFV600Emitfavc7 tumours 
compared to BRAFV600Ep53M214K tumours (shown as red-edged nodes, Figure 5.3). In 
contrast, another cluster identified a group of genes mostly down-regulated in 
BRAFV600Emitfavc7 tumours compared to BRAFV600Ep53M214K tumours that were 
associated with the cytochrome p450 (CYP) superfamily of hemoproteins (Figure 
5.3). The cluster also contained thirteen genes, eight of which were members of the 
CYP superfamily – CYP17A2, CYP2AA3, CYP2AA9, CYP2K16, CYP2K17, CYP2P7, 
CYP2X9 and CT737. All eight of these genes were down-regulated in 
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5.4.2 IMP network 
 
The second network used in the analysis was the IMP network, which represents 
functional similarity defined by GO-term co-annotation. Integrative multi-species 
prediction (IMP) is an interactive web server that provides access to a large, cross-
organism collection of functional predictions and networks (Wong et al., 2012). This 
network was used subsequent to the STRING network in order to provide a direct 
comparison of the clusters of genes differentially expressed between 
BRAFV600Emitfavc7 and BRAFV600Ep53M214K  melanomas. Similar to the first analysis, I 
took the top and bottom 1500 genes from the DESeq results and inputted them into 
IMP network using an R package. I then visualized the IMP network results using 
Cytoscape (Figure 5.4). The groups of genes (listed in Appendix I, Table A-2) shown 
by Cytoscape represent clustered genes, as defined by the network. Each node (circle 
within a cluster) represents an individual gene and are coloured either green or red to 
represent whether they are up- or down-regulated in BRAFV600Emitfavc7 melanomas 
compared to BRAFV600Ep53M214K melanomas, respectively.  
 
As a result of the IMP network analysis, another twenty clusters of differentially 
expressed genes that shared functional properties were identified (annotated in 
Figure 5.4). Similar to the STRING network analysis, a few of these pathways 
overlapped, including those involved in ion binding, transmembrane transport and 
fibroblast growth factors (FGFs). Interestingly, two of the clusters identified and 
classified as associated with transmembrane transport were found to contain genes 
both up- and down-regulated in BRAFV600Emitfavc7 melanomas compared to 
BRAFV600Ep53M214K melanomas. In one cluster of four genes, SLC22A7A, SLC22A7B, 
SLC22A11 and SLC22A16 were found to be up-regulated in BRAFV600Emitfavc7 
tumours (shown as green nodes, Figure 5.4). In another cluster of five genes, CKMB, 
SLC1A3, SLC5A1, SLC5A5 and SLC7A1 were found to be down-regulated in 
BRAFV600Emitfavc7 tumours (shown as red nodes, Figure 5.4). This result 
demonstrates how genes from the same family can be differentially regulated within 
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a single tumour subtype. Another interesting and positive result was the presence of 
genes within clusters from the IMP network analysis that were also identified within 
clusters using the STRING network. These genes were found in clusters that were 
functionally related by their association with G protein-coupled receptors and 
included GRIN2AA, GRIN2AB and GRIN2BB. Similar to the gene clusters associated 
with transmembrane transport, the GRIN genes and others associated with G protein-
coupled receptors were found to be both up- and down-regulated in 
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Using both STRING and IMP networks during the analysis allowed for a more 
comprehensive exploration of the differentially expressed genes between 
BRAFV600Emitfavc7 and  BRAFV600Ep53M214K melanoma subtypes. Whereas the 
STRING network reflects biological pathway co-membership based on KEGG, the 
IMP network reflects functional similarity and is based on GO-term annotation. 
Initial analysis using the STRING network alone provided a good set of clustered, 
differentially expressed genes with overlapping functions including ion binding, cell 
membrane-associated and proteolysis. A second, subsequent analysis using the IMP 
network allowed for a comparison of the functional annotation of the clusters, with 
similar groups including ion binding, transmembrane transport and G protein-
coupled receptors. By combining the analyses using STRING and IMP networks, I 
was able to recognise genes identified using both networks providing confidence in 
those selected for further validation.  
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5.4.3 qRT-PCR validation of differentially expressed genes identified by 
network analysis 
 
Clusters of differentially expressed genes identified by network analysis, with 
functional relevance through annotation by DAVID, were selected for further study. 
Two groups of genes were of particular interest, the phosphodiesterases (PDEs) and 
glutamate receptors (GRINs). Of the phosphodiesterases, PDE1a, PDE4a and 
PDE11a were chosen for validation. GRIN2aa, GRIN2ab and GRIN2bb from the 
glutamate receptor family were validated. 
 
DESeq determines the log fold change values for the difference in expression of 
these genes between BRAFV600Emitfavc7 and BRAFV600Ep53M214K melanomas (Table 
3). A positive log fold change value shows expression is higher in BRAFV600Emitfavc7 
compared to BRAFV600Ep53M214K melanomas. A negative log fold change value 
shows expression is higher in BRAFV600Ep53M214K compared to BRAFV600Emitfavc7 
melanomas.  
 
Table 3. Log fold change values for the expression of genes in BRAFV600Emitfavc7 and 
BRAFV600Ep53M214K  melanomas. 
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To validate these values, I carried out qRT-PCR using five tumours from each 
tumour genetic background. I hypothesised that I would observe the same trends of 
gene expression from both DESeq (RNA-seq) and qRT-PCR.  
 
I found that 2/3 of the expression trends for both the PDE and GRIN genes matched 
between the DEseq and qRT-PCR methods (Figure 5.5; 5.6). For the 
phosphodiesterases, the expression of PDE4a was significantly higher in 
BRAFV600Emitfavc7 melanomas than in BRAFV600Ep53M214K (p=0.0217) (Figure 5.5). 
The expression of both PDE1a and PDE11a was also greater in BRAFV600Emitf 
melanomas compared to BRAFV600Ep53M214K tumours, although neither of these 
expression trends was found to be statistically significant (Figure 5.5). Using both 
DESeq data and qRT-PCR validation, the expression of both PDE1a and PDE4a 
were higher in BRAFV600Emitfavc7 melanomas compared to BRAFV600Ep53M214K 
tumours (Table 3; Figure 5.5). In contrast, the DESeq data showed that expression of 
PDE11a was greater in BRAFV600Ep53M214K tumours (Table 3, log fold change = -
3.058), while qRT-PCR showed that it was greater in BRAFV600Emitfavc7 tumours 
(Figure 5.5), although this was not statistically significant.  
 
In a similar fashion to the PDEs, 2/3 of the expression trends for GRIN genes 
matched between the DEseq and qRT-PCR methods (Table 3; Figure 5.6). By qRT-
PCR, the expression of GRIN2aa was significantly greater in BRAFV600Emitfavc7 
melanomas compared to BRAFV600Ep53M214K melanomas (Figure 5.6). This qRT-PCR 
data validated the expression difference calculated by DESeq, in which the 
expression of GRIN2aa was also shown to be greater in BRAFV600Emitfavc7 tumours 
compared to BRAFV600Ep53M214K tumours (Table 3, log fold change = 3.542). Using 
both DESeq data and qRT-PCR validation, the expression of GRIN2bb was also 
found to be greater in BRAFV600Emitfavc7 melanomas compared to BRAFV600Ep53M214K 
tumours (Table 3; Figure 5.6). In contrast, while the DESeq data showed that the 
expression of GRIN2ab was greater in BRAFV600Ep53M214K tumours (Table 3, log fold 
change = -1.602), qRT-PCR data showed that it was greater in BRAFV600Emitfavc7 
tumours (Figure 5.6), although this was not statistically significant.  
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To summarise the validation approach, network analysis identified functionally- 
related groups of genes that were differentially expressed between two melanoma 
subtypes. The phosphodiesterases and glutamate receptors were selected from these 
groups as biologically interesting and chosen for further study. I was able to validate 
the significant changes in gene expression identified by network analysis by qRT-
PCR in 4/6 genes (PDE1a, PDE4a, GRIN2aa and GRIN2bb). This broadly validates 
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5.4.4 Validation of differentially expressed phosphodiesterase genes 
identified by network analysis using a cAMP assay 
 
The differential gene expression of the phosphodiesterases and particularly the high 
PDE4a expression in the BRAFV600Emitfavc7 melanomas shown by both RNA-seq and 
qRT-PCR (Figure 5.5; Table 3) lead to a hypothesis that cAMP levels may be lower 
in this tumour subtype. The role of phosphodiesterases is to degrade the 
phosphodiester bond in second messenger molecules cAMP and cGMP; hence if 
levels of these enzymes were higher in a tumour, I predicted that levels of cAMP 
and/or cGMP would be lower.  
 
To test this hypothesis, I carried out a cAMP ELISA assay using tumour tissue from 
BRAFV600Emitfavc7 and BRAFV600Ep53M214K melanomas. I calculated the cAMP 
concentration of six tumour samples from each melanoma subtype (Figure 5.7) and 
found that there was no significant difference between BRAFV600Emitfavc7 and 
BRAFV600Ep53M214K melanoma cAMP concentration (p=0.395). To confirm this result 
it would be useful to include more tumours in the experiment to overcome variation 
and eradicate outliers, as well include wild-type adult tissue samples to compare 
cAMP concentrations in tumour to normal tissue.  
 





Sequencing technologies have rapidly advanced to allow greater understanding of the 
human genome and the way in which it is altered in cancer. To explore both the gene 
mutation and expression landscape of BRAFV600E melanomas, I took an approach 
utilising both exome and transcriptome sequencing. By employing RNA-seq 
(transcriptome sequencing) methodology, I was able to investigate gene expression 
levels and the presence of splice variants, which exome and whole-genome 
sequencing do not provide. I hypothesised that differential gene expression identified 
between the two melanoma subtypes, driven by BRAFV600E-cooperating mutations 
mitf and p53, would provide greater understanding of the different histological 
characteristics of these melanomas. 
 
In 2010, Berger and colleagues carried out RNA-seq using eight patient-derived 
melanoma cultures and two melanoma cell lines. RNA-seq data in combination with 
chromosomal copy number data identified 11 novel melanoma gene fusions and 12 
novel readthrough transcripts (Berger et al., 2010). The tumour suppressor RB1 was 
part of one of the gene fusions identified and found in a region commonly deleted in 
melanoma, suggesting that inactivation of RB1 may contribute to melanoma 
pathology (Berger et al., 2010). This research provided a platform for future 
transcriptome studies and demonstrated ‘the capability of RNA-seq to interrogate the 
full spectrum of RNA-based alterations relevant to cancer through integrative 
analysis’ (Berger et al., 2010). 
 
With the premise initiated by previous successful RNA-seq studies, including that of 
Berger and colleagues (2010), I collected 34 melanoma samples from 
BRAFV600Emitfavc7, BRAFV600Ep53M214K, and BRAFV600Emitfavc7p53M214K genetic 
backgrounds to take forward for transcriptome sequencing. The initial analysis of the 
data using DESeq was inadequately fruitful, returning only 51 differentially 
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expressed genes in biologically unconnected pathways (Figure 5.2). It did, however, 
demonstrate similar expression levels of clusters of genes unique to one melanoma 
subtype.  
 
It was interesting that no fusion transcripts were identified by RNA-seq in any of the 
melanoma subtypes. Gene fusions that arise from translocations and other 
chromosomal abnormalities are a common and important feature of cancer, and until 
recently very few were known in melanoma. The study by Berger and colleagues 
(2010) identified eleven novel gene fusions involving four genes on separate 
chromosomes, but also suggested that unlike other tumour types with common gene 
fusions, these are low frequency events in melanoma (Berger et al., 2010). The 
absence of gene fusions from our RNA-seq data may therefore reflect this low 
frequency or the fact that these are very rapid onset tumours and hence provide much 
less time to rearrange and accumulate mutations compared to humans.  
 
To further explore the differential gene expression, I carried out network analysis, 
which returned functionally relevant clusters of genes in interesting molecular 
pathways. Due to time restraints, I selected two of these clusters to validate using 
qRT-PCR. This selection was based on established links between the associations of 
these genes with melanoma.  
 
The differential expression of genes from the glutamate receptor family, GRIN2aa, 
GRIN2ab and GRIN2bb, were of particular interest due to the recent association of 
several glutamate receptor signalling members and a pathogenic pathway in 
melanoma. The GRIN family members encode for glutamate (N-methyl-(D)-aspartic 
acid (NMDA)) receptor subunits of an ionotropic glutamate receptor. As previously 
described, GRIN2A was found to be the highest mutated gene in a screen of 14 
metastatic melanoma samples by Wei and colleagues (2011). Gene amplifications of 
GRIN2B and GRIN2C in melanoma cell lines have also been identified using 
combinations of RNA-seq, SNP-analysis and comparative genome hybridization 
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(CGH) (Valsesia et al., 2011). GRM3, a group 2 glutamate receptor, was also found 
frequently mutated in a targeted exome sequencing study of 11 metastatic 
melanomas (Prickett et al., 2011). Together, these three studies highlight the 
significance of glutamate receptor signalling in melanoma and indicate a potential 
novel therapeutic strategy. From RNA-seq and qRT-PCR data, I found the 
expression of both GRIN2aa and GRIN2bb to be greater in BRAFV600Emitfavc7 
melanomas than BRAFV600Ep53M214K melanomas (Figure 5.6; Table 3). The 
differential expression of these genes identified by RNA-seq and validated by qRT-
PCR, suggests these, and potentially other glutamate receptor family members may 
in part be responsible for the distinction between BRAFV600Emitfavc7 and 
BRAFV600Ep53M214K melanoma subtypes.  
 
The differential gene expression of the phosphodiesterases and particularly the high 
PDE4a expression in the BRAFV600Emitfavc7 melanomas shown by both RNA-seq and 
qRT-PCR (Figure 5.5; Table 3) led to a hypothesis that cAMP levels may be lower in 
this tumour subtype. As the role of phosphodiesterases is to degrade the 
phosphodiester bond in second messenger molecules cAMP and cGMP, I predicted 
that levels of cAMP and/or cGMP would be lower. Using three tumour samples from 
each melanoma subtype, I found no significant difference in cAMP levels between 
BRAFV600Emitfavc7 and BRAFV600Ep53M214K melanomas (Figure 5.7). Despite this 
result, it would be interesting to confirm this finding using greater numbers of 
tumour samples and include a wild-type control tissue sample, which would support 
more extensive follow-up experiments with phosphodiesterases.  
 
One of these follow-up experiments in relation to phosphodiesterases could involve 
the use of PDE inhibitors, which block the enzymatic activity of PDEs and prevent 
the inactivation of cAMP and cGMP. PDE inhibitors are currently used in a clinical 
setting: PDE4 inhibitors have shown promise for treatment of patients with 
autoimmune diseases (Kumar et al., 2013), while PDE5 specific inhibitors are used 
as a first-line treatment for patients with erectile dysfunction (Corona et al., 2011). In 
addition to the specificity of these PDE inhibitors currently used in a clinical setting, 
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of importance to this research are the relationships that have been identified between 
phosphodiesterases and melanoma.  
 
In 2011, Arozarena and colleagues found that downregulation of PDE5A elicits 
melanoma cell invasion. They showed that oncogenic, activated BRAF acts through 
MEK and BRN-2 to down-regulate PDE5A. This then leads to an increase in cGMP, 
which causes a rise of intracellular Ca2+ levels and a dramatic, consequential increase 
in melanoma cell invasion (Arozarena et al., 2011). They also showed that ectopic 
expression of any PDE5 isoform suppresses the invasive capacity of BRAFV600E 
mutant melanoma cells, and that PDE5A is downregulated in a number of melanoma 
lines that harbour oncogenic BRAF (Arozarena et al., 2011). This indicates that 
PDE5A downregulation may be a novel biomarker for increased invasiveness and 
consequent poor prognosis in melanoma. It also implies a novel therapeutic potential 
of up-regulating PDE5A in oncogenic BRAF melanomas, which in theory may 
reduce invasiveness and metastatic potential.  
 
More recently, Hiramoto and colleagues identified a role for PDE2 in melanoma 
growth and invasion. They showed that a specific PDE2 inhibitor, erythro-9-(2-
Hydroxy-3-nonyl) adenine (EHNA) inhibited the growth and invasion of a human 
malignant melanoma PMP cell line (Hiramoto et al., 2014). The effect of EHNA was 
mimicked by transfecting PDE2A-specific siRNA into melanoma cells. The authors 
conclude from these results that PDE2 could ‘play an important role in growth and 
invasion of the human malignant melanoma PMP cell line’ and that ‘selectively 
suppressing PDE2 might possibly inhibit growth and invasion of other malignant 
tumour cell lines’ (Hiramoto et al., 2014). 
 
Both of these studies provide evidence that members of the phosphodiesterase 
enzyme family could play an important role in melanoma invasion and lead to a 
hypothesis that specific phosphodiesterase inhibitors could be used as therapeutics to 
reduce invasive potential. In the Patton laboratory, a specific inhibitor of PDE4, 
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rolipram, has been used in the past as a chemical modifier of the cAMP pathway and 
shown to affect melanosome dispersal (Richardson et al., 2008). As the use of this 
drug is already established within the laboratory, it can be used to treat adult fish and 
directly test the effect of altering PDE activity and cAMP/cGMP levels. As well as 
testing PDE4 using rolipram, it would also be useful to test inhibitors of both PDE2 
and PDE5, as these have both been shown to affect levels of invasion in melanoma 
(Arozarena et al., 2011; Hiramoto et al., 2014). As the melanomas developed in the 
BRAFV600Ep53M214K background are characteristically invasive compared to   
BRAFV600Emitfavc7 melanomas, it would be interesting to test the effect of these PDE 
inhibitors on the invasive nature of these tumours. I could hypothesise that treatment 
of BRAFV600Ep53M214K melanomas with a PDE inhibitor would lead to a less invasive 
phenotype and losing this histopathological feature they would become more similar 
to BRAFV600Emitfavc7 melanomas. Ultimately, if use of any PDE inhibitor in this type 
of experiment affects the characteristic histopathlogical features of the 
BRAFV600Emitfavc7 or BRAFV600Ep53M214K zebrafish melanomas, it may help to 
uncover the role of phosphodiesterases and their inhibitors and show whether it 
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6.1 Concluding Remarks 
 
To refer back to the motivation of this thesis, in recent years the incidence of 
melanoma has increased more than any other cancer type (Seigel et al., 2012) and 
although there have been exceptional advances in therapeutics, the survival rate of 
patients diagnosed with metastatic melanoma is poor. Despite the improvement in 
our understanding of the genes and pathways that contribute to melanomagenesis, the 
driving force behind much of both academic and pharmaceutical research has been 
focused on BRAF and other MAPK pathway inhibitor strategies. In combination 
with BRAF inhibitors, MEK inhibitors such as trametanib (GlaxoSmithKline) have 
shown to improve rates of progression-free survival of patients with metastatic 
melanoma that harbour the BRAFV600E mutation, compared to chemotherapy 
(Flaherty et al., 2012). Combination therapies to address other mechanisms of BRAF 
inhibitor resistance including activation of the PI3K/Akt pathway are also being 
developed. AKT inhibition has been shown to reverse acquired drug resistance to 
BRAF inhibitors in melanoma cell lines and therefore provides evidence of the 
antitumour effect of this combination in patients currently receiving BRAF inhibitor 
therapy (Lassen et al., 2014). KIT inhibitors such as imatinib mesylate have also 
been developed and shown to result in significant clinical responses in patients with 
advanced melanoma harbouring KIT alterations (Carvajal et al., 2011).  
 
Although these therapeutic approaches have shown significant benefit to patients, 
particularly the use of vemurafenib in BRAFV600E mutant melanomas, the innate drug 
resistance and development of side effects associated with these strongly suggests the 
need for novel targets towards this disease. One such target could be MITF, as 
research including that shown here has highlighted the importance of this gene in 
melanoma progression, pathology and survival.  
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MITF has a complex role in melanoma and since 2005, when Garraway and 
colleagues identified a genomic amplification of MITF in melanoma (Garraway et 
al., 2005) and Wellbrock and Marais (2005) determined a relationship between 
MITF and BRAF, recent research has shown that BRAFV600E plays an important role 
in ensuring an “intermediate level” of MITF is sustained to allow tumour growth 
(Hoek and Goding, 2010). Until now, the effects of targeting MITF in vivo have not 
been understood as modulating MITF levels within an animal model had not been 
tested. Here, I present conclusive data showing that low levels of MITF are 
oncogenic with BRAFV600E to promote melanoma (Lister et al., 2014). Key to this 
research is that the melanomas developed in the BRAFV600Emitfavc7 zebrafish share 
similar features to human melanoma pathology, with a superficial spreading growth 
pattern and the presence of heavily pigmented macro-melanophages. In addition to 
these findings, the most remarkable discovery from this research was that abrogating 
MITF activity in BRAFV600Emitfavc7 causes tumour regression, which is characterised 
by melanophage infiltration and an increase in apoptosis. The observed melanoma 
regression caused by a reduction in MITF is a significant discovery and a major 
contribution to understanding the impact of MITF on melanoma development. It 
demonstrates that targeting MITF activity is an effective mechanism to prevent 
and/or inhibit tumour growth. Together, the results confirm a direct interaction 
between MITF and the survival of BRAFV600E melanoma and show that MITF plays 
a key role in the survival of BRAFV600E melanomas. 
 
As well as in melanoma, MITF mutations have been identified in pigment deficiency 
syndromes and renal cell carcinoma (RCC). A link between MITF and RCC lies in 
hypoxia inducible factor (HIF1A), which is a shared target of both MITF and kidney 
cancer susceptibility genes. In 2011, a germline variant in MITF (E318K) was 
identified in an individual with melanoma that affected SUMOylation and was 
significantly over-represented in cases with a family history of melanoma 
(Yokoyama et al., 2011). Also in 2011, Bertolotto and colleagues identified the same 
MITF variant that co-occurred in both melanoma and RCC patients. The MITFE318K 
mutation increased global MITF binding and its transcriptional activity and carriers 
Chapter 6 – Concluding Remarks and Future Directions 
 144 
of the mutation have a 5-fold increased risk of developing melanoma, RCC or both 
cancers (Bertolotto et al., 2011). In addition to melanoma and RCC, mutations in 
MITF are found in patients with Waardenburg syndrome type 2A (WS2A) and Tietz 
syndrome (TS), both characterised by hypopigmentation and deafness. Recently Grill 
and colleagues described how mutations in this single gene, MITF, could cause both 
of the pigment deficiency syndromes and melanoma. The study showed that different 
DNA-binding and transcription activation abilities of the MITF mutations were 
responsible for the different phenotypes they caused (Grill et al., 2013). These 
studies highlight the range of diseases in which MITF plays an important role and 
describe the way in which MITF mutations can lead to distinct disease phenotypes.   
 
As MITF amplifications as well as both somatic and germline mutations of MITF 
have been identified and I have shown that abrogating MITF in BRAFV600E 
melanomas causes regression, it seems valuable to consider MITF as a therapeutic 
target. In previous studies, HDAC inhibitors have been shown to target MITF and 
suppress its expression in melanocytes, melanoma and clear sarcoma cells 
(Yokoyama et al., 2008). In vitro studies have also shown that HDAC inhibitors 
suppress tumour growth in a human melanoma xenograft model (Yokoyama et al., 
2008). Although the mechanism by which HDAC inhibition suppresses MITF is 
unclear, it is thought to involve the suppression of one of its upstream transcriptional 
regulators. A better understanding of this mechanism and experiments testing the use 
of these drugs in a BRAFV600E mutant melanoma for example, may lead to 
identification of the true target of these drugs and the development of MITF 
inhibitors with increased specificity.   
 
As well as the genetic and in vivo evidence supporting MITF as a target gene for 
melanoma, it has also been supported by the discovery that MITF could act as a 
resistance mechanism for melanomas treated with the currently available therapeutics 
(Smith et al., 2013; Johannessen et al., 2013; Van Allen et al., 2014). In 2013, Smith 
and colleagues used human melanoma cells with both induced and de novo 
resistance to MEK inhibitors to show that the resistance correlated with an 
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overexpression of MITF. They found that the expression of MITF in these cells was 
regulated epigenetically by signalling related to TGF-β (Smith et al., 2013). The 
resistance also correlated with an increase in SMURF2 expression, a ubiquitin ligase 
that down-regulates the expression of inhibitory SMADS, including those that 
regulate PAX3 (Smith et al., 2013, Davies and Kopetz, 2013). Inhibiting MITF 
expression by treatment with TGF-β or knockdown of SMURF2, PAX3 or MITF 
itself using siRNAs sensitised the melanoma cells to apoptosis induction by MEK 
inhibition (Smith et al., 2013). The results of this recent study are extremely 
promising and if further research employed clinical specimens and achieved the same 
result, the case for MITF to be presented as a druggable target, in combination 
therapy with MEK inhibitors for example, would be very strong.  
 
In addition to the results from Smith and colleagues (2013), whole-exome 
sequencing identified an amplification of MITF in a melanoma patient with MAPK 
resistance (Van Allen et al., 2014). To test whether the amplification of MITF 
contributed directly to the resistance phenotype, Van Allen and colleagues 
overexpressed mutated MITF in BRAFV600E melanoma cells and cultured them in the 
presence of RAF, MEK and ERK inhibitors. They found that the forced 
overexpression of MITF rendered these BRAFV600E melanoma cells resistant to 
MAPK pathway inhibition (Van Allen et al., 2014). MITF was also overexpressed in 
two different BRAFV600E melanoma cell lines and the cells were treated with the 
BRAFV600E inhibitor PLX4720 (Plexxikon/Roche) before a cell growth inhibition 
assay was performed (Van Allen et al., 2014). In both cell lines, MITF 
overexpression increased the PLX4720 -driven growth inhibition by between 30- and 
80-fold (Van Allen et al., 2014). Both of these experiments confirm that alterations 
in MITF contribute to a clinical resistance mechanism in BRAFV600E melanoma and, 
together with results from Smith and colleagues, highlight the need to target MITF in 
BRAFV600E melanoma.  
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6.2 Future Directions 
 
6.2.1 Exploring MITF as a drug target 
 
The BRAFV600Emitfavc7 zebrafish melanoma model is temperature-sensitive and this 
has proven to be valuable in our ability to modulate MITF activity by temperature 
change. By taking advantage of this feature I have shown that low levels of MITF 
activity in BRAFV600E mutant zebrafish promote melanoma and that completely 
shutting off its activity causes melanoma regression. The regression observed in this 
model highlights the possibility that MITF could be a good drug target for human 
melanoma and also that successful therapeutics must be able to turn off MITF 
activity fully to elicit positive effects.  
 
As a transcription factor lacking ligand dependency, MITF is considered to be a 
difficult drug target using current therapeutics (Yokoyama et al., 2008). Yeh and 
colleagues (2013) now show that recent advances in drug delivery strategies that 
specifically target tumour cells as well as pharmacologic agents will allow 
transcription factors to be directly targeted in cancer (Yeh et al., 2013). Using these 
new technologies would allow specific inhibition of MITF to be tested. The crystal 
structure of MITF has recently been determined and identified both the DNA-binding 
and dimerization domains of MITF (Pogenberg et al., 2012). Together with advanced 
targeting technologies, identifying ligands that specifically bind to pockets within the 
MITF structure could elude to drugs that successfully inhibit its activity.  
 
To identify compounds that have potential to target MITF, a high-throughput drug 
screen could be initially used as an in vitro approach. If successful, such a screen 
could identify compounds that affect the expression of MITF and its downstream 
targets, which could be subsequently used to test the effect of targeting MITF in 
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BRAF mutant cells. It would also be very important to model the effects of targeting 
MITF in vivo and the BRAFV600Emitfavc7 melanoma model presented here would be a 
good animal model in which to do this. Newly identified compounds and inhibitors 
designed that target MITF could be used in future experiments to test if similar 
regression patterns are observed to those shown by shutting off MITF by temperature 
shift.  
 
BRAFV600Emitfavc7 melanomas that regressed after MITF activity was switched off 
were shown to recur when MITF activity was restored. One possible theory for this 
recurrence is that melanoma-initiating cells, which lie dormant when MITF is shut 
off, are stimulated upon MITF activity and repopulate the tumour. Using previously 
established fluorescent reporter lines such as mitfa-GFP (Dooley et al., 2013) and 
making genetic crosses with BRAFV600Emitfavc7 mutants we could visualise the 
mechanisms of tumour regression and recurrence using live imaging. This would 
provide an understanding of how melanoma-initiating cells repopulate the tumour 
site as well as how these cells respond to drug treatment.  
 
As MITF has been shown to act as a resistance mechanism to BRAF and MEK 
inhibition (Smith et al., 2013; Johannessen et al., 2013; Van Allen et al., 2014) it 
would be valuable to determine if MITF is important for survival in these recurrent 
melanomas. One approach would be to test identified targets of MITF in 
BRAFV600Emitfavc7 melanomas that recurred after MITF activity was restored. 
Identifying differences in the degree of tumour recurrence in these zebrafish after 
MITF inhibition could help to establish whether MITF is a good target in recurrent 
melanomas.  
 
BRAF and MEK inhibitors could also be used to treat BRAFV600Emitfavc7 zebrafish 
mutants to model resistance mechanisms and in combination with MITF inhibitors 
assess the potential for targeting MITF in resistant melanomas. Again, these 
experiments could be carried out using the mitfa-GFP fluorescent reporter line 
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crossed to BRAFV600Emitfavc7 mutants to visualise the effect of BRAF, MEK, MITF 
and combination inhibitor treatments in melanoma resistance.  
 
 
6.2.2 A BRAFV600E-independent, mitfavc7p53M214K  melanoma model 
 
In addition to the BRAFV600E melanoma models shown here, the mitfavc7p53M214K 
zebrafish melanomas present a new model for BRAFV600E-independent melanomas. 
These are important models for the development of therapeutic strategies to treat 
patients that do not harbour the BRAFV600E mutation. Similar to the BRAFV600Emitfavc7 
model, these melanomas depend on MITF activity for survival and therefore they 
could also be used to test modulators of MITF as potential new therapeutics.  
 
Preliminary research showed that the mitfavc7p53M214K melanomas were highly 
invasive, comparable to the BRAFV600Ep53M214K tumour growth pattern. Similar 
experiments carried out to those used to compare BRAFV600Emitfavc7 and 
BRAFV600Ep53M214K melanomas would allow further characterisation of the 
BRAFV600E-independent phenotype. It would be interesting for example to assess the 
mitotic activity of these tumours in light of their invasive behaviour and the 
expression of MITF target genes compared to the BRAFV600E melanomas. As 
described in section 3.2.4, the mitotic activity of mitfavc7p53M214K melanomas could 
be determined using the phospho-Histone H3 antibody. If high numbers of phospho-
Histone H3 stained cells, similar to those found in BRAFV600Ep53M214K tumours, were 
found in mitfavc7p53M214K melanomas this would indicate a high mitotic rate. As 
described by Thompson and colleagues (2011), the presence of mitotic figures within 
a tumour tissue implies that cells are actively dividing and usually that tumours will 
grow rapidly with an increased potential to metastasise. This study also confirmed 
that ‘a high tumour mitotic rate reflects a more aggressive tumour that is associated 
with a worse survival outcome’ (Thompson et al., 2011). A high mitotic rate in 
mitfavc7p53M214K melanomas could help to explain their aggressive, invasive growth.  
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The relative expression of C-MET in mitfavc7p53M214K melanoma would be also 
interesting to confirm. MET is frequently found overexpressed in human cancers and 
in particular contributes to the invasive capacity of tumour cells (Stella et al., 2010). 
In this study, I found that BRAFV600Emitfavc7 melanomas expressed higher levels of 
C-MET compared to BRAFV600Ep53M214K, despite the latter genotype showing a more 
invasive behaviour. If C-MET was found highly expressed in mitfavc7p53M214K 
melanomas, this could in part explain its striking invasive behaviour. Inhibitors of 
MET are currently in pre-clinical development (Flaherty, 2006) and if 
mitfavc7p53M214K melanomas have high C-MET expression levels it could act as an in 
vivo model in which to test these drugs.   
 
 
6.2.3 Identification of genes that distinguish between melanoma 
subtypes 
 
The RNA-seq analysis of BRAFV600Emitfavc7 and BRAFV600Ep53M214K zebrafish 
melanomas identified several interesting and biologically relevant groups of genes 
that were differentially expressed and that may help to understand the observed 
histopathological distinctions between these two subtypes. The phosphodiesterases 
were a promising example and although there was no significant difference in cAMP 
levels between the two subtypes, this may mean that the PDEs play an additional role 
to assisting degradation of cAMP in a tumour environment, or that the specific PDE 
genes identified to be differentially expressed do not assist with this role. Directly 
inhibiting the specific PDEs found to be differentially expressed in the tumours 
would allow us to identify how these genes contribute to the pathology of BRAFV600E 
melanomas. As described in Chapter 5, a link between phosphodiesterases and 
melanoma has already been established in two separate studies. Arozarena and 
colleagues (2005) showed that expression of PDE5 suppresses the invasive capacity 
of BRAFV600E mutant melanoma cells and that PDE5A is downregulated in a number 
of BRAF mutant melanoma cell lines. Hiramoto and colleagues (2014) showed that 
inhibiting PDE2 reduces the growth and invasion capacity of a human malignant 
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melanoma PMP cell line. Together these studies suggest an important role for PDEs 
in the invasive nature of melanoma cells and the potential to target these enzymes to 
reduce invasiveness of melanomas. As the BRAFV600Ep53M214K melanoma subtype 
was characteristically invasive compared to its BRAFV600Emitfavc7 counterpart it 
would be extremely valuable to test whether inhibitors of those PDEs found 
differentially expressed would be able to reverse this aggressive behaviour and if so, 
whether these could become novel therapeutic targets for the disease. 
 
The other interesting group of genes identified to be differentially expressed were the 
GRINs and as there is supporting data showing that other members of this gene 
family are involved in melanomagenesis, together the data highlights the significance 
of these genes as potential druggable targets in melanoma. Wei and colleagues 
(2011) found GRIN2A to be the highest mutated gene in a screen of metastatic 
melanomas, while Valsesia and colleagues (2011) identified gene amplifications in 
both GRIN2B and GRIN2C in melanoma cell lines. Prickett and colleagues (2011) 
found GRM3, a group 2 glutamate receptor, frequently mutated in metastatic 
melanomas. Together, these three studies highlight the significance of glutamate 
receptor signalling pathway in melanoma and suggest a potential novel therapeutic 
strategy. A link between glutamate receptors and cancer has previously been 
established in neuronal tumours (Takano et al., 2001). Malignant gliomas with high 
levels of glutamate release have a distinct growth advantage and grow more 
aggressively than parental glial cells (Takano et al., 2001). In a separate study, Shin 
and colleagues (2008) show that expression of GRM1 in melanocytes is sufficient to 
induce melanoma in vivo through activation of ERK. The natural ligand of GRM1 is 
glutamate and excess glutamate is released from GRM1 expressing melanocytic cells 
to promote melanomagenesis (Shin et al., 2008). Together, results from Takano and 
Shin imply a correlation between glutamate release and human cancers.  
 
Suppression of glutamate signalling using glutamate antagonists has been shown to 
inhibit the proliferation of human tumour cells of colon adenocarcinoma, breast and 
lung cancer cell lines (Rzeski et al., 2001). The anti-proliferative effect of these 
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antagonists reduces cell division and motility and increases cell death and invasive 
growth of tumour (Rzeski et al., 2001), further emphasizing the potential to target 
glutamate receptors in anticancer therapies. In a recent review by Stepulak and 
colleagues (2014) the clinical relevance of glutamate receptors in cancer was 
described as well as the attempts to inhibit glutamate receptors using agonists. There 
has been very little success in effective targets of glutamate receptors despite the 
depth of research implicating these molecules in several cancer types including bone, 
breast and prostate (Ren et al., 2012; Speyer et al., 2014; Koochekpour et al., 2012; 
Stepulak et al., 2014). The authors encouraged additional research to define the 
clinical significance of glutamate receptor expression and signaling in cancer, which 
they hope would lead to improved targeting of this pathway in the future.  
 
In a similar manner to the PDE inhibitors, it would be particularly interesting to test 
the effect of glutamate receptor inhibition on the BRAFV600Ep53M214K melanoma 
invasive subtype and identify whether inhibitors would alter the characteristic 
invasive nature. Glutamate antagonists used in previous studies (Rzeski et al., 2001) 
could be used to treat BRAFV600E melanomas in vivo, determine the role of GRINs in 
melanoma biology and validate if members of the glutamate signaling pathway are 


































To prepare 60X stock solution: 
 34.8g NaCl 
 1.6g KCl 
 5.8g CaCl2.2H2O 
 9.78g MgCl2.6H2O 
Dissolve above in H2O to a final volume of 2L. Adjust to pH7.2 using NaOH. To 
prepare 1L of 1X E3 media use 16.5ml 60X stock, make up to 1L with H2O, and add 
100µl 1% methylene blue (Sigma Aldrich).  
 
Tricaine 
Also known as 3-amino benzoic acid ethyl ester or 3-amino benzoate: 
 400mg tricaine (Sigma Aldrich) 
 2.1ml Tris (pH9) 
 97.9ml distilled H2O 
Prepare the above, dissolve using hot plate and stirrer and adjust to pH7. To use as an 
anaesthetic, place 4.2ml tricaine solution in 100ml clean system water.  
 
Paraformaldehyde 
Commercial 16% paraformaldehyde is diluted to a 4% working concentration with 
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EDTA 




A range of ethanol percentages (30-100) were used in various protocols.  
 
Bleach 
A bleaching solution of 10-13% sodium hypochlorite (Sigma Aldrich) is used to 
bleach zebrafish embryos at 24hpf, prior to transfer to the aquarium system. 180µl of 
bleach is mixed with 100ml system water in the bleaching process. 
 
TBS 
A 10X stock of Tris buffered saline (TBS) is made using: 
 61g Trizma base (Sigma Aldrich) 
 90g NaCl 
Prepare solution by dissolving reagents in 800ml of distilled H2O. Adjust to pH8.4 
using concentrated HCl and make up to final 1L volume using distilled H2O. Dilute 
1:10 with H2O to make a 1X working solution.  
 
TBST 
TBS-Tween is prepared using 1L of 1XTBS and adding 500µl Tween-20.  
  
PBS 
A 10X stock of phosphate buffered saline (PBS) is made using: 
 80g NaCl 
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 2g KCl 
 14.4g Na2HPO4 
 2.4g KH2PO4 
Prepare solution by dissolving reagents in 800ml of distilled H2O. Adjust to pH7.4 
using concentrated HCl and make up to final 1L volume using distilled H2O. Dilute 
1:10 with H2O to make a 1X working solution.  
 
PBST 
PBS-Tween is prepared using 1L of 1XPBS and adding 500µl Tween-20.  
 
Citrate buffer 
To prepare 1L 0.01M citrate buffer (pH6) for antigen retrieval: 
 18ml 0.1M citric acid 
 82ml sodium citrate 
 900ml distilled H2O 
Dissolve reagents in water using hot plate and stirrer and then adjust to pH6.  
 
EDTA buffer 
To prepare 1L EDTA buffer (pH8) for antigen retrieval: 
 3.72g EDTA 
 1L distilled H2O 
Dissolve EDTA in water using hot plate and stirrer and then adjust to pH8. 
 
DPX 
Commercial DPX (a mixture of distyrene, a plasticizer and xylene) is used as a 
mounting media for histological protocols. 
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Xylene 




A basic dye used for staining in histology. 
 
Eosin 
An acidic dye used for staining in histology. 
 
Lithium carbonate 
A 1% lithium carbonate solution is used to blue-up fixed sections after H&E staining 
in histology.  
 
Acid-alcohol solution 
1% HCl in 70% alcohol is used to remove excess stain and define nuclei after H&E 
staining in histology.  
 
PTU 
1-phenyl 2-thiourea (PTU) is used to treat embryos and inhibit melanogenesis, 
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7.2 Zebrafish husbandry 
 
Zebrafish were reared and raised according to the United Kingdom Home Office 
Animals (Scientific Procedures) Act (1986) and approved by the University of 




Wild type and transgenic adult zebrafish can be paired (male and one/two females in 
breeding tank with barrier) or marbled (plastic chamber with marbles and mesh 
layer) to collect embryos laid externally by females and fertilised by males. After 
collection, embryos are placed in a petri dish and incubated in E3 medium at 28°C 
until required for experiments or until 5 days post fertilization (dpf) when they can 
be transferred to the system. 
 
7.2.2 Raising embryos 
 
After 5dpf, embryos are large enough to be transferred to either static tanks or into 
the nursery contained within the zebrafish aquarium system. At this age they are fed 
twice daily with paramecium and ZM1000 powder. After 4-6 weeks, they are then 
moved to larger 30 litre tanks within the system and are fed twice daily with brine 
shrimp and dry food. At 3 months they are old enough to be paired for breeding.  
 
7.2.3 Strain origins 
 
BRAFV600E 
Gateway™ technology was employed to clone BRAFV600E under the control of the 
mitfa promoter to generate mosaic BRAFV600E zebrafish.  Single site cloning was 
carried out between a pENT 3C entry clone, containing human BRAFV600E and a 
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destination vector pT2Kmin-NP Dest RfA, carrying the mitfa promoter, flanked by 
Tol2 transposon sequences (provided by Dr. James Lister, USA). A single LR 
recombination reaction was carried out between these two vectors using an LR 
Clonase™ Mix (Invitrogen), according to the manufacturer’s protocol. Co-injection 
of this plasmid with transposase RNA (both at a 25ng/µl concentration) was carried 
out directly into the single-celled embryo. Embryos were transferred to the nursery 
after 5 dpf and raised to adulthood. 
 
mitfavc7 
The mitfavc7 transgenic line was identified from an ENU-mutagenesis screen and 
provided to us by Dr. James Lister, USA. Unlike previous mitfa mutants, in which 
melanocytes are completely absent, zebrafish homozygous for the mitfavc7 allele have 
variable numbers of developing melanocytes when grown at standard temperatures 
and conditions (Johnson et al., 2011). The advantage of this mutant was its 
temperature-sensitivity – the ability to regulate the levels of MITF and therefore the 
number of melanocytes that are able to develop by simply changing the temperature 
of the water in which the mutant was reared. To generate BRAFV600Emitfavc7 double 
homozygotes, genetic crosses were made and all generations of offspring were 
genotyped by PCR/sequencing to confirm BRAF and mitfa allele status. 
 
p53M214K 
 Zebrafish with a missense mutation in the tp53 DNA-binding domain were first 
identified using a target-selected mutagenesis study (Berghmans et al., 2005). The 
p53M214K mutation, used in cooperation with BRAFV600E in this study, causes 
malignant peripheral nerve sheath tumours (MPNST) in 28% of fish at 8.5 months of 
age (Berghmans et al., 2005). Patton et al. (2005) first showed that 
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To tail clip or image an adult zebrafish it must first be anaesthetised. To do this, 
4.5ml tricaine is mixed with 100ml water in a small tank. The zebrafish is then 
caught with a net and placed into the tank containing the anaesthetic until this has 
taken effect (2-3 minutes). After the tail clip or other procedure has been carried out 
during anaesthesia, the zebrafish is placed into a tank of distilled water for recovery 
and then back into its original tank.  
 
7.3.2 Tail clip 
 
Once under anaesthesia, the zebrafish can be placed onto a petri dish lid and a small 
piece of tail fin cut with a scalpel. The tissue is placed into a tube and kept at -20°C 
until required. The zebrafish are usually isolated after the tail clipping procedure 




Imaging of adult zebrafish whilst under anaesthesia or after sacrificing was carried 
out using Nikon light microscope to which a standard digital camera is attached. 
Zebrafish are placed onto a clean petri dish in a pool of distilled water, distributed 
using a plastic pipette. The petri dish is placed onto a white disc under the light 
microscope and brought into focus on the digital display of the camera. Sections of 
the zebrafish are photographed individually and saved. After photography is 
complete, images are downloaded from the camera and edited using Adobe 
Photoshop CS5. Separate images of an individual fish can be merged using the 
‘Photomerge’ tool.  






After sacrificing the zebrafish by immersion in tricaine solution, according to Home 
Office Schedule 1 methods, the fish is dissected in half transversely to increase 
penetration of the fixative. Tissues are then incubated in 4% paraformaldehyde (16% 
paraformaldehyde diluted in PBS) at 3 days at 4°C with agitation. Samples are 
washed with PBS and decalcified in 0.5M EDTA (pH8) for 5 days at 4°C with 
agitation. Tissue is washed again in PBS and then stored in 70% ethanol at 4°C until 
required.  
 
7.4.2 Embedding and sectioning 
 
Fixed tissues, of embryos, adult, or tumour, are embedded in wax to be serially 
sectioned. Sections are cut transversely at 5µm thickness using a macroscope. Cut 
wax sections are floated onto water within a water bath at 55°C, placed onto a slide 
and left to dry on a hot plate.  
 
7.4.3 Haematoxylin and eosin (H&E) staining 
 
H&E staining was carried out on cut, prepared sections on slides. The slides were 
deparaffinised in xylene, 2 x 5 minutes, and then rehydrated through graded alcohol 
solutions (100%, 90%, 70%, 50%, 30%, 5 minutes each) before washing thoroughly 
in running water. Slides were stained for 4 minutes in Mayer’s haematoxylin, washed 
with water, rinsed with 95% acid-alcohol solution for a few seconds, washed with 
water, then counterstained in eosin for 1-2 minutes.  Slides were dehydrated with 
95% alcohol (5 minutes) and absolute alcohol (2 x 5 minutes), and cleared with 2 x 5 
min xylene. DPX was used to mount the slides with coverslips and left to dry in the 
air.  
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7.5 Immunohistochemistry and immunofluorescence  
 
7.5.1 Immunohistochemistry  
 
For immunohistological staining, slides are treated as prior to H&E staining to 
deparaffinise and rehydrate the sections. Slides are then washed in water for 2 x 5 
minutes, bleached in 1% potassium hydroxide/3% hydrogen peroxidase for 15-30 
minutes and washed again in water for 3 x 5 minutes. Antigen retrieval is carried out 
with either citric acid or EDTA buffer: the desired buffer is brought to boiling point 
in a pressure cooker (lid off) in a microwave for 12 minutes; slides are placed into 
the buffer immediately, lid closed, and heated for 2 minutes, then 5 minutes, before 
removing from the buffer and leaving to cool. The slides are then washed with water 
for 3 x 5 minutes, before ensuring all endogenous peroxidase activity is removed by 
incubating in 3% hydrogen peroxidase for 10 minutes. Slides are washed again for 2 
x 5 minutes with water, then for 5 minutes with 1 x TBS and blocked with serum-
free blocking solution (DAKO) for 30 minutes at room temperature. The blocking 
solution is then removed from the slides and the sections are incubated with the 
desired primary antibody (diluted in antibody diluent (DAKO)) overnight at 4°C. 
The primary antibody is removed and the slides are washed in PBS for 3 x 5 minutes, 
before incubation with HRP Rabbit/Mouse secondary antibody (DAKO EnVision 
detection kit) for 30 minutes at room temperature. The secondary antibody is 
removed, washed in PBS for 2 x 5 minutes and the slides are incubated in DAB 
chromagen (DAKO) for 10 minutes to visualise the stain. The chromagen is washed 
off with water for 2 x 5 minutes, and the slides are counterstained: Mayer’s 
haematoxylin for 4 minutes; wash with water; blue-up with lithium chloride (few 
seconds) and wash thoroughly with running water. The samples are then dehydrated 
with one minute incubations in increasing ethanol concentrations (70%, 90%, 2 x 
100%), followed by 2 x 2 minute xylene washes and finally mounting with DPX 
mounting media and coverslips.  




For immunofluorescent staining, slides are treated as prior to H&E staining to 
deparaffinise and rehydrate the sections. Slides are then washed in water for 2 x 5 
minutes and 1 x TBS for 3 x 5 minutes. Antigen retrieval is carried out with citric 
acid buffer, as in the protocol detailed in 7.5.1 and then the slides are washed in 1 x 
TBST for 3 x 5 minutes. Samples are blocked using 10% heat inactivated donkey 
serum (diluted in 1 x TBST) in a humidifying chamber for 90 minutes at room 
temperature. The serum is removed and the primary antibody, diluted in 1% donkey 
serum, is added to the slides, incubating overnight at 4°C. The slides are washed with 
1 x TBST for 4 x 5 minutes, and the secondary antibody is added, incubating for 1 
hour at room temperature in a humidifying chamber away from the light. Slides are 
washed again in 1 x TBST for 4 x 5 minutes, before coverslips are mounted using 1-
2 drops of Prolong Gold (Molecular Probes) mounting media, covered and left to dry 
overnight, away from light, at 4°C. Coverslips are then sealed to the slides using a 
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7.6 Molecular biology techniques 
 
7.6.1 DNA extraction from tail clip 
 
Prepare 100µl of DNA extraction buffer/tail clip and add to tube containing tail clip. 
Mix by flicking tube and then incubate at 56°C for ≥ 3 hours, flicking the tube every 
½ -1 hour. Add 200µl ethanol/Na-acetate solution to each tube and mix by pipetting. 
Incubate at room temperature for 15 minutes. Centrifuge for 10-30 minutes at max 
speed (or until visible pellet forms). Remove supernatant and wash pellet by adding 
500µl 70% ethanol to each tube, centrifuge for 10 minutes, remove supernatant and 
allow pellet to dry in air for ~2 minutes. Re-suspend DNA in 20-50µl TE buffer and 
store at -20°C.  
 
7.6.2 RNA extraction from tail clip or tumour tissue 
 
 
Homogenize sample by adding 500µl Trizol to the tube and using a powered 
tip/crushing with mortar and pestle. Transfer the homogenized sample into tube and 
add additional Trizol (1ml/50-100mg tissue). Incubate for 5 minutes at room 
temperature to permit the complete dissociation of nucleoprotein complexes.  Add 
200µl of chloroform per ml of Trizol, shake with hand for 15 seconds and incubate at 
room temperature for 2-3 minutes. Centrifuge at 12,000G for 15 minutes at 4°C. 
Transfer the upper aqueous phase to fresh tube using cut-off tip and mix with 
isopropanol (250µl isopropanol/500µl Trizol). Incubate the samples at room 
temperature for 10 minutes, then centrifuge at 12,000G for 10 minutes at 4°C. Make 
sure there is a visible pellet, then remove the supernatant and discard. Wash the RNA 
pellet once by adding 750µl 75% ethanol to the tube and pour off to leave pellet. 
Spin briefly and remove excess ethanol with tissue. Briefly dry the RNA pellet in the 
air, then re-suspend in RNase-free water (20-50µl) and incubate at 60°C for 10 
minutes before storing at -80°C.  
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7.6.3 cDNA preparation from RNA 
 
For RT-PCR/qRT-PCRs, use the Superscript II/III RT kit, using 1µg total RNA in a 
10µl total reaction volume. Prepare a master mix of oligo (dT)12-18 (500µg/ml) and 
dNTPs (5mM). For each reaction, a total of 3µl, use 2.25µl RNA (or RNA with 
RNase-free water) and 0.75µl master mix. Incubate at 65°C for 5 minutes, then 
quickly chill on ice. Prepare a master mix of 5 x First Strand buffer, DTT (0.1M), 
RNase OUT (40 units/µl) and Superscript II/III RT. To each 3µl reaction, add 2µl 
master mix, mix and place in PCR machine set with the following programme: 
Heated lid 110°C, 42°C for 5 minutes, 50°C for 1 hour, 70°C for 10 minutes, 4°C 




To genotype an adult zebrafish, a tail clip must be taken followed by extraction of 
the tail clip DNA and, using the DNA prepared, a PCR using the appropriate primer 




cDNA is prepared as described and relevant primers are diluted to 10µM 
concentration. The SYBR Green JumpStart Taq ReadyMix (Sigma) is used and 
contains a mixture of SYBR Green I (a commonly-used fluorescent DNA binding 
dye), JumpStart Taq DNA polymerase, deoxynucleotides and a reaction buffer. For 
gene of interest to be quantified by this method, a mastermix of SYBR Green 
JumpStart Taq ReadyMix, distilled water and primers are used. 4µl of cDNA is 
placed in wells of a 384-well plate to which the primer mastermix is added. β-actin 
primers are used to normalise the data and distilled water is added to wells instead of 
cDNA to act as a negative control. cDNA and primer mix are added to wells in 
triplicate as a technical replicate. Once cDNA and the primer/JumpStart Taq 
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mastermix has been added to the plate, it is covered and placed in a centrifuge where 
it is spun down (1000rpm for 1 minute) to mix and draw the contents of the wells to 
the bottom of the plate. The plate is then transferred to a Fast Real-Time PCR system 
(HT7900, Applied Biosystems).  
 
7.6.6 Western Blotting 
 
Preparation of the gels 
 
8% Resolving gel. Makes 10ml for 2 gels 
dH2O   3.47ml  
Tris (pH 8.8)  3.73ml  
Acrylamide  2.7ml 
TEMED  10µl 
10% SDS  100µl 
25% APS  40µl 
 
Stacking gel. Makes 4ml for 2 gels 
 
dH2O   2.8ml  
Tris (pH 6.8)  0.5ml  
Acrylamide  0.67ml 
TEMED  10µl 
10% SDS  40µl 
25% APS  20µl 
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Using the above recipes, 0.75 or 1.5mm SDS polyacrylamide gels were prepared. 
Approximately 4ml of resolving gel mixture was placed between glass plates 
(BioRad). To speed up polymerisation and ensure no bubbles formed on top of the 
gel layer, 1ml of isopropanol was pipetted onto the layer of resolving gel. When the 
gel polymerised, the isopropanol was poured off and 1.5ml stacking gel mixture was 
poured on top, before adding a 12 or 15-well comb between the plates.  
 
Preparation of the lysates 
 
To prepare lysates from embryos, these must first be collected, placed in skirted 
tubes with all media removed and snap-frozen for storage at -80°C. Embryos are 
usually aliquoted in 10s to allow ease of lysis and equal protein concentration 
preparation. The lysis buffer is prepared and can be stored at -20°C for subsequent 
use.  
 
Lysis (RIPA) buffer. Makes 10ml 
 
2M Tris HCl (pH 7.5)  250µl 
5M NaCl   300µl 
1% NPO4   100µl 
Na deoxycholate  0.5g 
10% SDS   100µl 
dH20    to make up to 10ml 
 
To lyse embryos, add 40µl prepared lysis buffer to each tube containing 10 embryos, 
as well as about 50 acid-washed glass beads. Ribolyse the samples using a ribolyser 
for 6 seconds at 6.5 speed. Incubate the samples on ice for 15 minutes and centrifuge 
using a table-top centrifuge at maximum speed for 15 minutes. Transfer the 
supernatant to a clean 1.7ml eppendorf tube. Measure the protein content of the 
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lysate by calculating the A380 absorbance using a NanoDrop 2000 
Spectrophotometer.  
Samples must be denatured prior to gel loading by adding respective volumes of 
Sample Buffer according to each lysate’s protein content to make a final volume of 
50µl. Lysate and Sample Buffer mixture is denatured at 95°C for 5 minutes, before 
loading into wells while still warm.  
 
Performing Western Blots 
 
Running the gel 
 
After samples were loaded, the gel was run in a 1xSDS running buffer at 80V. Once 
the samples had reached the level at the bottom of the stacking gel, the voltage was 
increased to 120V until the samples had run out of the gel.   
 
 
Semi-dry protein transfer 
 
To transfer the proteins to synthetic membrane, semi-dry blotting equipment and 
protocol were used (BioRad). First, the gel and membrane were equilibrated in 
1xTransfer Buffer for 15 minutes at room temperature. Filter paper was also soaked 
in 1xTransfer Buffer prior to protein transfer. Using the BioRad apparatus, the pre-
soaked filter paper was placed onto the platinum anode, before placing the 
equilibrated membrane and subsequently the membrane, on top. Another layer of 
pre-soaked filter paper was placed on top of the membrane and air bubbles removed 
using a roller. Lastly, the cathode was placed onto the transfer stack and safely 
sealed. The assembly was connect to a power supply and run at 10V for 30 minutes. 
After successful transfer, the membrane can be removed and incubated with Ponceau 
S stain for 1-2 minutes to detect protein. Prior to blocking, the stain can be removed 








Subsequent to successful protein transfer, the membranes were incubated in a 1% 
milk/TBST solution for 30 minutes at room temperature with agitation.  
 
Primary antibody incubation 
 
The desired primary antibody concentration was prepared in 5ml 1% blocking 
solution. The membrane was placed in a sealed plastic sleeve and incubated with the 
primary antibody overnight at 4°C, with agitation. After overnight incubation, the 
primary antibody was poured off and the membrane washed with 0.1% blocking 
solution for 2 minutes at room temperature, with agitation. After the initial wash, the 
membrane was washed three times with 1xTBST for 5 minutes each at room 
temperature, with agitation.  
 
Secondary antibody incubation 
 
The desired secondary antibody concentration was prepared (usually between 
1:1000-1:2000) in 5ml 1% blocking solution and the membrane incubated in the 
solution for 1 hour at room temperature, with agitation. After secondary antibody 
incubation, the membrane was washed four times with 1xTBST for 5 minutes each, 
at room temperature, with agitation.  
 
Exposure and developing membranes 
 
After the secondary antibody was washed off, the membrane was left briefly to air-
dry. With the protein-side up, the membrane was incubated with 1ml of ECL Plus 
(GE Healthcare) for 5 minutes at room temperature. The membranes were then 
placed onto a glass plate within a developing cassette and sealed with cling film and 
directly exposed on x-ray film for varying lengths of time. The x-ray films were 
developed and scanned using an HP ScanJet 4300C scanner.  
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7.6.7 cAMP ELISA assay 
 
Preparation of tissue samples 
 
The cAMP assay was carried out using a cAMP ELISA kit (Enzo Life Sciences). To 
prepare samples from tumours, frozen tissue is ground to a fine powder under liquid 
nitrogen using a mortar and pestle. After the liquid nitrogen has evaporated, the 
tissue is weighed and homogenised in 10 volumes of 0.1M HCl. The sample is 
centrifuged for 10 minutes at max speed to pellet the debris. The supernatant is then 
used directly in the assay or frozen for a later analysis.  
 
 
Preparation of cAMP standards 
 
cAMP standards are prepared for the standard curve during analysis. As tissue 
samples were prepared using 0.1M HCl, this is also used as the standard diluent. To 
prepare the standards, a 2000pmol/ml cAMP stock (Enzo Life Sciences) is used and 
warmed to room temperature. 900µl of 0.1HCl is placed into five eppendorf tubes 
labelled numbers 1-5. 100µl of 2000pmol/ml standard stock is placed into tube 1 and 
vortexed thoroughly. 250µl of tube 1 is then transferred to tube 2 and vortexed 
thoroughly. 250µl of tube 2 is then transferred to tube 3 and vortexed thoroughly. 
This process is repeated for tubes 4 and 5 to prepare cAMP standards of 0.78, 3.13, 
12.5, 50 and 200pmol/ml concentrations. The diluted standards must then be used for 
the assay within 1 hour of preparation. 
 
Set-up and running of the cAMP assay 
 
To prepare the assay, a Goat anti-Rabbit IgG 96-well microtitre plate (Enzo Life 
Sciences) is used. As well as standards and samples, two blanks (B), two total 
activity (TA), two non-specific binding (NSB) and two zero standard (Bo) wells are 
prepared. Into each well except the blank and TA wells, 50µl of Neutralizing 
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Reagent (Enzo Life Sciences) is added. 100µl of 0.1M HCl is then added to the NSB 
and Bo wells. 50µl of 0.1M HCl is added to the NSB wells. 100µl of each standard 
(1-5) is pipetted into duplicate standard wells and 100µl of each sample is then added 
to each sample well, also in duplicate. 50µl of blue conjugate (Enzo Life Sciences) 
then placed into each well except the blank and TA wells. 50µl of the yellow 
antibody (Enzo Life Sciences) is then placed into each well except the blank, TA and 
NSB wells. The plate is then sealed and incubated for 2 hours on a plate shaker at 
room temperature. After incubation, the contents of the wells are emptied and 
washed three times by adding 400µl of wash buffer (Enzo Life Sciences) to each 
well. After the final wash, the plate is firmly tapped onto a clean, lint-free paper 
towel to remove any remaining wash buffer. 5µl of blue conjugate is then placed into 
the TA wells and 200µl of the substrate solution is pipetted into each well. The plate 
is incubated for a second time for 1 hour at room temperature without shaking. After 
incubation 50µl of stop solution (Enzo Life Sciences) is added to each well to stop 
the reaction. To analyse the reactions, a microplate reader (1420 Multilabel Counter, 
PerkinElmer) is used. The plate reader is blanked using the substrate blank and then 
the optical density (OD) of each well is read at 405nm. To calculate cAMP 
concentration (pmol/ml) a standard curve is drawn using the OD values of the 
standard cAMP concentrations used. From the regression line equation of this curve, 
the cAMP concentration of each unknown sample can be calculated. 
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Table A-1 Genes derived from STRING network analysis 
Each cluster is shown and referred to by row and number, as shown by Cytoscape 
(Figure 5.3). Both Ensembl gene ID and name are given, as well as the results of 
functional analysis using DAVID.  
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ENSDARG00000051852 kcnc1a Voltage-gated 
potassium channel ENSDARG00000069117 kcnh5b 
ENSDARG00000002241 KCNA2 
ENSDARG00000029511 KCNS3 (2 of 2) 
ENSDARG00000062906 kcnv2b 







ENSDARG00000040741 KCNAB1 (3 of 3) 
ENSDARG00000061288 kcnc4 
ENSDARG00000076854 KCNA10 (1 of 2) 
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ENSDARG00000089869 EVA1B (5 of 5) Coiled-coil domain 



































ENSDARG00000021186 PTH2R (2 of 2) 
Row 2 
(4)  
ENSDARG00000045835 si:dkey-14d8.6 Proteolysis 
ENSDARG00000043722 cpa4 


















ENSDARG00000033542 nitr12 Novel immune-











ENSDARG00000070597 prelp Leucine-rich 









ENSDARG00000037840 actc1b Ion binding,  
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synaptic vesicle 
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Table A-2 Genes derived from IMP network analysis 
Each cluster is shown and referred to by row and number, as shown by Cytoscape 
(Figure 5.4). Both Ensembl gene ID and gene symbol are given, as well as the results 
of functional analysis using DAVID.  
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A Conditional Zebrafish MITF Mutation Reveals
MITF Levels Are Critical for Melanoma Promotion vs.
Regression In Vivo
James A. Lister1,5,6, Amy Capper2,3,5, Zhiqiang Zeng2,3, Marie E. Mathers4, Jennifer Richardson2,3,
Karthika Paranthaman2,3, Ian J. Jackson2 and E. Elizabeth Patton2,3,6
The microphthalmia-associated transcription factor (MITF) is the ‘‘master melanocyte transcription factor’’ with a
complex role in melanoma. MITF protein levels vary between and within clinical specimens, and amplifications
and gain- and loss-of-function mutations have been identified in melanoma. How MITF functions in melanoma
development and the effects of targeting MITF in vivo are unknown because MITF levels have not been directly
tested in a genetic animal model. Here, we use a temperature-sensitive mitf zebrafish mutant to conditionally
control endogenous MITF activity. We show that low levels of endogenous MITF activity are oncogenic with
BRAFV600E to promote melanoma that reflects the pathology of the human disease. Remarkably, abrogating MITF
activity in BRAFV600Emitf melanoma leads to dramatic tumor regression marked by melanophage infiltration and
increased apoptosis. These studies are significant because they show that targeting MITF activity is a potent
antitumor mechanism, but also show that caution is required because low levels of wild-type MITF activity are
oncogenic.
Journal of Investigative Dermatology (2014) 134, 133–140; doi:10.1038/jid.2013.293; published online 15 August 2013
INTRODUCTION
Driver genes that stimulate proliferation and survival are
important drug targets in cancer. The discovery of BRAFV600E
mutations in nevi and melanoma has directly led to the
development of small-molecule inhibitors with clear clinical
benefit (Flaherty et al., 2012). Despite these dramatic impro-
vements, drug resistance remains a critical problem, and most
patients with metastatic melanoma eventually succumb to
the disease within a year. It is therefore necessary to identify
additional therapeutic targets in melanoma that can be used in
combination with available treatments (Tsao et al., 2012).
One of the important genes in melanocyte development and
melanoma is the highly conserved ‘‘master melanocyte tran-
scription factor’’ microphthalmia-associated transcription
factor (MITF) (Levy et al., 2006). MITF responds to multiple
signaling cascades to orchestrate genes involved in
melanocyte growth, differentiation, and survival (Cheli et al.,
2010). Although MITF mutations in development lead to
similar phenotypes across species, the function of MITF in
melanoma is complex and not fully understood. MITF is
expressed in most melanomas, although MITF protein levels
vary between melanoma specimens, with some subsets of
melanoma showing high levels and others showing low levels
of MITF (Flaherty et al., 2012). MITF activity can also vary
within an individual melanoma, such that low levels of MITF
promote invasion and stem-cell like phenotypes and moderate
levels of MITF activity promote cell cycle progression (Goodall
et al., 2008; Hoek and Goding, 2010; Cheli et al., 2011; Strub
et al., 2011; Cheli et al., 2012). The ability of MITF to activate
cancer hallmark genes makes it an important mediator of
oncogenic signaling in cancer. This is underscored by
evidence that MITF is at least partially responsible for the
oncogenic potential of BRAF in cells (Wellbrock and Marais,
2005; Wellbrock et al., 2008). Studies from melanoma cells
indicate that a key function of BRAFV600E seems to be to
maintain MITF activity at a critical threshold where it promotes
proliferation, invasion, and survival, without promoting
differentiation (at higher levels) or apoptosis or senescence
(at lower levels) (Giuliano et al., 2010; Hoek and Goding,
2010; Cheli et al., 2011; Strub et al., 2011; Cheli et al., 2012)
However, MITF may have additional cooperating functions
in melanoma. MITF is amplified in some melanomas, and
expression of ectopic MITF can cooperate with BRAFV600E to
transform primary human melanocytes and neural crest cells
(Garraway et al., 2005; Kumar et al., 2013). In addition, MITF
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mutations have been identified in BRAFV600E melanomas
including somatic mutations with either hypomorphic or
increased activity (Cronin et al., 2009), and a germline
SUMOylation E318K mutation that is a melanoma risk factor
and confers differential gene expression of MITF target genes
(Bertolotto et al., 2011; Yokoyama et al., 2011). Thus, MITF is
important in melanoma because it is an effector of oncogenic
signaling, and also because it may have additional activity that
contributes to melanomagenesis.
How MITF activity contributes to melanoma development
and survival in an animal is unknown. Animal models are
fundamental in establishing how genetic mutations contribute
to cancer in vivo. Although many Mitf mutant mouse lines
exist (Hou and Pavan, 2008), they do not permit conditional
control of MITF activity in melanoma development or survival.
Here, we address the importance of MITF activity in
melanoma in vivo using a conditional mitfa temperature-
sensitive zebrafish mutant (mitfavc7) in which endogenous
MITF activity can be altered by changing the temperature of
the water (Johnson et al., 2011; Taylor et al., 2011). In
zebrafish, there are two mitf genes (mitfa and mitfb), and
mitfa is essential for the development of neural crest–derived
melanocytes (Lister et al., 1999). Thus, by using a mitfa mutant
we specifically control endogenous MITF activity in skin
melanocytes, and avoid the potential complication of MITF
activity in other tissues, such as those described in mouse
mutants (Hou and Pavan, 2008). We show that low levels
of wild-type MITF activity are oncogenic with BRAFV600E
to promote melanoma in vivo, and that abrogating MITF
activity in melanoma leads to rapid tumor regression. These
results reveal that critical thresholds of MITF lead to
dramatically different melanoma outcomes, and indicate
that although targeting MITF activity is a potent antitumor
approach, simply reducing MITF activity is sufficient to drive
melanoma in BRAFV600E melanocytes.
RESULTS
Hypomorphic MITF is oncogenic with BRAFV600E in
melanomagenesis
We sought to test whether hypomorphic levels of MITF activity
could contribute to melanoma development in vivo using
a zebrafish mitf temperature-sensitive mutant, mitfavc7
(Figure 1a–d; Johnson et al., 2011; originally characterized
as fh53) and a transgenic line expressing BRAFV600E in
melanocytes that we have previously developed and has
been effective in the identification of cooperating driver
genes (Figure 1e) (Patton et al., 2005; Ceol et al., 2011). The
mitfavc7allele is a splice site mutation at the intron 6 splice
donor site that leads to a reduction in melanocytes when
zebrafish are reared at o26 1C, and an almost complete loss of
melanocytes at 428 1C (Figure 1b–d) (Johnson et al., 2011).
We performed two generations of genetic crosses with the
BRAFV600E transgenic fish to the mitfavc7 mutant zebrafish
to generate BRAFV600E/V600Emitfavc7/vc7 (BRAFV600Emitf) zebra-
fish. As expected, BRAFV600Emitf zebrafish did not develop
melanocytes at the restrictive temperature (28.5 1C) because
there is not sufficient MITF activity to generate melanocytes
(Figure 1f). Importantly, at o26 1C, BRAFV600Emitf zebrafish
developed nevi (Figure 1g), some of which progressed to
melanoma (n¼ 18/67; Figure 1h–j). The mitfavc7 allele is a
splice site mutation, and we confirmed that the BRAFV600Emitf
melanomas expressed the mis-spliced þ intron6 variant with
hypomorphic levels of correctly spliced mitfa (Figure 1k). As
controls, neither BRAFV600E transgenic fish carrying wild-type
mitfa alleles nor mitfa mutants lacking the BRAFV600E trans-
gene developed melanoma at any temperature (Patton et al.,
2005; Johnson et al., 2011; data not shown). We compared
the incidence of melanoma in BRAFV600Emitf compared with
BRAFV600E/V600Ep53M214K/M214K (BRAFV600Ep53) zebrafish, and
found that the incidence was similar between the two
genotypes (n¼48/177; Figure 1j). These results show that
hypomorphic levels of MITF activity interact genetically with
BRAFV600E to promote melanoma in vivo.
BRAFV600Emitf melanomas display characteristic
histopathological features
We wanted to know whether the mitf and p53 cooperating
mutations contributed to melanoma pathology. We found that
most BRAFV600Emitf melanomas displayed a superficial
spreading growth pattern with some invasion into the under-
lying muscle (Figure 2a; n¼ 22/26). This pattern was reminis-
cent of superficial spreading melanoma, the most common
subtype of human melanoma. A striking characteristic feature
of BRAFV600Emitf melanomas was the presence of large,
heavily pigmented cells throughout the tumor (n¼26/26),
and often found in the kidney (the site of the hematopoietic
compartment in zebrafish). Macrophages laden with melanin
(melanophages) are often a feature of human malignant
melanoma, and express CD68. We found these large cells
to correspond to CD68-positive cells in the BRAFV600Emitf
melanomas and characterized them as melanophages
(Supplementary Figure S1 online). BRAFV600Emitf melanomas
were composed of spindle- and epithelioid-shaped tumor
cells, marked by few mitoses and showing only mild nuclear
pleomorphism. These histological features were characteristic
of BRAFV600Emitf melanomas, and allowed reliable identifica-
tion of these tumors on blind assessment by a clinical skin
pathologist (MEM; n¼ 26/26; Figure 2a). By comparison, most
BRAFV600Ep53 melanomas progressed rapidly, displaying a
nodular and a highly invasive growth pattern into multiple
organs (n¼19/21; Figure 2b). No melanophages were
observed in BRAFV600Ep53 melanomas, and the tumors were
composed primarily of epithelioid cells, with features indica-
tive of aggressive cancers including numerous mitoses and
moderate-to-severe nuclear pleomorphism.
We analyzed the activation state of the MAPK cascade in
the BRAFV600Emitf and BRAFV600Ep53 mutant melanoma by
performing immunohistochemical analysis with anti-phospho-
extracellular signal–regulated kinase (ERK; Figure 2c). As
expected, phospho-ERK signal was detected in the majority
of melanoma cells in both BRAFV600Emitf and BRAFV600Ep53
melanoma, and BRAFV600Ep53 had increased levels of p53
mutant protein (Figure 2d). Both melanomas stained positively
for Melan-A, a MITF target gene and marker for melanoma
and melanocytes in human specimens (Du et al., 2003)
(Figure 2e). Increased mitotic activity in BRAFV600Ep53
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melanomas compared with BRAFV600Emitf melanoma cells
was confirmed by immunostaining for phospho-histone H3, a
marker of late-G2/M phase (Figure 2f and g). These results
show that there is a strong genotype–phenotype correlation for
cooperating mutations that can directly affect growth features
and cellular histology.
Differential MITF target gene expression between melanoma
genotypes
We wanted to understand how hypomorphic MITF activity
contributed to melanoma, and hypothesized that MITF target
genes may be differentially expressed between the melanoma
genotypes. We performed quantitative real-time PCR on MITF
target genes involved in proliferation (cdk2), cell cycle arrest
(p16, p21), differentiation (tyr, dct), and survival (bcl-2, hif1a,
c-met) (Figure 3). Despite the differences in phospho-histone
H3 staining between the genotypes, the differences in cdk2,
p16, and p21 cycle threshold (Ct) values between melanoma
genotypes were not statistically significant (Figure 3a–c).
Neither was there a significant difference in the cycle thres-
hold values for expression of p53, bcl-2, or hif1a between
melanoma genotypes (Figure 3f–h). These results indicate that
despite the reduced levels of MITF activity in BRAFV600Emitf
melanomas, there is sufficient MITF activity to control MITF
target genes involved in cell proliferation and survival. Strik-
ingly, BRAFV600Emitf melanomas expressed lower levels of
differentiation genes (tyr and dct), as indicated by higher cycle
threshold values (Figure 3d and e). Unexpectedly, we
found that BRAFV600Emitf melanomas expressed significantly
higher levels of c-met compared with BRAFV600Ep53
melanoma (Figure 3i). c-met is a MITF target gene, but is also
transcriptionally regulated by Pax3 in melanoblasts and mela-
nomas (McGill et al., 2006; Beuret et al., 2007; Mascarenhas
et al., 2010). The tumor-initiating potential of cell types can
vary within a lineage and differing tumor potentials may exist
within the melanocyte lineage (Kumar et al., 2013). Although
the tumors are heterogeneous, the low expression of
differentiation genes (tyr and dct) coupled with high c-met
gene expression pattern suggests that hypomorphic MITF
activity may maintain melanocytes in a less differentiated
state that is more susceptible to BRAFV600E transformation.
Loss of MITF causes melanoma regression
MITF is a lineage survival oncogene in cells, but the effect of
abrogating MITF activity in an animal model of melanoma
in vivo is unknown. To develop an animal system that could
directly validate MITF as a drug target, we tested the effects of
dramatically reducing MITF activity on melanoma survival by
increasing the water temperature to the restrictive conditions
(32 1C); none of the aberrant mitfavc7 splice products are
sufficient for melanocyte development at these restrictive
temperatures (Johnson et al., 2011), and MITF activity is not
required to maintain the activity of the mitfa promoter
fragment driving the BRAFV600E transgene (Supplementary
Figure S2 online; Dooley et al., 2013). BRAFV600Emitfvc7
zebrafish were reared at o26 1C to promote melanoma
development, and then the temperature of the water was
raised to 32 1C to turn off MITF activity. Within 2 weeks, 8/12
melanomas had dramatically regressed (Figure 4a; fish 1
































Figure 1. The microphthalmia-associated transcription factor (MITF) is oncogenic with BRAFV600E in melanomagenesis. (a) Adult wild-type zebrafish or (b) adult
mitfavc7 mutant zebrafish living in water at 28 1C or (c, d) o26 1C. At o26 1C some melanocytes are visible in the body (d: enlarged region, white arrows). (e) Adult
transgenic line expressing human BRAFV600E in the melanocytes. (f–i) Genetic crosses of BRAFV600Emitf at the semirestrictive temperatures develop nevi (*) and
melanoma (on the tail of the middle fish, and on the head of the bottom fish). (j) Melanoma incidence curves of BRAFV600Ep53 and BRAFV600Emitf (o26 1C) genetic
crosses. (k) Real-time PCR (RT-PCR) analysis of the mitfa transcript in BRAFV600Ep53 and BRAFV600Emitf melanomas.
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mutation and not just the water temperature because BRAF-
V600Ep53 zebrafish upshifted to 32 1C for 2 weeks showed no
tumor regression and even continued growth (n¼6/6;
Figure 4b). By 2 months, 12/15 very large tumors showed
regression, and 6 of these fish showed complete regression
and even healing at the tumor site (Figure 4c; fish 3 and 4).
Interestingly, despite the striking levels of melanoma regres-
sion, melanomas recurred following a temperature shift to
o26 1C, indicating that a subpopulation of melanoma cells
with very low MITF activity survive and are capable of
repopulating the tumor site (Supplementary Figure S3 online).
To understand the process of melanoma regression, we
shifted BRAFV600Emitf zebrafish to the restrictive temperature
(32 1C) for 7 days to analyze melanoma regression in progress.
Histological analysis of the regressing melanomas showed
evidence of tumor regression, characterized by marked loss of
tumor cell density and accumulation of heavily pigmented






























































Figure 2. Comparative histopathology of BRAFV600E melanomas. (a) Cross-section of adult BRAFV600Emitf zebrafish with superficial spreading melanoma (dotted
line). Infiltrating melanophages in the kidney are indicated (yellow arrows). i, intestine; k, kidney; l, liver; m, muscle; o, ovary; s, spinal column; sb, swimbladder.
(Top and bottom panels) Hematoxylin and eosin (H&E) stain of BRAFV600Emitf melanoma, indicating large melanophages (red arrows), spindle or epithelioid cell
shapes (yellow arrows), and pigmented melanoma cells (white arrow). Scale bars¼ 20 mm. (b) Cross-section of adult BRAFV600Ep53 zebrafish with invasive
melanoma (dotted line). (Top and bottom panels) H&E stain of BRAFV600Ep53 melanoma, indicating pigmented melanoma cells (white arrows) and nuclear
pleomorphisms (yellow arrow). Scale bars¼ 20mm. (c–f) Immunohistochemistry staining for (c) phospho-extracellular signal–regulated kinase (ERK), (d) p53,
(e) Melan-A, and (f) phospho-histone H3. Scale bars¼50mm. (g). Box plot of mean percentage phospho-histone H3–stained cells in BRAFV600Emitf and
BRAFV600Ep53 tumors (n¼11 melanomas of each genotype). Bars represent interquartile range; Student’s t-test P¼ 0.0078.
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apoptosis contributed to regression, we stained sections of the
regressing BRAFV600Emitf melanomas with antibodies to detect
active (cleaved) Caspase-3. We found high levels of active
Caspase-3 in the regressing tumors compared with BRAFV600E-
mitf melanomas at o26 1C (n¼5 in each group; Figure 5c).
We conclude that there is a genetic dependency on MITF
activity in BRAFV600Emitf melanoma.
DISCUSSION
Identifying BRAFV600E cooperating mutations that drive mela-
noma progression is critical for developing new therapeutic
approaches and tackling drug resistance. Accumulating evi-
dence indicates that MITF activity is a key contributing factor
in melanoma (Tsao et al., 2012). We now show in an animal
that a low level of wild-type MITF activity is oncogenic with
BRAFV600E and that abrogating MITF activity in melanoma
leads to tumor regression.
The BRAFV600Emitf model is relevant to human melanoma,
because for some patients, low expression of MITF is asso-
ciated with disease progression and poor prognosis (Salti
et al., 2000; Levy et al., 2006). In these contexts, exoge-
nous expression of MITF leads to inhibition of proliferation
(Selzer et al., 2002; Wellbrock and Marais, 2005). This is in
apparent contrast to evidence that MITF amplification is also
an indicator of poor prognosis, and that MITF cooperates with
BRAFV600E to transform melanocytes (Garraway et al., 2005).
These differences in MITF activity may reflect distinct
subtypes of melanoma; however, another possibility is that
MITF amplification indicates the need for melanoma cells to
maintain sufficient MITF activity for survival in the context of
high BRAFV600E signaling (Garraway et al., 2005; Wellbrock
et al., 2008). Thus, a common feature of melanoma may
involve maintaining sufficient MITF activity for survival
and proliferation while at the same time restricting higher
levels of MITF activity that promote cell cycle arrest and
differentiation or lower levels that lead to cell cycle arrest
and apoptosis (Gray-Schopfer et al., 2007; Hoek and
Goding, 2010). Here, the temperature-sensitive nature of
the zebrafish mitfavc7 mutant allele enables MITF activity to
be varied within an individual animal by altering
the water temperature, thereby revealing the role of MITF
activity levels in melanomagenesis and survival in vivo,
although we cannot exclude the possibility that the mitfavc7
mutant has additional functions that contribute to
melanoma.
Histopathological characteristics of melanoma are deter-
mined by a number of factors, and at least some are genetically
determined (Whiteman et al., 2011). This is illustrated by
the clinical classification of BRAFV600E melanomas as a
subgroup based on histomorphological features (Viros et al.,
2008). We show here that cooperating mutations also have
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Figure 3. MITF target gene expression. (a–i) Box plots of quantitative real-time PCR (qRT-PCR) of MITF target genes and p53. The y-axis indicates the difference
between the cycle threshold (Ct) value of the gene of interest and the Ct value of b-actin in each sample. Note that the y-axis is inverted for ease of interpretation.
Bars represent interquartile range; P-values determined by Student’s t-test. Also see Supplementary Table S1 online. MITF, microphtholmia associated transcription
factor.
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of melanoma. We find that low, oncogenic levels of MITF
activity contribute to melanoma pathology, possibly by
maintaining melanoma cells in a progenitor-like state.
Notably, macrophages laden with melanin (melanophages)
were a diagnostic feature of the BRAFV600Emitf melanomas.
Melanophages are found in human melanomas, are indicative
of an immune response, and predict an improved prognosis
for patients, possibly because of tumor regression through
macrophage engulfment of melanoma cells (Handerson et al.,
2007). Thus, BRAFV600E cooperating mutations can directly
influence tumor morphology, as well as tumor–immune cell
interactions.
The dramatic recurrence of melanomas in patients follow-
ing treatment with the BRAFV600E inhibitor, vemurafenib,
indicates that combination therapies that target multiple
pathways in melanoma may be necessary to improve patient
outcome. MITF activity has been implicated as an important
drug target (Flaherty et al., 2012; Tsao et al., 2012), and we
now show that shutting off endogenous MITF activity in vivo
leads to dramatic and rapid melanoma regression,
characterized by melanophage infiltration and apoptosis.
The melanomas recur at the same location following
reactivation of MITF activity (Supplementary Figure S3 online),
although at this stage we cannot distinguish whether this
reflects incomplete tumor regression or a cancer-initiating
population that can survive with low-to-no MITF activity.
Notably, although melanophages are presumably participat-
ing in melanoma regression and/or clearance (Figure 5), we
do not know their function in melanoma growth (Figure 2a):
macrophages can lead to both melanoma regression
(Nakashima et al., 2012) and promotion (Zaidi et al.,
2011), or form melanoma–macrophage hybrids (Pawelek,
2007).
In conclusion, our zebrafish model provides in vivo genetic
evidence that targeting MITF activity—either directly or
through regulators of MITF—may be an effective approach
to melanoma therapy. Critically, our studies show that
although targeting MITF activity is a potent antitumor mechan-
ism, it must be done with caution because partial or
ineffective targeting of MITF is oncogenic.
MATERIALS AND METHODS
All zebrafish work was done in accordance with the United Kingdom
Home Office Animals (Scientific Procedures) Act (1986) and
approved by the University of Edinburgh Ethical Review Committee,
and in the United States in compliance with protocol AM10415,
approved by the Institutional Animal Care and Use Committee of
Virginia Commonwealth University. The temperature-sensitive mit-
favc7 mutant is described in Johnson et al. (2011), and the mitfavc7
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Figure 4. Abrogation of MITF activity causes melanoma regression. (a) Images of adult BRAFV600Emitf zebrafish at o26 1C, and transferred to water at 32 1C for 14
days (bottom images). Red dotted lines outline the tumors before and after the temperature shift. (b) Control BRAFV600Ep53 melanoma fish at o26 1C and at 32 1C.
Areas of increased tumor growth are indicated with yellow asterisks. (c) Adult BRAFV600Emitf zebrafish at o26 1C and after 2 months at 32 1C. MITF,
microphtholmia associated transcription factor.
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Histopathology
Adult zebrafish were prepared for histopathology as described
previously (Patton et al., 2011). Antibodies and antigen retrieval
methods were as follows: anti-phospho-extracellular signal–regulated
kinase 1/2, 1:1,000, EDTA buffer (Cell Signaling Technology,
Danvers, MA); p53 5.1, 1:500, citrate buffer; phospho-histone H3,
1:1,000, citrate buffer (Cell Signaling Technology); Melan-A, 1:75,
citrate buffer (DAKO, Cambridge, UK). For the proliferation analysis,
the total melanoma cell population in each of the six images was
counted (between 1,000 and 3,000 cells) and the percentage of
phospho-histone H3–stained cells calculated.
PCR analysis
Total RNA was isolated using TRIzol reagent (Invitrogen, Paisley, UK).
First-strand complementary DNA was synthesized from 1mg of total
RNA in a 10ml reaction using SuperScript III Reverse Transcriptase
(Invitrogen). Complementary DNA was then amplified by PCR using
primers covering the alternative splicing region in the mitfavc7 gene.
Quantitative real-time PCR was performed using SYBR Green
Jumpstart Taq Readymix for high-throughput real-time PCR (Sigma,
St Louis, MO). Reactions were run in an ABI PRISM 7900 HT
Sequence Detection System (Applied Biosystems, Paisley, UK) using
the SYBR Green protocol. The zebrafish b-actin gene was used
as reference. Primers sequences are presented in Supplementary
Table S1 online.
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Figure 5. Melanoma regression is associated with melanophage and apoptotic activity. (a) Hematoxylin and eosin (H&E) staining of a regressing BRAFV600Emitf
melanoma showing almost total regression with prominent melanophages (scale bar¼ 200mm). Boxed region is enlarged in right panel (scale bar¼ 100mm).
(b) A regressing tumor, showing subtotal regression with melanoma cells present (scale bar¼100mm). Boxed region is enlarged in right panel (scale bar¼ 50mm).
(c) Images of nonregressing (o26 1C) and regressing (32 1C) BRAFV600Emitf melanomas (as shown in b), stained with an antibody to detect cleaved-Caspase-3
(scale bar¼50mm).
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Zebrafish as a model system to
investigate the function of MITF
in melanoma
Amy Capper and E. Elizabeth Patton
Background
Melanoma is the most lethal form of skin cancer, and incidence continues to rise rapidly in
Western populations. The American Cancer Society currently estimates that there are 120,000
new cases ofmelanoma diagnosed in theU.S. each year withUV exposure playing amajor role in
susceptibility. BRAFV600E is one of the most common somatic mutations associated with
melanoma and the recent development of drugs that target BRAFV600E has led to clinically
significant improvements in outcomes for melanoma patients. Despite these improvements,
many patients with metastatic melanoma eventually succumb to the disease, making it
imperative that new therapeutic strategies are developed to identify additional melanoma
target pathways (1).
One such important and emerging melanoma target is microphthalmia-associated transcrip-
tion factor (MITF; Fig. 1). MITF is the "master" transcription factor in melanocyte devel-
opment, and it plays a complex role in melanoma. Germline MITF mutations have been
identified as risk factors for melanoma, and amplifications of the MITF gene, as well as somatic
MITF mutations have been identified in melanoma (2). In human cancers and zebrafish
melanoma models, MITF activity is finely balanced to provide sufficient activity for melanoma
survival and proliferation, but not differentiation (higher activity levels) or senescence/
apoptosis (low to no activity levels). In this educational session, we discuss how the zebrafish
has been developed as a preclinical model for testing the function of MITF mutations in
melanoma.
Discussion
MITF is a highly conserved transcription factor required for melanocyte
development
Melanocytes are the pigment producing cells that color our hair, skin and eyes, and function as
an important barrier against the harmful effects of UV-irradiation.Melanocytes are found in all
vertebrate species, including the zebrafish, where these cells help to form the stripes for which
the fish is named. As small, aquarium fish, zebrafish are now widely used as a vertebrate model
system because they share many genomic, developmental, anatomical and clinical features with
humans (3).
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One of the critical melanocyte genetic factors in both fish and humans is MITF. MITF is a
transcription factor that regulates a suite of target genes involved in melanocyte specification,
proliferation, and differentiation (4). MITF is required for melanocyte development during
embryogenesis in fish and mammals, and human germline mutations in MITF lead to
Waardenburg Type IIa and Teitz syndromes, characterized by hypopigmentation, deafness,
and facial features (Fig. 1A). In zebrafish, an ancestral genome duplication event gave rise to two
mitf genes,mitfa andmitfb, and loss of function mutations inmitfa lead to a complete loss of all
neural crest derived melanocytes that pigment the skin of the fish (Fig. 1B and C) (5).
MITF ismutated and amplified inmelanoma, and is amelanoma-predisposition
gene
While it is well established thatMITF is essential for melanocyte development, its function in
melanoma is less well understood. Germline MITF mutations have been identified as risk
factors for melanoma, and MITF amplifications as well as somatic MITF mutations have been
identified in melanoma (6–10). An important issue in the field is to understand and reconcile
how differing MITF mutations contribute to melanoma. For example, some somatic MITF
mutations have reduced activity (6), while the germline MITFE318K mutation has a dominant
function by altering MITF target gene expression and conferring increased nevi numbers and
non-blue eye color (9, 10). One explanation for the varied MITF activity observed between
melanoma samples is that MITF is a lineage survival oncogene: Sufficient MITF activity is
required to maintain melanoma survival, but higher MITF activity leads to differentiation and
cell cycle arrest, while loss of MITF leads to senescence and/or apoptosis (11–16). Thus, the
levels ofMITF activity in everymelanoma isfinely tuned to be "just right" to promotemelanoma
without leading to differentiation or cell cycle arrest/apoptosis (11, 12).
Fig. 1. Human cancer and developmental mutations inMITF, and a loss of functionmutation in zebrafishmitfa. A.MITF is a
basic helix-loop-helix leucine zipper transcription factor, and mutations have been identified that lead to Waardenburg
Type IIA and Tietz syndrome (bottom) andmelanoma (top). B. A loss of functionmutation inmitfa leads to a complete loss
of all neural crest melanocytes in the zebrafish embryo, and C. in adult zebrafish. The eyes remain pigmented due to
expression of amitfb, a paralog of mitfa that arose through an ancient genome duplication event. Fig. 1A kindly provided
by Eirikur Steingrimsson (25).
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Zebrafish as a model system for MITF activity in melanoma
An essential part of the challenge to identify melanoma target pathways is the development of
animal disease models that reproduce the aetiology and progression of the disease within the
context of a whole animal. Zebrafish cancers, including melanomas, are histopathologically
similar to the human disease, and parallel molecular mechanisms underlie melanoma in both
species (17). We have previously demonstrated that expression of BRAFV600E in zebrafish
melanocytes leads to the development of nevi, and when combined with a mutation in p53,
many nevi progress to melanoma (Fig. 2A) (18). The BRAFV600Ep53 mutant melanomas are
highly aggressive and invasive, have a high mitotic index, are genetically unstable, and can be
transplanted into wild type zebrafish.
Fig. 2. MITF mutations with lowered activity cooperate with BRAFV600E in melanoma. A. Adult zebrafish with melanoma
(arrows). Top fish: BRAFV600E p53mutant zebrafish. Bottom fish: BRAFV600E co-operates with low levels of MITF activity
to promote melanoma. B. Complete loss of MITF activity in BRAFV600Emitfa melanomas causes melanoma regression.
Here, the mitfa genetic mutation is temperature sensitive, and shifting the fish to 32C leads to complete loss of MITF
activity in body melanocytes andmelanoma regression (outlined area). C. BRAFV600Ep53 (left panel) and BRAFV600Emitfa
(right panel) melanomas have characteristically distinct growth patterns. Cross section of adult zebrafish with
melanomas indicated (arrows). BRAFV600Ep53 melanomas are highly invasive into the underlying musculature, while
BRAFV600Emitfamelanomas display superficial spreading along the skin, with very little invasion and have an abundance
of infiltrating melanophages that darkly pigment the tumor. D. BRAFV600Ep53 (top panel) and BRAFV600Emitfa (bottom
panel) melanomas are histopathologically distinct and represent different melanoma subtypes. Arrows indicate nuclear
pleomorphisms (top panel) and infiltratingmacromelanophages (bottom panel). Note differences inmelanoma cell shape
and organization between subtypes.
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While evidence from human melanoma suggested that MITF activity could be oncogenic,
there was no genetic animal model to address MITF activity in melanoma promotion and
survival. Recently, Lister and colleagues have identified a temperature-sensitive mutant allele of
mitfa, such that when the fish are grown inwater at 24C,MITF is active and the animals develop
pigmented melanocytes (19). However, when the temperature of the water is raised to above
28C, MITF is inactive and the fish are white. This enables control of MITF activity by simply
altering the temperature of the water. Utilizing thismitfa temperature sensitive allele, we found
that lowered levels of MITF activity cooperated with BRAFV600E mutations to promote nevi
and melanoma in vivo, and that loss of MITF in established melanomas led to rapid melanoma
regression (Fig. 2A and B) (20). Furthermore, while melanoma incidence was similar in
BRAFV600Ep53 and BRAFV600Emitf fish, the histopathology of the melanomas were strikingly
different. BRAFV600Emitfmelanomas were characterized by a high degree of pigmentation, low
mitotic index and superficial spreading through the skin, in contrast to the aggressive and
invasive nature of BRAFV600Ep53melanoma (Fig. 2C and D). An important implication from
this animal model is the validation ofMITF as a drug target in melanoma, but also that caution
would be needed in this approach, because insufficient targeting of MITF activity (leading to
simply a reduction in MITF activity) could be oncogenic (20).
Future Directions
With an animal model of MITF activity in melanoma in hand, the next series of challenges
can begin to be addressed:
Develop conditional genetic models of melanoma that recapitulate MITF
mutations found in humans
New technological advances in genome editing in zebrafish using the CRISPR/Cas9 system
now make this possible (21). This is important to directly test the function of MITF cancer
genes in vivo, and would enable direct validation of MITF as a target in otherwise MITF wild
type cancers. Additional zebrafish MITF models could also illuminate the mechanisms
underlying MITF oncogenic activity, and enable the identification of MITF cooperating
pathways (such as by exome sequencing of zebrafish melanomas, as recently described (22)).
Understand MITF activity in melanocyte and melanoma stem cells
In zebrafish, low expressing mitfþ cells associated with the dorsal root ganglia may mark
melanocyte stem cells (23), and low MITF expression is associated with a tumor-promoting
population in humanmelanoma (24). It will be of great interest to establish the impact ofMITF
cancer mutations on the melanocyte stem cell in development, in melanoma initiation and
progression, and response to therapy.
Develop zebrafish as a pre-clinical system to test and validate drug-leads and
drug-targets
Aunique feature of the zebrafish vertebrate system is the ability to performwhole animal small
molecule screens for drug-leads that target melanocyte and MITF pathways in vivo. Zebrafish
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embryos are fertilized outside the mother and are transparent, enabling visualization and
manipulation of development from a single cell embryo through organogenesis and disease. This
system provides the potential to identify target pathways in development that can then be
applied in the adult zebrafish melanoma and mammalian systems (3).
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